Determining the Role of Serotonin in Antidepressant Action, as Revealed Utilizing the SERT Met172 Mouse Model by Nackenoff, Alexander Greer
DETERMINING THE ROLE OF SEROTONIN IN ANTIDEPRESSANT ACTION, AS 
REVEALED UTILIZING THE SERT MET172 MOUSE MODEL 
 
By 
 
Alexander Greer Nackenoff 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
in 
Pharmacology 
May, 2016 
Nashville, Tennessee 
 
Approved: 
 
Eugenia Gurevich, Ph.D. 
Ron Emeson, Ph.D. 
Ariel Deutch, Ph.D. 
Gregg Stanwood, Ph.D. 
Randy Blakely, Ph.D. 
 
 
  
 
 
 
 
 
 
 
DEDICO HAC DISSERTATIONE PARENTUM 
 
 iii 
ACKNOWLEDGEMENTS  
 
I would like to thank my mentor, Randy Blakely, for providing the environment for which I could 
pursue my graduate career. Without the financial support I was afforded due to the stringent budget 
nature of the field of science, there was no guarantee that I could find a laboratory that could 
support me in a way that would allow me to attain my doctorate degree. Additionally, his scientific 
leadership was instrumental in my personal development as a research scientist. As this level of 
academic research was relatively new to me when I joined his lab, I was only able to be successful 
given the environment he was able to provide.  
 
I would also like to thank my committee. My chair, Dr. Eugenia Gurevich, has provided much 
assistance in the guidance and direction of the project. Dr. Ariel Deutch was instrumental in 
providing research reagents and methodological guidance for the hippocampal neurogenesis 
studies, as well as helpful guidance and direction for all other aspects. Dr. Gregg Stanwood was 
incredibly helpful when we were designing behavioral experiments that would best test the 
anxiolytic and antidepressant properties of drugs we have tested in the lab, and also provided 
guidance and research assistance for the vortioxetine project. Dr. Ron Emeson served an excellent 
capacity in the direction of general research methodology and design, enabling me to best pursue 
my thesis goals and providing intellectual balance to the ideas proposed by myself and Dr. Randy 
Blakely. 
 
Given my relative naïveté to the type of research environment in which I found myself in Randy’s 
lab, I need to thank the research technicians profusely. My incessant queries for procedural details 
 iv 
and research support was immeasurable. Initially, these queries fell upon Kathryn Lindler (now 
Kathryn Stevens), who was incredibly patient with me and was an incredibly gifted researcher and 
friendly face in lab. I next need to thank Sarah Whitaker (now Sarah Sturgeon), who was 
immensely valuable for experimental advice, specifically as we both pursued our experiments in 
immunohistochemistry, as well as being a great friend in lab. Next, I need to thank Tracy Moore-
Jarrett, who was immensely valuable helping me with mice as I learned the arts of animal 
husbandry. I must thank her profusely for her efforts backcrossing the SERT Met172 mouse onto 
the C57Bl/6 genetic background. Without this work, my thesis project would be near impossible 
if not much more headache inducing. I must also individually acknowledge Jane Wright, who is 
vastly underappreciated for the quality and quantity of work she pursues, in addition to her 
thankless and selfless efforts to assist my scientific efforts throughout my entire stay in the lab. 
Lastly I must recognize the rest of the research staff, Angela Steele for having to deal with us crazy 
lab folk and being a good friend, Qiao Han, for helping my early cell culture efforts, and Chris 
Svitek, for keeping is [mostly] in line as lab manager. 
 
My time in lab was made so much more enjoyable given the great people that compose it, and the 
great times we have shared. I’d like to thank Marc Mergy, Dhananjay Sakrikar, and David Lund 
for being early examples of successful scientists in the lab. I’d also like to thank Andrew Hardaway 
for his constant assistance and mentorship throughout the time we overlapped in the lab. I’d also 
like to thank the rest of the graduate students who’ve been sources of inspiration and friends 
throughout my time in the lab; Cassie Retzlaff, Chelsea Snarrenberg, Raajaram Gowrishankar, 
Gwynne Davis, and Meagan Quinlan have been great to me, and I wish them luck in their future 
endeavors. I’d also like to recognize Linda Simmler for her guidance and friendship in the lab. Her 
 v 
help was immensely valuable as I developed into the person I am today. I’d also like to thank Matt 
Robson for being a great friend to bounce scientific ideas and other cultural facets off of each 
other. I’d also like to thank Nicole Baganz for her help and guidance throughout the years. 
 
I also need to acknowledge and thank the undergraduates that I’ve had the pleasure of mentoring. 
When I first joined the lab, I oversaw the honors project of Peter Chisnell, who worked upon 
serotonin actions of cocaine in the SERT Met172 model. I felt that I gained much from my 
interactions with him, as he could guide me through the inner workings of the lab and his 
experimental setup, all while providing him with the advice and analyses that I could provide. I 
am confident that he could have achieved highest honors without my assistance, and I’m glad I got 
a chance to mentor him in his time in the lab. Next, I had the pleasure of mentoring Alexandra 
Moussa-Tooks. She was a passionate learner in the lab and quick to attain proficiency of the 
multitude of techniques I use in the lab. We were able to make much progress with split 
responsibilities and coordinated tasks. I’d also like to thank Austin McMeekin, who took over for 
Alexandra in that role and helped when I needed to be in three places at the same time. 
 
I also need to thank John Allison who has been incredible to me and has helped me out of more 
than a few binds in the behavior core over the years. The Neurobehavioral center is an incredible 
resource, and his thankless management of that core facility has greatly impacted countless lines 
of research that occur within the walls of Vanderbilt. 
 
I’d also like to thank the mentorship I received outside of the lab from Aurelio Galli. His guidance 
has helped ground me more than a few times, and I value his friendship.  
 vi 
Lastly I’d like to thank my friends and family for their support over the years. Peter Hamilton was 
a great random encounter and blind roommate application that turned into a bond I hold deeply 
and will hold forever. He and Grace are incredible friends and have helped me through this journey 
of graduate school. Sonja and Braden Fulmer also remain close friends and helped me through this 
process. And to Emily, whose companionship helped make the dissertation writing process as 
pleasant as possible. 
  
 
 vii 
TABLE OF CONTENTS 
 
Page 
DEDICATION ................................................................................................................................ ii 
ACKNOWLEDGEMENTS ........................................................................................................... iii 
LIST OF TABLES ......................................................................................................................... ix 
LIST OF FIGURES .........................................................................................................................x 
Chapter 
I. INTRODUCTION .......................................................................................................................1 
 Clinical Significance of Depression ............................................................................................1 
 Serotonergic Pathways and Pathophysiology of Depression ......................................................2 
 Early Treatments of Depression and Emergence of Psychopharmacology ................................8 
 Biomechanistic Determinations of Antidepressant Efficacy.....................................................13 
 The Serotonin Transporter (SERT) and SSRIs .........................................................................17 
 The Serotonergic Hypothesis of Depression .............................................................................22 
 Serotonergic Mechanisms Contributing to SSRI Antidepressant Efficacy ...............................24 
 Serotonergic Evidence of SSRI Efficacy by Direct Receptor Analysis ....................................28 
 SERT-Independent Targets of SSRIs ........................................................................................33 
 The SERT Met172 Mouse Model for Assessing 5-HT Dependence of Drug Action ...............37 
 Rationale for Thesis Studies ......................................................................................................41 
 
II.  BIOCHEMICAL CHARACTERIZATION OF SERT MET172...........................................45 
 
 Introduction ...............................................................................................................................45 
 Materials ....................................................................................................................................47 
 SERT Western Blotting Studies ................................................................................................48 
 Brain Monoamine Steady State Composition ...........................................................................51 
 Saturation Uptake Kinetic Analysis of SERT Met172 ..............................................................52 
 Synaptosomal Competition Serotonin Uptake Analysis ...........................................................55 
 Conclusions ...............................................................................................................................59 
 
III.  ACUTE BEHAVIORAL SENSITIVITY OF SERT MET172 TO SSRI ..............................61 
 
 Introduction ...............................................................................................................................61 
 Animal Procedure ......................................................................................................................64 
 Tail Suspension Test .................................................................................................................65 
 Forced Swim Test ......................................................................................................................66 
 Conclusions ...............................................................................................................................70 
 viii 
 
IV.  CHRONIC BEHAVIORAL AND BIOCHEMICAL SENSITIVITY OF SERT MET172 TO 
SSRI  ..............................................................................................................................................73 
 
 Introduction ...............................................................................................................................73 
 Materials ....................................................................................................................................77 
 Novelty Induced Hypophagia (NIH)  ........................................................................................78 
 Hippocampal Neurogenesis .......................................................................................................81 
 Conclusions ...............................................................................................................................85 
 
V.  ANTIDEPRESSANT SENSITIVITY TO THE NOVEL ANTIDEPRESSANT 
VORTIOXETINE IN SERT MET172...........................................................................................89 
 
 Introduction ...............................................................................................................................89 
 Animals .....................................................................................................................................91 
 Drugs .........................................................................................................................................93 
 In Vitro Transfected Cell Competition 5-HT Uptake ................................................................93 
 Ex Vivo Synaptosomal Competition 5-HT Uptake ...................................................................96 
 Ex Vivo SERT Occupancy .........................................................................................................99 
 In Vivo Chronoamperometry ...................................................................................................102 
 In Vivo Microdialysis ..............................................................................................................103 
 Acute Behavioral Paradigm Animal Procedure ......................................................................107 
 Tail Suspension Test (TST) .....................................................................................................108 
 Forced Swim Test (FST) .........................................................................................................110 
 Novelty Induced Hypophagia (NIH) .......................................................................................112 
 Hippocampal Neurogenesis .....................................................................................................116 
 Conclusions .............................................................................................................................120 
 
VI.  CONCLUSIONS AND FUTURE EXPERIMENTATION .................................................125 
 
Appendices  ..................................................................................................................................135 
 
APPENDIX A. Sensitivity of the Mixed Action SNRI Antidepressant/Pain Medicines 
Milnacipran and Duloxetine to the SERT Met172 Substitution .............................................136 
 APPENDIX B. Characterization of the Disrupted Pharmacological Inhibition of Cocaine  
upon Ex Vivo Derived Synaptosomes from C57Bl/6 Backcrossed SERT Met172 Mice .......141 
APPENDIX C. Adaptation of Novel Fluorescence-Based SERT Uptake Assay for         
Ninety-Six Well Transfected Cell Format ...............................................................................147 
 
 
REFERENCES ............................................................................................................................153 
        
 ix 
LIST OF TABLES 
 
Table                                                                                                                                           Page  
1. Highlighted Major 5-HT Receptors ...........................................................................................30 
2. Biogenic Amines in SERT Met172 ...........................................................................................53 
 
 x 
LIST OF FIGURES 
 
Figure                                                                                                                                         Page  
1. Location of Serotonergic Raphe Nuclei and Projections .......................................................3 
 
2. Biosynthetic Pathway of Serotonin ............................................................................................5 
 
3. Comparison of the Structures of Isoniazid and Iproniazid ......................................................10 
 
4. Structural Comparisons of Iminodibenzyl, Chlorpromazine, and G-22355 ............................14 
 
5. Sequence Alignment of SERT Protein ....................................................................................39 
 
6. Structure of SERT with I172M Substitution .........................................................................40 
 
7. SERT Protein Expression in SERT Met172 ............................................................................50 
 
8. Saturation Uptake Kinetics ......................................................................................................56 
 
9. Synaptosomal Competition of 5-HT Uptake ...........................................................................57 
 
10. Tail Suspension Test ................................................................................................................67 
 
11. Forced Swim Test ....................................................................................................................69 
 
12. Novelty Induced Hypophagia Test ..........................................................................................80 
 
13. Hippocampal Neurogenesis .....................................................................................................83 
 
14. Stem cell proliferation in SVZ ................................................................................................84 
 
15. Research Strategy for Vortioxetine in SERT Met172 .............................................................92 
 
16. In Vitro Vortioxetine Competition 5-HT Uptake ....................................................................95 
 
17. Ex Vivo Vortioxetine 5-HT Uptake Competition ....................................................................98 
 
18. Ex Vivo Vortioxetine SERT Occupancy ...............................................................................101 
 
19. In Vivo Chronoamperometry of Vortioxetine-Inhibited 5-HT Clearance .............................104 
 
20. In Vivo Microdialysis of Vortioxetine-Induced Elevations in Extrasynaptic 5-HT ..............106 
 
 xi 
21. Tail Suspension Test with Vortioxetine .................................................................................109 
 
22. Forced Swim Test with Vortioxetine .....................................................................................111 
 
23. Novelty Induced Hypophagia with Vortioxetine ...................................................................114 
 
24. Hippocampal Neurogenesis: Proliferation Stimulation by Vortioxetine ...............................118 
 
25. Hippocampal Neurogenesis: Survival Preservation with Vortioxetine .................................121 
 
 
 
 
 
 1 
CHAPTER I 
 
INTRODUCTION 
 
Clinical Significance of Depression 
 
The earliest depictions of depression-related disorders arose in Hippocrates, Nature of Man 
(Hippocrates), in which he postulated that the presentation of ‘melancholy’ was due to humoural 
imbalance. Specifically, oversaturation of ‘black bile’ (melaina kholé) produced a state currently 
best described as depression, and whose treatment involved bloodletting in order to restore the 
balance of the humours. Although these treatments have long since been discredited, these early 
classifications of depression were foundational for more progressive analyses and diagnosis of 
depression. Depictions of melancholy began to expand as a defined phenomena of the mind, most 
notably described at length in 1621 by Robert Burton in The Anatomy of Melancholy (Burton). 
Here, we begin to see parallels to modern diagnostic formulations through more deliberate analysis 
of the core states of melancholy and depression.  Depression is now defined and diagnosed upon 
the presentation of multiple symptoms including prolonged depressed mood, suicidal ideation, 
lethargy, anhedonia, and perceptions of low self-worth, as set forth by the Diagnostic and 
Statistical Manual (DSM-V). Depression symptom presentation can vary across different forms of 
depression, of which major depression, atypical depression, melancholic depression are most 
common (Benazzi, 2006).    
These historical observations were common not only due to the budding scientific curiosity 
surrounding depression, but is also due to the high prevalence and persistence of the disorder. 
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Depression is one of the most common psychological disorders and roughly affects at least 7% of 
the US population at any given time (Kessler et al, 2005), and lifetime prevalence estimates range 
from ranges of 1 in 10 (Andrade et al, 2003) to 1 in 5 (Kessler, 2005).  World Health Organization 
estimates conclude that depression is the primary basis of disability (using the Years Lived with 
Disability metric) and among the leading contributor to the global burden of disease (2000).  
Depression is already the second most burdensome disease among 15-44 year olds (measured 
using the Disability Adjusted Life Years metric), and is projected to further increase in burden 
across all age groups. The economic impact of depression is dramatic and has been estimated to 
have reduced economic output in the USA (non-inflation adjusted dollars) by $43.7 billion in 1990 
(Greenberg et al, 1993), $52.9 billion in 2000 (Greenberg et al, 2003), and $210 billion in 2010 
(Greenberg et al, 2015). Additionally, depression and related mood disorders are the predominant 
risk factors for suicide attempts (CDC, WISQARS, 2014). In the United States, the suicide rate for 
adults is 11.3 suicide deaths per 100,000 people with 11 suicide attempts occurring for every 
suicide death (CDC, WISQARS, 2014).   
 
Serotonergic Pathways and Pathophysiology of Depression 
 
Most serotonergic (5-HT) neurotransmission originates in the raphe nuclei, which are 
located in the midbrain.  Raphe neurons project in both an ascending and descending manner, 
projecting to the spinal cord, the forebrain, and to major components of the limbic system (Figure 
1).  These serotonergic neurons project to areas implicated in pain processing, fear, emotion, 
memory formation, and attribution of salience.  Serotonin is synthesized from dietary tryptophan, 
and its delivery into the CNS is the rate limiting step in serotonin synthesis.   
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Figure 1. Location of Serotonergic Raphe Nuclei and Projections 
  
 4 
 
Tryptophan is hydroxylated by tryptophan hydroxylase (TPH; TPH2 in the CNS) to form 
5-hydroxytryptophan (5-HTP). 5-HTP is then decarboxylated by aromatic amino acid 
decarboxylase (AADC) to form 5-hydroxytryptamine (5-HT), also known as serotonin. 5-HT is 
then packaged into synaptic vesicles via vesicular monoamine transporter (VMAT; VMAT2 in 
CNS), and this 5-HT is released upon neuronal action potential propagation to the nerve bouton, 
where the synaptic vesicles fuse with the neuronal membrane, releasing the contents into the 
synapse. This 5-HT is then free to bind and activate pre and post-synaptic 5-HT receptors, which 
carry the signal propagation of a synaptic signaling event. The 5-HT neurotransmission is 
primarily terminated by presynaptic serotonin transporters (SERT), which utilize the Na+/Cl- ion 
gradient to transport 5-HT up its concentration barrier in a symporter manner. 5-HT is either then 
recycled, preserving the energy required for synthesis, or metabolized by monoamine oxidase 
(MAO) located upon the surface of mitochondria into 5-hydroxyindoleacetic acid (5-HIAA) 
(Figure 2).  
SERT (SLC6A4) belongs to the SLC6 gene family of Na+/Cl- coupled symporters that 
include the dopamine transporter (DA; DAT) and norepinephrine transporter (NE; NET), as well 
as γ-aminobutyric acid transporter (GABA, GAT1), glycine transporter, creatine transporter, and 
other amino acid transporters (Hahn and Blakely, 2007).  SERT rapidly clears 5-HT from the 
extracellular synaptic cleft following 5-HT synaptic release, resulting in a tightly controlled neural 
signaling event.  The serotonergic system is targeted by multiple drugs of abuse, including 3,4-
methylenedioxymethamphetamine (MDMA; ‘ecstasy’), lysergic acid diethylamide (LSD), 
dimethyltryptamine (DMT), psilocybin, as well as cocaine.   
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Figure 2. Biosynthetic Pathway of Serotonin. Biosynthetic pathway of serotonin (5-HT), and 
metabolism by MAO. The rate limiting step in the production of CNS 5-HT is the dietary delivery 
of tryptophan to the brain. Tryptophan is hydroxylated by TPH, forming 5-HTP, which is then 
decarboxylated by a general AADC enzyme, forming 5-HT. 5-HT is metabolized primarily by 
MAO, located intracellularly on the surface of the mitochondrial membrane, into 5-HIAA 
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While LSD, DMT, and psilocybin act as serotonin receptor agents, MDMA and cocaine 
target SERT. MDMA acts as a substrate for SERT, and like amphetamine for the dopaminergic 
system, acts to disrupt vesicular stores of 5-HT, causing 5-HT to pool in the neuronal bouton and 
allowing non-vesicular release of 5-HT into the synapse via efflux through SERT (Rudnick and 
Wall, 1992). Cocaine, in addition to major activity at DAT and minor activity at NET, acts as a 
transporter blocker, much like SSRIs, and with comparable affinity as other SERT blockers (Uhl 
et al, 2002). While most of the research into the behavioral and biochemical actions of cocaine are 
directed to its major activity at DAT, the activity of cocaine at SERT that could be essential for 
subtle neuromodulatory activity requisite for certain features of the drug, as for example the actions 
of cocaine to disrupt regulation of circadian rhythm (Prosser et al, 2014) as well as contributions 
to cocaine use and addiction (Howell and Cunningham, 2015).   
Disruptions in the serotonergic system, specifically SERT expression, have been observed 
in several psychological disorders noted for anxiety phenotypes, including obsessive compulsive 
disorder, autism, and depression.  Polymorphisms in the SERT promoter region have been 
discovered in human populations, and it has been shown that the short allele of the SERT promoter 
produces reduced transcription efficiency of SERT (Lesch et al, 1996). People who are 
homozygous or heterozygous carriers of the short allele of SERT display more depressive 
symptoms compared to those who were homozygous for the long allele promoter (Caspi et al, 
2003).  It was also shown in the same study that those with two copies of the short allele displayed 
increased sensitivity to life stressors, measured by risk for the development of depression, thus 
showing a gene-by-environment interaction for depression risk factors (Caspi et al, 2003).  As 
noted previously, several findings indicated that serotonergic tone was dramatically reduced in 
depressed individuals.  Pharmacological intervention strategies have shown that drugs that 
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increase serotonergic tone are effective antidepressants.  First generation tricyclic antidepressants 
target both SERT and NET, but had some untoward cardiovascular side effects due the 
enhancement of the noradrenergic (NE) system.  Thus new versions of antidepressants were 
generated and designed to remove the NE component, and thus spawned the second generation of 
antidepressants, the serotonin selective reuptake inhibitors (SSRIs). 
The primary treatment for those afflicted with depression diagnoses are serotonin (5-HT) 
selective reuptake inhibitors (SSRIs) (Blakely et al, 1998). SSRIs act to block the 5-HT transporter 
(SERT; 5-HTT), and by doing so prolongs 5-HT signal duration by inhibiting synaptic 5-HT 
clearance, and it is thought that this 5-HT signal enhancement, over time, produces antidepressant 
effects in the clinic. Patients diagnosed with depression, however, do not uniformly respond to 
SSRIs. In fact, roughly only two thirds of patients respond to the first administered SSRI 
antidepressant (Ananth, 1998; Souery et al, 2006), roughly 20% of afflicted patients are 
completely resistant to all SSRI antidepressant pharmacotherapies (Ananth, 1998; Souery et al, 
2006), and full remission of depression symptoms is not achieved in 50-75% of treated patients 
(Souery et al, 2006). Moreover, even in those patients who do respond to SSRI pharmacotherapy, 
no clinically significant effects occur until after 4-8 weeks of administration (Ananth, 1998; 
Warden et al, 2007). These clinical results raise questions regarding the serotonergic basis of 
depression and the mechanism of SSRI antidepressant efficacy, especially considering the 
mechanisms by which we know SSRIs function acutely are obviously not immediately responsible 
for clinical efficacy, as central nervous system (CNS) SERT inhibition by SSRIs occur in minutes 
whereby clinical efficacy requires weeks of SSRI treatment. Simply, this temporal disconnection 
of pharmacological effects and clinical efficacy illuminates that our understanding of the 
mechanisms of antidepressant suggests that our appreciation for how SSRIs produce 
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antidepressant actions are possibly more complicated than simply SERT antagonism. 
Alternatively, it could also mean that the adaptive changes following repeated SSRI administration 
require lengthy periods of time to produce an antidepressive state, all while being dependent upon 
5-HT signal enhancement. In order to better understand the complex nature of SSRI antidepressant 
efficacy and the 5-HT hypothesis of depression, let us explore how this theory came to be and how 
SSRIs were created to treat major depressive disorder. 
 
Early Treatments of Depression and Emergence of Psychopharmacology 
 
 The treatments that we develop for disorders of the body are largely crafted based upon the 
presentation of the disorder and the nature in which it debilitates the individual. While we can 
bandage bleeding wounds and brace broken legs, how does one remedy disorders of the mind? 
The presentation of depression and other mood disorders are much more gradient than physical 
maladies. There is no normal amount of regular human bleeding; a leg is either broken or it is not. 
Diagnosis of such mood disorders is complicated enough given that it requires an assessment of 
abnormal presentation of semi-regular human conditions. In short, the treatments for disorders of 
the mind cannot be as simple as disorders of the physical form. Unsurprisingly, the early treatment 
options for depression were highly experimental and questionably effective. While the most 
effective treatments stemmed from counseling efforts to find the psychological ‘root causes’ of the 
disorder (Freud, 1953), some aimed to reset the mind through convulsions (Payne and Prudic, 
2009) to a normal state as with electroshock therapy (while successful, its mechanism of action is 
still largely unknown), and others randomly tried a swath of biologically active chemical agents 
including lithium salts (Cade, 1949), barbiturates, amphetamines, and opiates, among other 
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questionably effective agents including lactic acid, succinic dinitrite, and malonic nitrite (López-
Muñoz and Alamo, 2009).  
Happenstance discoveries were not uncommon in this era of experimentation, though the 
careful observation and analysis of behavioral outcomes is responsible for the extraction of utility 
and development of future treatments.  The field of antidepressant pharmacology stems from many 
sequential chance discoveries. The origins of antidepressant pharmacology can be traced to a 
number of instances, though the importance of early chemistry must not be understated. German 
chemists Hans Meyer and Josef Malley synthesized isonicotinylhydrazide in 1912, mostly for the 
purpose of academic chemical derivatizations of hydrazine hydrate (López-Muñoz and Alamo, 
2009). Isonicotinylhydrazide was largely forgotten until the 1950s when German World War II 
stockpiles of hydrazine (utilized as rocket fuel (Sandler, 1990)) were distributed to scientists and 
industrial research groups at low cost for academic pursuits, when isonicotinylhydrazide was 
resynthesized and discovered later to have anti-tubercular properties in trials in 1951 by Harry 
Yale at Squibb and Herbert Fox at Hoffmann-La Roche (Sneader, 1985), and was later given the 
name Isoniazid (López-Muñoz and Alamo, 2009). Isoniazid spawned chemical derivatives for 
optimal human efficacy against tuberculosis, one of them being iproniazid (Figure 3)Error! 
Reference source not found.. It was this drug that was given to a small tuberculosis patient group 
to test this hypothesis of increased efficacy over isoniazid in New York in 1952. In this study, the 
practitioners observed much more pronounced psychological cognitive effects that they attributed 
to a side effect of the drug (Selikoff et al, 1952). Because of these reports on psychostimulation, 
iproniazid was later directly studied for its mood elevating properties as a direct endpoint of a 
clinical study, and was shown to act as an antidepressant, though this terminology was not utilized 
until later (Ayd, 1957; Crane, 1957).   
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Figure 3. Comparison of the Structures of Isoniazid and Iproniazid. Comparison of the structures 
of isoniazid and its derivative iproniazid. Isoniazid originated as a treatment for tuberculosis. 
Iproniazid was developed as an alternative treatment molecule, but also produced antidepressant-
like effects among tuberculosis patients, an effect that was not observed with isoniazid. It was 
discovered later that iproniazid acted additionally as a monoamine oxidase inhibitor (MAO; 
MAOI). MAO acts to degrade and metabolize 5-HT, and MAOIs prevent this 5-HT metabolism. 
The net effect of MAOIs with respect to 5-HT signaling is to prolong the serotonergic tone 
indirectly by increasing 5-HT levels. This mechanism is proposed for the antidepressant effect of 
MAOIs, and helped the 5-HT hypothesis of antidepressant effects in addition to the 5-HT 
hypothesis of depression. 
  
Isoniazid Iproniazid 
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Iproniazid was then subjected to clinical studies using patients with direct indications of 
depression and mood disorders, and following their successful completion, the drug was no longer 
solely prescribed for tuberculosis and was administered to an upwards of 500,000 people (Sneader, 
1985), indicating the large unmet pharmacological need for antidepressant medications. It was 
discovered that iproniazid coincidentally, but not isoniazid, could inhibit the recently discovered 
monoamine-oxidase (MAO) enzyme (Zeller et al, 1952), whose activity includes the oxidation 
and metabolism of 5-hydroxytryptamine (5-HT; serotonin) into 5-hydroxyindoleacetic acid (5-
HIAA). By inhibiting MAO, iproniazid could slow the metabolism of biogenic amines, including 
5-HT into 5-HIAA and trigger increases in brain levels of 5-HT, though it was unclear at the time 
whether this mechanism was responsible for the mood elevating qualities of iproniazid. 
Concurrently, it was discovered that the antihypertensive drug reserpine could produce depressive-
like symptoms as a side effect, and was also found to reduce 5-HT tissue levels (Pletscher et al, 
1955). Given these findings, effort proceeded in the development of intentionally designed MAO 
inhibitors (MAOIs) as antidepressant drugs (Ban, 2001; Sandler, 1990). These MAOIs found great 
clinical and commercial success, and further developments for lower toxicity (eg. reversible 
inhibitors) and toward pharmacological specificity for MAO-A (responsible for the metabolism of 
serotonin and norepinephrine) vs. MAO-B (largely responsible for metabolism of dopamine and 
trace amines) leading to improved versions of MAOIs for the treatment of depression. MAOIs, 
despite pharmacological advancements, were limited in effective dose range by drug interactions 
and toxicity, and additionally proved not to be the chemical magic bullet for the treatment of 
depression that clinicians had hoped; there were significant populations of people who met clinical 
thresholds for depression diagnoses, but were not successfully treated with MAOIs. Though the 
development of these first generation antidepressants represented a momentous advancement in 
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the field of psychopharmacology, specifically advancing the idea that modulation of brain 
chemistry could alter and alleviate psychological maladies, previously thought to be only remedied 
through intensive psychotherapy. The development of MAOI antidepressants indicated that it was 
possible to treat these disorders through chemical means, though their limited efficacy indicated 
incomplete knowledge of the disorders, but represented the most efficient means of 
pharmacological treatment to date. The early determination of the pharmacological actions 
impacting 5-HT and NE homeostasis would prove useful for future drug development and 
hypotheses related to the origins and optimal treatment of depression.   
Another important trajectory in the development of antidepressant pharmacology stems 
from the early investigations of antihistamines and antipsychotics. Based upon some research 
implying that antihistaminergic drugs could be useful as antipsychotics, researchers at Geigy 
Pharmaceuticals began synthesizing derivatives of iminodibenzyl (a tricyclic ring structure 
originally synthesized for potential use as a dye in textiles) (Schindler and Häfliger, 1954). These 
researchers found that functional consequences of their derivatives were largely due to the 
composition of the lateral chain additions of the molecule. One of these derivatives (G-22150) was 
sent to a local clinician, Ronald Kuhn, for testing in schizophrenic patients, but it was discovered 
to have poor efficacy. Interestingly, Kuhn noted an unexpected elevation of mood in the treated 
individuals (Shorter, 2008), though Geigy decided not to pursue the project. Interest was renewed 
when positive results were announced in 1952 for the efficacy of another molecule, 
chlorpromazine (later to be named thorazine), in the treatment of schizophrenia. In the wake of 
these findings, Geigy sent Ronald Kuhn more chemicals to test in his schizophrenic patient 
population. In 1956 they sent him G-22355, which possesses the same tricyclic ring structure as 
G-22150, but contains the same lateral N,N-dimethylpropanamine chain as chlorpromazine. G-
 13 
22355 unfortunately lacked any appreciable efficacy in schizophrenic patients, though Kuhn noted 
remarkable mood elevating effects in a smaller group of depressed patients (Kuhn, 1957). A larger 
study was performed to confirm Kuhn’s suspicions, and the positive results were presented in 1957 
(Kuhn, 1958). This compound was renamed to imipramine, and represented the first tricyclic 
antidepressant (Figure 4). Much like the discovery of iproniazid and the MAOIs, these results 
were entirely serendipitous.  
 
Biomechanistic Determinations of Antidepressant Efficacy 
 
After the introduction of imipramine and its clinical efficacy were widely observed, many 
other tricyclic derivatives soon followed onto the market to ride the coattails of the advancements 
made by imipramine. The clinical viability of iproniazid and imipramine further developed and 
solidified this novel concept that chemical agents could impact brain function and psychiatric 
disorders, using this new concept of biological psychiatry. This hypothesis triggered curiosities 
into the biochemical mechanisms of actions for these chemicals and how they produced their 
neuropsychiatric effects. Through the development of new imaging-mediated quantification 
techniques via the creation of spectrophotofluorimetry, it was then possible to accurately detect 
levels of monoamines in collected samples, which were suspected to be involved in the actions of 
these antidepressants. Through the use of this technique, it was observed that the previously 
identified phenomenon of reserpine causing depressive-like behaviors in animals correlated with 
the depletion in 5-HT and NE (Brodie et al, 1955; Curzon, 1990). Further studies determined that 
pretreatment of iproniazid alone could block the reserpine-induced reductions in brain serotonin 
as well as the sedative effects of reserpine (Chessin et al, 1957).  
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Figure 4. Structural Comparisons of iminodibenzyl, chlorpromazine, and G-22355. Comparisons 
of the structures of iminodibenzyl, chlorpromazine (better known as the antipsychotic thorazine), 
and G-22355 (better known by its later name imipramine). Iminodibenzyl was derivitized, seeking 
new antipsychotic, hypnotic, or antihistiminergic psychotropic drugs. One of these derivatives was 
crafted intelligently, based upon the southern nitrile tail of chlorpromazine, already known to be 
an effective clinical antipsychotic. The resulting compound G-22355 did not possess any 
antipsychotic effects, though patients treated with the compound displayed antidepressant effects 
after repeated administration. These effects were confirmed later with antidepressant evaluations 
as proper endpoint analyses, and stimulated the development of tricyclic antidepressants (TCAs). 
It was later discovered that TCAs block the reuptake of serotonin and norepinephrine.  
 
Iminodibenzyl 
G-22355 
(Imipramine) 
Chlorpromazine 
(Thorazine) 
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Additionally, iproniazid was shown to be able to increase levels of brain serotonin and 
norepinephrine (Besendorf and Pletscher, 1956). These studies were the first to suggest that certain 
neuropsychiatric disorders could be due to imbalance in brain monoamines, either due to low levels 
of serotonin, or norepinephrine, or both.  
It was at this point that certain advances in the field were made surrounding imipramine 
and the now growing family of other tricyclic antidepressants (TCAs). In a series of studies 
utilizing new radiochemical labelling, Julius Axelrod showed that pretreatment of imipramine and 
other TCA derivatives could block the uptake of [3H]-norepinephrine into nerve endings in 
peripheral tissues (Axelrod et al, 1961) as well as in intact rat brain (Glowinski and Axelrod, 1964). 
These studies supported the hypothesis that norepinephrine was being released and reabsorbed in 
a similar manner that had been observed in the periphery, and additionally, that imipramine and 
these TCAs functioned as reabsorption blockers. Earlier studies had shown that imipramine could 
reverse the pro-depressive effects of reserpine, and that these effects were lost when 
catecholamines (which include dopamine and norepinephrine) were depleted using alpha-
methylparatyrosine (AMPT; a selective antagonist of tyrosine hydroxylase, which is the rate 
limiting enzyme for the biosynthesis of the catecholamines dopamine and norepinephrine), 
indicating that norepinephrine was essential for the behavioral actions of imipramine. Taken 
together, these studies were seminal for the development of the norepinephrine hypothesis of 
depression, pioneered by Joseph Schildkraut, given that promoting norepinephrine signaling could 
produce antidepressant-like effects (Schildkraut, 1965). Clinical depression was posited to be the 
result of norepinephrine deficits, either due to levels of the hormone or another requisite 
component on the signaling cascade (Schildkraut, 1965). This hypothesis inspired such terms as 
‘chemical imbalance’ as a means to describe depression that is still somewhat in use today. 
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In parallel with the norepinephrine-directed line of research, converse efforts were being 
taken to test the other known functions of imipramine and the TCAs, namely their ability to 
modulate the serotonergic system. In parallel work corroborating the potential role of serotonin 
depletion in the pro-depressive behavioral actions of reserpine, studies with MAOIs showed that 
the pre-administration of tryptophan, a biosynthetic precursor to serotonin, could amplify the 
antidepressant-like effects of MAOIs in animals (Coppen et al, 1963). Mimicking the work 
performed upon norepinephrine uptake blockade, Arvid Carlsson showed that imipramine could 
also inhibit the uptake of serotonin into nerve terminals (Carlsson et al, 1968). Importantly, 
Carlsson noted in this study that the celebrated effect of imipramine to block norepinephrine 
uptake was much less potent than imipramine’s ability to inhibit the uptake of serotonin, 
suggesting that imipramine’s actions on serotonin homeostasis might be more significant clinically 
than its actions pertaining to norepinephrine. While these studies were highly important to the field 
from technical standpoints, more work was needed to link how imipramine and the TCAs were 
able to bring about their antidepressant effects, and by which neurotransmitter to perform those 
actions. 
The serotonin hypothesis of depression (and conversely the proposed mechanism for 
imipramine and TCA efficacy) began taking shape from these findings. They were also supported 
by various observations linking reduced concentrations of serotonin and its metabolite 5-HIAA in 
post-mortem brain samples of completed suicide victims (Shaw et al, 1967), as well as 
demonstrations of reduced cerebrospinal fluid levels of 5-HIAA in living depressed patients 
(Ashcroft et al, 1966). Moreover, there were mild clinical antidepressant effects of serotonin 
precursors tryptophan and 5-hydroxytryptophan (Coppen, 1967). Given these findings, a research 
team was assembled by Eli Lilly to embark on the development of new antidepressants targeting 
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the inhibition of serotonin reuptake pumps. These serotonin reuptake pumps were only known to 
exist through their function by this point and were not yet available in isolated nor concentrated 
preparations. A crucial development on this front was the invention of a technique by Victor 
Whittaker for the purpose of isolating and studying nerve terminals for the study of synapse-
enriched cellular components (Whittaker et al, 1964). Whittaker developed a technique by which 
these neurons would be mechanically ruptured at the point of disrupted cell membranes, and these 
budded nerve terminals would preferentially close back upon themselves encapsulating a 
functional nerve terminal. Through buffer optimization and centrifugal separation, Whittaker 
could isolate these nerve terminals, termed ‘synaptosomes’ (Whittaker et al, 1964).  
At this point, it was known that these serotonin reuptake pumps likely resided and were 
enriched in nerve terminals. Soloman Snyder adapted the synaptosomal technique to concentrate 
monoamine containing synaptosomes from the rest of the homogenized brain material for the 
purpose of studying synaptic reuptake pumps (Gfeller et al, 1971; Kuhar et al, 1970). Using these 
synaptosomes, Snyder and colleagues were able to determine with high resolution the kinetics of 
specific serotonin uptake through these reuptake pumps for the first time (Wong et al, 1973). Using 
the synaptosome preparation, Lilly’s team embarked on a directed high-throughput path towards 
rationally designing a serotonin reuptake blocker, leading to the development of the first serotonin 
selective reuptake inhibitor (SSRI), later to be known as fluoxetine (Prozac) (Wong et al, 1974).    
 
The Serotonin Transporter (SERT) and SSRIs 
 
 It is important to note that these discoveries and creation of the first specific serotonin 
reuptake inhibitor occurred only using nerve terminal concentrated populations and without the 
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aid purified transporter proteins or cloned transporter cDNAs. Through analyses of serotonin 
uptake kinetics (Wong et al, 1973) and pharmacological inhibition of serotonin uptake (Carlsson 
et al, 1968; Wong et al, 1974), it was likely that there was only a single specific serotonin transport 
pump responsible for the uptake of serotonin, though there was evidence for separate low affinity 
uptake mechanisms apart from this serotonin transporter (Shaskan and Snyder, 1970).  
 Researchers began to investigate the regional composition of this purported serotonin 
transporter and the serotonin pathway, by which SSRIs produce their behavioral effects. Initial 
early investigative efforts were built upon through technological advancements whereby studies 
could utilize autoradiographic and electron microscopic imaging to investigate where 
intraventricularly injected [3H]5-HT could be actively absorbed in the intact rodent brain 
(Aghajanian and Bloom, 1967), notably indicating the localization of the serotonergic neurons 
(here also showing that different types of neurons absorb serotonin or norepinephrine, 
respectively), and that serotonin [and norepinephrine] are predominantly absorbed into nerve 
terminals. Though it was known in some capacity that certain brain regions were more enriched 
with serotonin, this study confirmed those finding by finding high rates of [exogenous] serotonin 
absorption in the midbrain (Aghajanian and Bloom, 1967). Another study found high rates of 
serotonin absorption in rat brain slices containing hypothalamus, striatum, and cerebral cortex, as 
well as demonstrating a sodium dependent uptake process for both norepinephrine and serotonin 
uptake (Shaskan and Snyder, 1970). Other studies that utilized [3H]imipramine binding to localize 
fluoxetine competition sensitive serotonin transporter sites corroborated these findings, especially 
when known serotonin stores were localized to nerve terminals, by indicating high imipramine 
binding at midbrain, cortex, striatum, hypothalamus, and hippocampus, among others, as well as 
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corroborating low presence of serotonin in the cerebellum (Fuxe et al, 1983; Palkovits et al, 1981; 
Raisman et al, 1980). 
 Initial attempts to visualize the location of serotonin in the brain were aided by the creation 
of the histofluorescence technique, pioneered by Falck and Hillarp allowed for the fluorescent 
detection of endogenous monoamines in brain tissue (Carlsson et al, 1961; Falck et al, 1982; Falck 
and Torp, 1961). These approaches were adapted for the detection of serotonin, though this 
technique was plagued with limited fluorescent detection time (Sladek et al, 1974; Smialowska, 
1975; Stefano and Aiello, 1975). Another approach was taken to identify the location of 
serotonergic neurons via creation of antibodies against serotonin (Steinbusch et al, 1978). 
Immunohistochemistry approaches improved over earlier attempts to localize serotonergic 
neurons by targeting biosynthetic enzymes that synthesize serotonin (eg. tryptophan hydroxylase). 
In this effort, Steinbusch and colleagues created an antibody to serotonin using bovine serum 
albumin (BSA) linked to serotonin, injected into rabbits for polyclonal antibody creation, isolated 
the antibodies against serotonin (via affinity chromatography and saturation of antibodies against 
BSA with BSA), and applied that diluted antibody (recognizing serotonin) to rodent brain sections. 
Binding of the antibody to formaldehyde immobilized serotonin was detected with fluorescently 
labeled sheep anti-rabbit antibody [for photodetection methods], and revealed serotonin specific 
labeling and positive affirmation that the location of serotonin containing neurons and projections, 
including axons in the caudate nucleus (of the striatum), the dorsal horn of the spinal cord, and the 
raphe magnus nucleus (Steinbusch et al, 1978). Using this technique, Steinbusch further examined 
in fine detail the regional distribution of serotonin containing neurons and projections throughout 
the rodent brain (Steinbusch, 1981). 
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 While these studies were helpful to determine the likely site of action of SSRIs and the 
neurological subset of cells that they seemed to be acting upon, they did not solidly conclude the 
existence of the purported serotonin transporter, the site that was proposed that these TCA and 
SSRI antidepressants were acting. The discovery and identification of this protein gene product 
would further aid drug development for future antidepressants as well as highlight a new target for 
the study of the manifestations of depression and mood disorders. This opportunity was greatly 
advanced by the cloning of cDNAs encoding the norepinephrine transporter (NET) (Pacholczyk 
et al, 1991) and the γ-aminobutyric acid transporter (GABA; GAT1) (Guastella et al, 1990). The 
effort to clone the serotonin transporter was initiated using polymerase chain reaction (PCR) 
primers targeted to conserved regions of NET and GAT1, yielding a range of PCR products, among 
them partial clones of unknown genes that were sequenced and found to be have significant 
conservation of amino acid sequence conservation to NET (Blakely et al, 1991). One of these 
cDNA clones, rMB6-25, was produced in radiolabeled form to visualize the distribution of the 
complementary mRNA via in situ hybridization in rodent brain slices. Intense labeling was 
identified in the dorsal raphe, which had been known to contain highly enriched in serotonin and 
serotonin containing cell bodies (Steinbusch et al, 1978). A separate sequence of rMB6-25 was 
used to screened a rat cDNA library (from brainstem) using plaque hybridization. A positively 
identified plaque (BS4E-10) was isolated, and the phage insert cloned into a vector for mammalian 
cell expression. This vector was then transfected into HeLa cells, and these cells displayed 
saturable, Na+ dependent 5-HT uptake, as well as sensitivity to all major reuptake inhibitors, with 
known SSRIs (Blakely et al, 1991). The rMB6-25 identified cDNA was designated as the rat 
serotonin transporter (rSERT). 
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 When the primary sequences of the cloned transporters were compared, rSERT, hNET, and 
rGAT1 were found to share highly conserved regions, particularly those suggested to encode 
transmembrane alpha-helices. Additionally, some commonalities displayed among rSERT and 
hNET shared sequences are not present in rGAT1, which could be due to relative similarities of 
their substrate, as well as their shared interactions with TCAs (Blakely et al, 1991). The proposed 
structure of rSERT contains 12 transmembrane domains, cytoplasmic N- and C-termini (with a 
predicted phosphorylation site on the N-terminal tail, distal from the membrane), and a large 
extracellular loop 2 (with multiple predicted glycosylation sites). Other studies validated this 
model were purely using biochemical methods to validate SERT topography, until a three 
dimensional crystal structure was elucidated for the bacterial leucine transporter (LeuT), a genetic 
member of the solute carrier family (SLC), of which SERT and NET are members (Yamashita et 
al, 2005). The LeuT structure provided critical clues for the tertiary structure for these SLC 
transporters, with respect to transmembrane domain arrangement as well as the critical orientation 
and amino acid residues necessary for substrate recognition. Given familial level sequence 
homology between LeuT and hSERT, the three dimensional crystal structure of LeuT was used to 
design a predicted three dimensional model for SERT. Specifically, the electron space map the 
comprises the LeuT structure was used as a shell by which the linear sequence of SERT was 
inserted into the model, and given the known structure of LeuT and the presence of its domains in 
the structure, a homology based three dimensional structure for SERT was established (Jørgensen 
et al, 2007; Kaufmann et al, 2009; Ravna et al, 2006; Tavoulari et al, 2009). Based upon this 
predictive mapping and in vitro data confirmation, it was determined that Ile172 and Tyr95 were 
integral for the high affinity binding of SSRIs at SERT, among other structural discoveries (Henry 
et al, 2006; Kaufmann et al, 2009; Ravna et al, 2006; Tavoulari et al, 2009).  
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The Serotonin Hypothesis of Depression 
 
The link between 5-HT and depression had been initially postulated based upon the 
antidepressant efficacy of enhancing serotonergic signaling via serotonin reuptake inhibitors 
(TCAs and SSRIs). As such, researchers began to investigate the converse argument, namely 
whether clinical depression correlated with the presentation of lowered basal serotonin, ie. whether 
depression was due to a chemical imbalance and deficits in serotonin. These clues led investigators 
to examine whether depressed individuals display any aberrations in 5-HT homeostasis. 
The first observations were directed towards patients with the most severe forms of 
depression.  Researchers examined the brain concentrations of 5-HT in suicide victims and control 
samples; multiple research groups found significant reductions in brain 5-HT in the suicide victims 
compared to the control samples (Lloyd et al, 1974; Pare et al, 1969; Shaw et al, 1967).  Further 
investigations found that cerebrospinal fluid (CSF) levels of 5-hydroxyindoleacetic acid (5-HIAA; 
the primary metabolite of 5-HT) were inversely correlated with the severity of depression in a 
living sample, and overall levels of CSF 5-HIAA in depressed individuals were lower than a 
control sample (Asberg et al, 1976).  Moreover, among those in the study that had attempted 
suicide, CSF 5-HIAA levels were inversely correlated with the severity of the violent nature of the 
suicide attempt (Asberg et al, 1976).  Further analyses discovered links to depression and the 
expression of the serotonin transporter (SERT), which is a key component in the termination of 5-
HT signaling in the brain.   
SERT is also present in the gut and platelets, and is involved in non-psychological 
processes of gut motility and platelet aggregation, respectively (Mawe and Hoffman, 2013).  These 
other sites of SERT expression can be useful for relatively non-invasive biomarker screens directed 
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at SERT related disorders.  This approach was taken to examine SERT expression levels in 
untreated depressed individuals (Briley et al, 1980).  Blood was collected from the untreated 
depressed sample along with untreated non-depressed age matched individuals, and SERT 
expression was measured using [3H]-imipramine binding.  It was found that the depressed sample 
had significantly lower maximal [3H]-imipramine binding than the control sample, meaning that 
SERT expression on platelets was lower in the depressed sample than the non-depressed control 
sample (Briley et al, 1980).  Several studies have replicated this finding, and it was presumed that 
similar mechanisms could be involved that control SERT expression in the brain as are in platelets, 
implicating the potential for using platelet SERT expression as a biomarker approach for the 
diagnosis of depression (Owens and Nemeroff, 1994).  Other approaches seemed to support the 
assertion that platelet SERT expression was not only decreased in depressed individuals, but could 
be predictive of brain SERT expression.  Post mortem analyses were able to confirm these 
suspicions, and showed that SERT expression was significantly reduced in depressed individuals 
compared to a control sample, using [3H]-cyanoimipramine audioradiographic imaging techniques 
(Arango et al, 1995; Mann et al, 2000; Owens and Nemeroff, 1994).  More advanced techniques 
utilizing positron emission temography in addition to radiolabeled SERT ligands found similar 
reductions in SERT expression in living untreated depressed individuals compared to untreated 
non-depressed control samples (Malison et al, 1998; Willeit et al, 2000).  Additionally, it was 
found that dietary restriction of tryptophan (a 5-HT precursor) could trigger a relapse of depression 
in an at-risk patient sample (Bremner J et al, 1997; Delgado et al, 1990; Smith et al, 1997). Patients 
that had been successfully treated with SSRIs were given diets that were devoid of tryptophan, an 
obligate necessary dietary amino acid that is synthesized into serotonin. These patients rapidly 
relapsed into a depressive-like state. These findings sculpted the hypothesis that depression either 
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coincided with—or is caused by—disruptions in serotonergic tone.  Pharmacological approaches 
would then aim to restore serotonergic tone for the treatment of depression; the most direct 
mechanism for accomplishing this seemed to be for targeted inhibition of SERT.  
 
Serotonergic Mechanisms Contributing to SSRI Antidepressant Efficacy 
 
Much of the initial work on the evaluation of antidepressant drug action began with the 
examination of serotonergic neuronal morphology and the macronetwork of serotonergic fiber 
innervations. Following the discovery of SERT and the regional distribution of serotonergic 
neurons and fiber projections, attention was turned to the identification of important biological 
responses and requirements involved in the antidepressant response.  Serotonergic raphe neurons 
mediate their own firing rate via autoreceptors, due in part to the somatodendritic serotonin 1A (5-
HT1A) autoreceptor (Hjorth et al, 2000).  5-HT1A receptors are 7-transmembrane G-protein coupled 
receptors (GPCRs) that couple to Gαi/o, which are inhibitory in nature, by preventing neuronal 
firing and 5-HT vesicle mediated release (Barnes and Sharp, 1999).  These autoreceptors 
counteract the actions of SSRIs by inhibiting raphe firing rates after activation by 5-HT; when 
SSRIs mediate the elevation of extracellular levels of 5-HT, this in turn mediates the increased 
activation of these inhibitory autoreceptors, thus offsetting the actions of SSRIs (Blier, 2003).  
Much attention has been given to this issue, as well as the adaptations in these systems that occur 
alongside behavioral/clinical efficacy.  It has been observed that 5-HT1A receptors are eventually 
desensitized over the course of a few weeks, which could explain the delayed efficacy of SSRIs 
(Blier, 2003; Blier et al, 1987; Hensler, 2002; Le Poul et al, 1995).  Interestingly, 5-HT1A receptor 
desensitization was not the result of decreased surface expression of 5-HT1A receptor, but rather 
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due to a decreased coupling efficiency, measured by 5-HT1A receptor-stimulated [
35S]GTPγS 
binding (Hensler, 2002).  The hypothesis that 5-HT1A receptor desensitization is required for the 
efficacy of SSRIs was further tested after the creation of the 5-HT1A receptor knockout mouse.  
These mice displayed reduced basal immobility in the tail-suspension test (TST) compared to WT 
controls, and displayed no further decrease in immobility after fluoxetine or paroxetine treatment 
at doses that produced effects in WT mice (Mayorga et al, 2001).  These data show that mice 
lacking 5-HT1A receptors may display a basal ‘antidepressive’ phenotype, but also suggest that 5-
HT1A receptors may be necessary for the acute effects of SSRIs (Mayorga et al, 2001).  5-HT1A 
receptor KO mice are also unresponsive to chronic SSRI administration in the novelty-suppressed 
feeding paradigm (Santarelli et al, 2003).  The 5-HT1A receptor KO mouse globally eliminates 5-
HT1A receptors, which includes not only autoreceptors but postsynaptic receptors as well, so the 
behavioral effects of 5-HT1A receptor KO mice cannot be solely attributed to the lack of raphe 
neuronal autoinhibition.  These data illustrate one potential explanation of delayed SSRI efficacy, 
and overall, indicate the importance of 5-HT1A receptors on the behavioral efficacy of SSRIs. 
Another important observation provides further clues to the nature of neurological 
aberrations that are a result of—or caused by—depression.  It was reported that hippocampal 
volume was significantly decreased in subjects diagnosed for major depressive disorder (MDD) 
compared to age- and sex-matched healthy controls, using magnetic resonance imaging (MRI) and 
subsequent image size analysis (MacMaster and Kusumakar, 2004).  Many research groups had 
already observed that rodents display adult neurogenesis in various regions of the brain, including 
the hippocampus (Gage et al, 1998), though it was thought to be a rodent-selective feature. 
Though, in other animal studies, researchers found that extended stress paradigms led to decreases 
in hippocampal volume, and could be reversed via antidepressant treatment, displaying parallels 
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to the human findings (Czéh et al, 2001; Murray et al, 2008).  This line of research is largely 
influenced by a seminal study that showed that human hippocampal neurogenesis can occur into 
and through adulthood (Eriksson et al, 1998).  Further studies have shown that antidepressant 
treatment stimulates the production of hippocampal neural progenitor cells, measured in post-
mortem brain tissue of depressed individuals compared to both untreated depressed subjects and 
non-depressed untreated subjects (Boldrini et al, 2009).  These results highlight interesting effects 
of chronic antidepressant administration, but they cannot indicate that hippocampal neurogenesis 
is required for antidepressant efficacy.  In order to test for efficacy, studies were performed that 
both chronically dosed SSRIs and blocked hippocampal neurogenesis.  When hippocampal 
neurogenesis was prevented via focal X-ray irradiation of hippocampal progenitor cells, the 
behavioral efficacy of chronic SSRI was blocked in the NSF assay (Santarelli et al, 2003).  In this 
same study, the researchers also tested 5-HT1A receptor KO mice—which are unresponsive 
behaviorally to chronic SSRI administration—and those mice did not exhibit the same increase in 
hippocampal neurogenesis as do WT mice under the same chronic SSRI administration paradigm 
(Santarelli et al, 2003).  These data suggest that the 5-HT1A receptor may be necessary for the 
SSRI mediated stimulation of hippocampal neurogenesis, as well as behavioral efficacy.  
Hippocampal neurogenesis may be required for SSRI behavioral efficacy, but do not seem to be 
required for the efficacy of tricyclic antidepressants, CRF-R antagonists, nor vasopressin 
antagonists (Santarelli et al, 2003; Surget et al, 2008).  Altogether these findings provide the 
strongest evidence for a requirement of hippocampal neurogenesis for SSRI antidepressant 
behavioral efficacy, that SSRI action is mediated via 5-HT signaling, and can support the delay in 
SSRI clinical efficacy as arising from delayed neurogenic processes that occur on the same 
timescale as behavioral/clinical efficacy (van Praag et al, 2002). 
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It has also been shown that several antidepressant strategies ranging from exercise, 
pharmacological intervention, and electroshock therapy enhance hippocampal neurogenesis in the 
critical SGZ of the hippocampus (Malberg et al, 2000; van Praag et al, 1999; Scott et al, 2000), 
and do so through enhancement of division of neural progenitor cells (Encinas et al, 2006). 
Electroshock therapy and antidepressant treatments also potentiate the expression of brain-derived 
neurotrophic factor (BDNF) mRNA and protein in rat hippocampus (Altar et al, 2003; Russo-
Neustadt et al, 2000).  Peripheral administration of BDNF has also been shown to produce 
antidepressant effects in the novelty suppressed feeding assay (NSF), the forced swim task (FST), 
unpredictable chronic mild stress (UCMS), and in the elevated plus maze (EPM) (Schmidt and 
Duman, 2010).  The BDNF receptor trkB neurotrophin receptor has been shown to be rapidly 
activated after acute administration of SSRI and seems to be required for behavioral efficacy 
(Saarelainen et al, 2003).  These effects do not seem to be simply due to increasing cell number; 
chronic stress paradigms, like those used to induce a ‘depressed’ state in animals, show that while 
there is a decrease in hippocampal volume, the effect is not due to reduction in hippocampal cell 
number (Lucassen et al, 2001; Müller et al, 2001).  Comparable findings showed that stress induces 
dendritic remodeling of CA3 pyramidal neurons, reduces the number of synapses on those neurons, 
and impairs neurogenesis in the dentate gyrus (Fuchs et al, 2006).  Other studies have suggested 
similar mechanisms for their findings, namely that neurogenesis and dendritic spine growth could 
be involved in SSRI response (Costa e Silva, 2004; D’Sa and Duman, 2002).  These findings 
strongly suggest a neurotrophic effect of SSRI efficacy (Castrén, 2004).  Although the evidence is 
strong that hippocampal neurogenesis is required for SSRI antidepressant efficacy, further studies 
need to be performed to establish the pathway leading from increased 5-HT signaling to 
hippocampal neurogenesis. 
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Serotonergic Evidence of SSRI Efficacy by Direct Receptor Analysis 
 
 As noted above, mechanistic determination for the molecular actions of SERT antagonist 
based antidepressant began long prior to the molecular cloning of SERT. Through the analyses 
that drugs or treatments that reduced 5-HT tone could produce depressive-like effects and drugs 
and treatments that enhanced 5-HT tone could produce antidepressive-like effects helped solidify 
the role of 5-HT system disruption in depression pathology. Due to the serendipitous discovery of 
reuptake based antidepressants, primarily considering the serotonergic system and SERT, 
serotonin specific reuptake inhibitors (SSRIs) are the most general and means of ubiquitous 
enhancement of serotonergic signaling. This strategy, however, does not provide much direction 
to the specificity of the effects, and by which 5-HT receptor—or receptors—is the antidepressant 
effect of serotonergic signal enhancement enacted. It may be of great scientific interest to 
investigate which receptors, or set of receptors, is responsible for the antidepressant effect of 
SSRIs, as this determination could allow for more targeted approaches in the future that could 
bypass the delay in antidepressant clinical efficacy and/or improve the side effect profile of future 
antidepressant drugs. 
 Following sufficient SSRI induced SERT blockade, 5-HT levels elevate in the synapse and 
activate pre- and post-synaptic serotonin receptors.  There are 7 main types of 5-HT receptors, of 
which there exist subfamilies within some types, totaling over 20 different kinds of 5-HT receptors 
in the mammalian system, not including RNA edited 5-HT receptors (Fitzgerald et al, 1999). All 
but one of these are 7-transmembrane G-protein coupled receptors (GPCRs), the exception being 
the 5-HT3 receptor, which is a ligand gated ion channel (Table 1).  
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 The 5-HT1A receptor has received much attention with respect to the actions of SSRIs as it 
is the main autoreceptor for serotonergic neurons, regulating the firing rate of 5-HT neurons by 
negative feedback (Barnes and Sharp, 1999). 5-HT1A receptors are coupled to Gαi, which inhibits 
the activity of adenylate cyclase, thus acting as a negative regulator of synaptic firing and signal 
propagation via cAMP and PKA pathways. The delay in SSRI clinical efficacy is thought to be 
due to the counterproductive initial diminishing of serotonergic firing rate, as SSRI mediated 
SERT blockade and enhancement of post-synaptic 5-HT receptor signaling will activate 5-HT1A 
autoreceptors and suppress the firing rate of serotonergic neurons, diminishing overall serotonergic 
signaling tone (Le Poul et al, 1995). Chronic and clinical SSRI efficacy is thought to be the result 
of, in part, 5-HT1A desensitization, allowing these medications to potentiate 5-HT signaling 
following a recovery of normal firing rates. In support of this idea, recovery from 5-HT1A receptor 
desensitization follows the timecourse of chronic SSRI efficacy (Le Poul et al, 1995). 5-HT1A 
receptors also exist postsynaptically, where they act in regulatory manners on non-serotonergic 
neurons, and this may be involved with the SSRI response. 5-HT1A receptor global knockout mice 
are behaviorally insensitive chronically to SSRIs and additionally do not display increased 
proliferation of hippocampal stem cells, a trait that is required for chronic SSRI behavioral efficacy 
(Santarelli et al, 2003). When targeted specifically with direct agonism at 5-HT1A, WT animals 
display an antidepressive-like effect in the forced swim test (FST) (Detke et al, 1995; López-
Rubalcava and Lucki, 2000; Robinson et al, 1990).  
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Table 1. Highlighted Major 5-HT Receptors. Table displays their major subtypes and Gα 
couplings, if applicable, and the functional result of their activation. 
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Though, when a 5-HT1A receptor antagonist was added to the SSRI fluoxetine, the decrease 
in immobility is enhanced in the FST (Detke et al, 1995). These findings suggest a complicated 
role of 5-HT1A receptors in the antidepressant like effects of SSRIs, though this could be a result 
of various 5-HT1A selective ligands having preference for pre- versus post-synaptic 5-HT1A 
receptors with unknown mechanism (Lladó-Pelfort et al, 2010), which could explain the 
differential effects of these different ligands in various assays. Though different experiments yield 
conflicting results regarding the utility of 5-HT1A in antidepressant efficacy and in the 
antidepressant activity of SSRIs, these data show the important role of the receptor in the ability 
to regulate antidepressant-like effects in vivo.  
 Another important receptor in the actions of SSRI actions is the 5-HT2C receptor. The 5-
HT2C receptor is a GPCR coupled to the Gαq G-protein, which, upon 5-HT2C receptor activation, 
activates PLC which cleaves PIP2 to IP3 (which stimulates the release of intracellular Ca
2+ stores) 
and DAG (which activates PKC along with increased Ca2+ levels). 5-HT2C receptor agonists, like 
SSRIs, induce significant decreases in immobility time in the FST (Cryan and Lucki, 2000). 
Importantly, 5-HT2C receptor antagonists pretreatment blocked the immobility inducing effects of 
fluoxetine (Cryan and Lucki, 2000). Additionally, 5-HT2 receptors are implicated for the 
regulatory role in hippocampal neurogenesis (Klempin et al, 2010). These studies show that 5-
HT2C signaling is critical for early phase SSRI antidepressant-like effects, and suggest that specific 
5-HT2C receptor agonists might serve as effective antidepressants on their own. 5-HT2C could serve 
as a viable pharmacological target for future antidepressants, though it has largely been avoided 
due to the high homology to the 5-HT2 receptor subtypes, specifically 5-HT2A, which often has 
oppositional effects (Bressa et al, 1987), as well as the potential for untoward clinical effects due 
 32 
to a role of 5-HT2A/2C in the hallucinatory effects brought about by LSD, psilocybin, and DMT 
(Baumeister et al, 2014; Cussac et al, 2008). 
 Other studies have highlighted the role of 5-HT1B in the actions of SSRIs. 5-HT1B, like 5-
HT1A, is a Gαi coupled GPCR. 5-HT1B specific agonists have been shown to possess 
antidepressant-like effects in the FST (Tatarczyńska et al, 2005), and antagonists of 5-HT1B 
receptor, block the SSRI induced decrease in immobility in the FST (Chenu et al, 2008).  
5-HT4 receptor agonism is also capable of producing antidepressant-like effects (Lucas et 
al, 2010). 5-HT4 is a Gαs coupled GPCR, that when activated, stimulates the activity of adenylate 
cyclase, which elevates levels of cAMP, activating PKA pathways and promoting signal 
propagation. Additionally, targeting other 5-HT receptors have been shown to be capable of 
producing antidepressant-like effects. Of note, antidepressant-like effects can be generated via 
antagonism of 5-HT2A (Patel et al, 2004), 5-HT3 (Ramamoorthy et al, 2008), and 5-HT7 
(Wesołowska et al, 2006) receptors.  
These data reinforce the importance of serotonergic signaling in both antidepressant-like 
effects alone in addition to their role in SSRI produced antidepressant-like effects. These effects 
provide evidence that SSRIs mediate their effects through 5-HT receptors, albeit globally. Due to 
the antidepressant-like effects that are generated via blockade of 5-HT2A, 5-HT3, and 5-HT7 
receptors, engagement of these targets via global enhancement in serotonergic signaling via SSRI 
treatment may actually be deleterious to the desired antidepressant effect. In fact, agonists of 5-
HT3 receptor block the effect of SSRIs in the FST (Nakagawa et al, 1998). Future antidepressant 
drug development may aim to selectively target the desired 5-HT receptors and either avoid or 
antagonize these pro-depressive receptors for a better range of efficacy. In this aim, a newly 
approved antidepressant, vortioxetine, possesses activity at SERT (blocker), 5-HT1A (agonist), 5-
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HT1B (partial agonist), 5-HT3 (antagonist), and 5-HT7 (antagonist), all in the aim of attaining faster 
clinical efficacy (Guilloux et al, 2013; Mørk et al, 2012). Vortioxetine is discussed in detail in 
Chapter 5, though this novel approach represents an approach to update serotonin based 
antidepressants using modern research directives catering to the multifaceted roles of serotonin in 
the brain.   
 
SERT-Independent Targets of SSRIs 
 
 SSRIs, despite the eponymous claim to specificity, are sufficiently promiscuous in their 
off-target actions to warrant evaluation of other targets besides SERT (Bianchi, 2008; Owens et 
al, 1997).  The prevailing thought deemed these off-target binding events are suggested to 
contribute towards SSRI side-effect profiles.  At face value, this seems appropriate, but it is 
important to consider first how drug selectivity screens are generally performed.  Most screens are 
limited to a select panel of targets due to cost limitations, and binding events with a kD higher than 
1 μM are generally discarded (Bianchi, 2008).  This practice is problematic when it comes to SSRIs 
in particular, because upon normal dosing paradigms, central nervous system (CNS) 
concentrations of SSRIs are estimated to range from 1-10 μM (Karson et al, 1993).  Taking into 
consideration this expanded window of potentially relevant binding events, many more targets 
should be considered as relevant to antidepressant mechanisms.  SSRIs and their metabolites bind 
to—and modulate—a sizable number of non-trivial targets at physiologically relevant 
concentrations, which could be contributing to efficacy (Bianchi, 2008; Owens et al, 1997).  These 
targets include multiple voltage gated ion channels, activation of GABA-A receptors, inhibition of 
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nicotinic acetylcholine receptors (nAChR), and activity at various serotonin receptors (Bianchi, 
2008; Owens et al, 1997; Zhang et al, 2010).   
One prominent example of the potential contribution towards efficacy is the inhibition of 
TREK-1 channel, which is a widely expressed potassium channel.  These channels contribute to 
the leak current, are regulatable, and are heavily expressed in areas relevant to antidepressant 
mechanisms, including hippocampus, cortex, striatum, amygdala, and hypothalamus (Heurteaux 
et al, 2006).  It has been found that fluoxetine (and its metabolite norfluoxetine), sertraline, and 
paroxetine all inhibit the TREK-1 channel and have IC50’s well within the predicted brain 
concentration for SSRIs (Bianchi, 2008).  TREK-1 KO mice display a basal antidepressive 
phenotype, and appear behaviorally insensitive to SSRIs (Heurteaux et al, 2006).  Interestingly, 
these mice still exhibited an enhancement in hippocampal neurogenesis, and displayed even 
stronger SSRI potentiated hippocampal neurogenesis than WT control mice (Heurteaux et al, 
2006).   
It has also been shown that certain SSRIs can activate σ-1 receptors, and that directed 
activation of the σ-1 receptor is sufficient for antidepressant-like actions, with effects blocked by 
specific σ-1 receptor antagonists, and are absent in σ-1 receptor KO mice (Villard et al, 2011; 
Wang et al, 2007).  Furthermore, σ-1 receptor activation can potentiate NGF driven neurite 
outgrowth, effects that are prevented with specific σ-1 receptor antagonists (Nishimura et al, 
2008).  On this note, the SSRI citalopram induces neurite outgrowth in embryonic thalamic 
explants, effects due to its activation of the σ-1 receptor (Bonnin et al, 2012). The growth 
promoting effects of citalopram can be blocked by a σ-1 receptor antagonist, and are retained in a 
citalopram insensitive mouse line (SERT Met172) (Bonnin et al, 2012). 
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The SSRI sertraline has been shown to be biologically active in yeast, despite the fact that 
yeast do not express any version of SERT (Rainey et al, 2010). Furthermore that sertraline was 
able to inhibit PLA1, PLC, and PLD while stimulating PLA2 in vitro (Rainey et al, 2010).  PLA2 
has been implicated in the antidepressant effects of maprotiline (a norepinephrine reuptake 
inhibitor; NRI) (Lee et al, 2011), and PLCβ & PLCγ inhibition produces an antidepressant effect 
in the forced swim task (FST) (Galeotti and Ghelardini, 2011).  Sertraline has also been shown to 
activate the glucocorticoid receptor and lead to hippocampal neurogenesis, and that this effect 
could be blocked with a glucocorticoid receptor antagonist (Anacker et al, 2011).    
SSRIs also have activity directly at 5-HT receptors (Owens et al, 1997; Zhang et al, 2010), 
which, when these 5-HT receptors are stimulated directly, can produce antidepressant-like effects 
on their own. If SSRIs can produce antidepressant effects directly through their actions at 5-HT 
receptors, then SERT might not be required for their activity. Additionally, certain SSRIs have 
activity at alpha-1 and alpha-2 receptors (Owens et al, 1997). These receptors are norepinephrine 
receptors, and though not the focus of this document, norepinephrine signal enhancement is 
sufficient to produce antidepressant effects (Lee et al, 2011; Santarelli et al, 2003; Sulser, 1984), 
like serotonin, though serotonin has garnered the majority of the research focus due to the 
biological links to the chemical and the clinical presentation of depression.  
Certain SSRIs display high affinity for muscarinic acetylcholine receptors (mAChR) 
(Owens et al, 1997; Snyder and Yamamura, 1977) as well as the nicotinic acetylcholine receptor 
(nAChR) (García-Colunga et al, 1997). Nicotinic acetylcholine receptors have been proposed to 
be a new target for antidepressant development, as their targeting can produce antidepressant-like 
behavioral effects (Shytle et al, 2002). Scopolamine, a muscarinic receptor agonist, has also been 
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demonstrated to have antidepressant activity, particularly for the rapid treatment of depression 
(Drevets et al, 2013).  
As noted above, there is significant crossover of antidepressant effects from multiple 
monoaminergic systems. Selective norepinephrine reuptake inhibitors (eg. desipramine) and 
agents that target dopamine receptors (eg. pramipexole) exist as clinically viable antidepressants 
in their own right, as well as the importance of the mesolimbic dopaminergic system in depression 
pathophysiology (Nestler and Carlezon, 2006). On this note, it is important to illuminate that these 
monoaminergic reuptake proteins have significant substrate affinity crossover, leading to 
situations whereby SERT can feasibly uptake dopamine, where it can be packaged alongside 5-
HT in vesicles (Larsen et al, 2011), as well as the potential for 5-HT uptake via dopamine and/or 
norepinephrine transporter (DAT; NET) (Daws, 2009). The SSRI fluoxetine, at the high doses 
required for clinical efficacy, can also induce elevations in norepinephrine and dopamine levels 
(Koch et al, 2002). The SSRIs paroxetine, sertraline, and fluoxetine all possess moderate affinity 
for NET and DAT, indicating a potential role for non-SERT effects of their actions supporting 
antidepressant mechanisms (Owens et al, 2001).   
These findings described above raise an interesting possibility, namely that these off-target 
effects of SSRIs may contribute to, or drive antidepressant efficacy of SSRIs.  It is not known how 
important these effects are to the overall efficacy of SSRIs, since it has been impossible to separate 
the 5-HT based mechanisms of SSRIs from these off-target effects. Alternatively, these non-SERT 
actions of SSRIs could be contributing to the extent or magnitude of effects driven by SERT 
antagonism.  
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The SERT Met172 Mouse Model for Measuring 5-HT Dependence  
 
 In order to distinguish off-target effects from 5-HT dependent effects, initial attempts 
utilized mice possessing a genetic deletion of the serotonin transporter gene (SERT KO).  Although 
a seemingly appealing strategy, these animals display major compensatory alterations that limit 
their utility as an animal model (Baganz et al, 2008; Kalueff et al, 2010; Murphy and Lesch, 2008).  
These SERT KO animals display a dramatic reduction in brain in 5-HT levels (Bengel et al, 1998), 
5-HT neurons (Lira et al, 2003), expression of various 5-HT receptors (Cour et al, 2001; Fabre et 
al, 2000; Li et al, 2000; Rioux et al, 1999), and changes dorsal raphe firing rate (Lira et al, 2003).  
These changes also impact basal behavior; SERT KO mice display spontaneous ‘depressed’ 
phenotypes in various behavioral assays (Lira et al, 2003), including an unusual basal ‘learned 
helplessness’ phenotype whereby SERT KO mice require no training to produce escape failures in 
the shuttlebox assay, whereas WT mice do require training (Caldarone et al, 2000; Vaugeois et al, 
1996).  These aberrations in normal neurobiology and behavior make it extremely difficult to link 
the subtle effects of SSRIs and extrapolate to the context of normal physiology of serotonin 
neurons and their synapses. 
 Our lab realized that to pursue the separation of 5-HT and off-target effects of SERT 
blockers, including SSRIs, a mouse model was needed that could reduce SSRI interactions at 
SERT without any disruptions of normal physiology or the serotonergic network.  Such a model 
essentially required disruption of SERT binding for SERT targeted drugs, but not for 5-HT.  It has 
been observed that human and Drosophila melanogaster SERT (hSERT and dSERT, respectively) 
display markedly different sensitivities to most SSRIs while having similar 5-HT transport 
abilities.  Through a careful set of mutagenesis experiments, our lab discovered that the species 
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dependence of SSRI sensitivity could be attributed to variation at a single amino acid residue in 
the inner pore structure of the transporter proximal to the predicted 5-HT binding site (I172 in 
human and mouse, M167 in fly) (Henry et al, 2006) (Figure 5) (Figure 6).  Mutating I172 in 
hSERT and mSERT to Met172 could recapitulate the dramatic reduction in inhibition efficacy for 
many SERT antagonists as is seen in dSERT, without affecting 5-HT transport (Henry et al, 2006). 
Interestingly, paroxetine displays highly potent inhibition of dSERT as well as hSERT and 
mSERT, and is unaffected by the I172M substitution (Henry et al, 2006). Additionally, mutating 
dSERT to the respective mammalian amino acid (M167I) produces a gain in SSRI potency (Henry 
et al, 2006). With this knowledge, our lab then created a mouse with the I172M substitution in 
SERT (Thompson et al, 2011).  These mice displayed normal growth, normal SERT expression, 
and no overt morphological differences or basal phenotype (Thompson et al, 2011).  The mice also 
displayed normal 5-HT uptake, 5-HT clearance rate, and 5-HT induced reductions in raphe firing 
rates (Thompson et al, 2011).  As expected, ex vivo synaptosomal analyses revealed that this 
mutation rendered dramatic reductions in inhibition efficacy of [3H]5-HT uptake for many SERT 
blockers (Thompson et al, 2011).  Consequently, these SERT Met172 mice do not exhibit normal 
increases in extracellular 5-HT after citalopram or fluoxetine administration (20 mg/kg, i.p.) as 
measured by in vivo microdialysis, displayed no reduction in dorsal raphe firing rate after 
administration of 1 μM citalopram in ex vivo slice recordings, and displayed no alterations in 5-
HT clearance rate after administration of citalopram and fluoxetine (Thompson et al, 2011).  Next, 
our lab assayed for behavioral sensitivity to SSRIs in the forced swim task (FST) and the tail 
suspension test (TST), which have predictive validity for monoaminergic antidepressants and are 
sensitive to acute antidepressant administration (Lucki et al, 1994).  The results of these studies 
were not completely clear.   
  
 39 
 
 
 
 
 
 
 
 
Figure 5. Sequence Alignment of SERT Protein. Linear sequence alignment of various SERT 
proteins across phylogeny, highlighting transmembrane 3 domain of SERT. Membrane primary 
structure displays high sequence conservation across this transmembrane region. Highlighted is a 
prominent example of a sequence variant seen in drosophila at position 172. The drosophila SERT, 
while displaying capable uptake of 5-HT, it displays disrupted affinity for many SERT blockers. 
This lowered affinity can be attributed to this single amino acid substitution Ile172Met. 
  
Modified from: Henry, L. K. et al. J. Biol. Chem. 2006;281:2012-2023 
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Figure 6. Structure of SERT with I172M Substitution. A. 2D Structure of SERT, Based upon 
LeuT Structure. Two dimensional homology model mapping of SERT, based upon the LeuT 
crystal structure. These data align with previous predictions made upon the cloning of the rodent 
SERT, that the protein contains 12 transmembrane domains. Highlighted is the position of amino 
acid 172, and the position of the Ile172Met substitution, derived from the dSERT studies. When 
this flattened model is remapped onto three dimensional space, Ile172 is positioned directly 
adjacent to the predicted ligand (both SSRI and 5-HT) binding site (“L” triangle, above), and 
required for high affinity binding of SERT blockers at SERT. The drosophila SERT, where our 
model intellectually originated, while displaying capable uptake of 5-HT, it displays disrupted 
affinity for many SERT blockers. This lowered affinity can be attributed to this single amino acid 
substitution Ile172Met. B. 3D homology model of hSERT with computational binding of s-
citalopram. The I172M substitution perturbs structural binding potential for s-citalopram in 
hSERT, predicted to reduce affinity for the drug for SERT Met172 
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Whereas the SERT Met172 mice displayed a lower change in immobility in the TST 
compared to WT animals following treatment with the SSRIs citalopram and fluoxetine, these 
results did not attain significance (Thompson et al, 2011).  Furthermore, when tested in the FST, 
WT animals responded with significant increases in immobility following treatment with SSRIs, 
but the SERT Met172 mice were insensitive to SSRI treatment of citalopram and fluoxetine, but 
remained sensitive to paroxetine (Thompson et al, 2011).  We suspected that the behavioral assays 
were hampered by to the genetic background of the mouse.  The original SERT Met172 line was 
generated using 129S6 derived embryonic stem cells (ES cells).  It has been reported that mice 
with a 129 genetic background have poor response to SSRIs compared to other mouse and rat 
models, and that a C57BL/6 background would be more suitable for behavioral assays of this 
nature (Crowley et al, 2005; Gingrich and Hen, 2000; Jacobson and Cryan, 2007; Lucki et al, 
2001). 
 
Rationale for Thesis Studies 
 
 Although there is much support for a 5-HT link to depression and the actions of SSRIs, 
there are reasons to be cautious as to our attribution of drug actions in vivo as solely linked to 
alterations in 5-HT signaling. Most troubling is the well-known issue that SSRIs are not 
immediately efficacious, even though these drugs block SERT within minutes. This observation 
indicates that time-dependent plasticities such as changes in membrane excitability, synaptic 
morphology and/or stem cell production are needed to achieve therapeutic benefit, though it is not 
clear whether these changes all derive from SERT-dependent drug targeting.   In this regard, many 
proteins encoded in the human genome do not have assays that can be used to define, holistically, 
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the nature of drug specificity.  Even within the “druggable genome” SSRIs have been found to 
interact with a sizable number of non-trivial targets at physiologically relevant concentrations.  
These targets, when manipulated specifically, can induce some of the biochemical and behavioral 
effects of both acute and chronic SSRI administration, raising the question as to whether all of the 
effects of SSRIs are 5-HT mediated. In order to separate the 5-HT/SERT-dependent effects of 
SSRIs from their non-5-HT/SERT/independent effects, I utilize a novel transgenic mouse strain 
developed by the Blakely lab wherein a point mutation has been introduced in Slc6a4 to convert 
an Ile at amino acid 172 to Met (Ile172Met; I172M), a substitution that confers insensitivity to 
many SERT blocking drugs both in vitro and in vivo.  Critically, the I172M transgenic model 
displays normal levels of SERT protein and 5-HT clearance, eliminating concerns of compensatory 
changes in 5-HT homeostasis and signaling physiology that attend many other transgenic models. 
Using the SERT Met172 model backcrossed to the C57Bl/6 background, I sought to establish 
whether SERT blockade in vivo is required for both acute and chronic SSRI-modulated behavior 
and biochemistry. These efforts provide the most definitive analysis to date of the relationship of 
5-HT signaling to SSRI action in vivo. To achieve these goals, I pursued the following Specific 
Aims: 
 
Ascertain the Biochemical Inconsequentiality of Backcrossing the SERT Met172 Mouse onto the 
C57Bl/6 Genetic Background: 
 Due to the necessity to backcross the SERT Met172 mouse model onto a more suitable 
genetic background for further behavioral assessment, I first test to ensure that the act of 
backcrossing the SERT Met172 model from the 129S6/S4 hybrid background onto the C57Bl/6 
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genetic background has not somehow negatively impacted aspects that would impede my efforts 
in planned further studies, such as differential gene regulation impacting SERT Met172 
expression. I test whether backcrossing has impacted SERT protein expression, SERT protein 
uptake function, biogenic amine concentrations, and lastly whether the backcrossing has impacted 
our expected shifts in pharmacology for fluoxetine and citalopram, and preservation of sensitivity 
to paroxetine. 
 
Determine Whether Acute Behavioral Sensitivity to SSRIs Requires SERT Blockade: 
Using adult, male SERT Met172 mice congenic on a C57BL/6J background, I examine the 
actions of SSRIs that either are or are not influenced by the I172M substitution using behavioral 
assays known to be sensitive to acute SSRI treatment.  These assays are known to possess 
predictive validity for antidepressants utilized in the clinic, and have been well characterized by 
antidepressant researchers for acute antidepressant drug sensitivity. It is with these assays that 
many off-target/non-SERT targets of SSRIs have been tested and claim non-SERT antidepressant 
effects of SSRIs, rendering them most suitable to test the requirement of SERT for the acute 
antidepressant-like actions of SSRIs 
 
Determine Whether Chronic Behavioral and Biochemical Sensitivity to SSRIs Requires SERT 
Antagonism: 
 As with the studies testing whether acute behavioral sensitivity to SSRIs require SERT 
antagonism, I examine the SSRI sensitivity of SERT Met172 mice following chronic 
 44 
administration of SSRIs in a model that is sensitive to chronic—but not acute—administration of 
SSRI. The assays chosen, novelty induced hypophagia and hippocampal neurogenesis, are thought 
to probe different facets of SSRI efficacy, and through their use, I will seek to establish the SERT-
dependence of SSRI actions acutely and chronically. I will also investigate biochemical processes 
that are required for behavioral efficacy in this chronic behavioral antidepressant sensitivity model. 
Increased hippocampal stem cell proliferation and/or survival have been proposed to be critical for 
the actions of antidepressants in some, but not all, behavioral changes arising from chronic SSRI 
administration. In this Aim, I will employ BrdU-based methods to determine whether changes in 
stem cell generation and/or survival following SSRI administration require SERT blockade. 
 
Evaluate the Requirement of SERT Antagonism for the Novel Multimodal Antidepressant 
Vortioxetine: 
 Utilizing the above assays, I test whether the removal of SERT antagonism from the 
pharmacological profile of vortioxetine, through the use of the SERT Met172 mouse model, would 
result in preserved antidepressant-like activity in assays that are sensitive to acute and chronic 
antidepressant administration. Such findings, regardless of outcome, would illuminate the 
necessity of SERT for future serotonergic antidepressants. 
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CHAPTER II 
 
BIOCHEMICAL CHARACTERIZATION OF SERT MET172 
 
Note: The work presented in this chapter was published as: Nackenoff AG, Moussa-Tooks AB, 
McMeekin AM, Veenstra-VanderWeele J, Blakely RD (2015). Essential Contributions of 
Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram 
in the SERT Met172 Mouse. Neuropsychopharmacology  
 
Introduction 
 
The initial studies on the SERT Met172 animals were performed upon a mouse line of the 
genetic background of 129 lineage. From in vitro and in vivo studies, these prior studies were able 
to demonstrate and recapitulate prior hypotheses that the SERT I172M substitution yields a SERT 
completely able to be expressed, trafficked to the plasma membrane, and to uptake 5-HT with 
normal kinetics while rendering SERT Met172 incapable of being high affinity interactions with 
most SERT antagonists. The initial mouse line onto which the SERT Met172 substitution was 
introduced via knock-in techniques, however, was observed to exhibit low spontaneous activity in 
many behavioral tasks, low basal anxiety, and poor behavioral sensitivity to neuropsychiatric drugs 
(Jacobson and Cryan, 2007), which limits their utility in studies that rely upon behavioral screening 
endpoints to evaluate the specificity of SSRI action. It was for this reason that we sought to 
improve upon previous studies (Thompson et al, 2011), which required further manipulations in 
order to assess our hypothesis regarding the ablation of SSRI behavioral sensitivity rendered by 
the SERT Met172 substitution. It was therefore necessary to mobilize this genetic substitution onto 
a genetic background that would be more conducive to baseline anxiogenic behavior and 
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behavioral drug sensitivity studies. In these aims, we backcrossed the original 192S6/S4 line onto 
the C57Bl/6 genetic background, as described in detail below.  
 The backcross, simply put, aims to preserve the SERT gene locus from the engineered 129 
mouse line, but replace the rest of the genome with C57Bl/6 derived DNA. The theory here is that 
any and all genes that would render the 129 mouse useless in behavioral tests are replaced by the 
C57Bl/6 versions of these genes. A major consideration, however, is that we cannot know all the 
interplay of physically interacting and regulatory proteins and kinases that interact with SERT that 
would also be altered in this process. In other systems, notably 7-transmembrane G-protein 
coupled receptors (GPCRs), there are proteins that regulate the pharmacological sensitivity to 
endogenous and exogenous ligands (eg: Han et al, 2010), which, if their expression or function 
were altered through protein expression level or through phylogenetic sequence differences, would 
alter the perception of GPCR pharmacology between mouse strains, though we would potentially 
be blind to the mechanism. SERT is also known to be regulated by a number of kinases, and the 
magnitude of SERT regulation may differ across different mouse strains (Carneiro et al, 2009; 
Veenstra-VanderWeele et al, 2012; Ye and Blakely, 2011). We must therefore consider that 
backcrossing the SERT Met172 mice onto the C57Bl/6 genetic background could have unintended 
consequences pertaining towards SERT Met172 sensitivity to SSRIs or to its affinity and 
trafficking potential for 5-HT. Failure to do so could confound future conclusions pertaining to the 
I172M substitution were the backcrossing onto the C57Bl/6 genetic background be to blame.  
Therefore, following the successful backcrossing of both the wildtype SERT Ile172 and 
knock-in SERT Met172 allele onto the C57Bl/6 background, I tested important facets of ex vivo 
SERT function to confirm the biochemical findings performed previously. Based upon these 
results, I tested—and expected to find—that the backcrossing onto the C57Bl/6 background did 
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not alter total SERT protein expression, biogenic amine homeostasis, SERT specific 5-HT uptake. 
Importantly, this backcrossing did not impact the reduced affinity for the SSRIs fluoxetine and 
citalopram, while maintaining equipotent inhibition of the SSRI paroxetine. 
 
Materials 
 
Animals 
SERT Met172 knock-in mice on a 129S6/S4 background were created as described 
previously (Thompson et al, 2011). To move to a background more conducive for the study of 
SSRI sensitivity (Crowley et al, 2005; Gingrich and Hen, 2000; Jacobson and Cryan, 2007; Lucki 
et al, 2001), we backcrossed animals until the SERT Met172 allele was >99% congenic onto a 
C57BL/6J background using a single nucleotide polymorphism-based speed congenic approach 
(Jackson Labs, Bar Harbor, Maine, USA). Because the SERT gene (Slc6a4) in the 129S6 
embryonic stem cells used to generate the SERT Met172 knock-in line harbors a functional, two 
amino acid difference with the C57BL/6J SERT (129: E39R152 haplotype; C57: G39K152 haplotype; 
Carneiro et al, 2009), it was also necessary to establish a second backcrossed line where the 
wildtype 129S6 Slc6a4 gene was expressed on a C57BL/6J background, also established as >99% 
congenic. A cross of the latter line with the C57BL6/J SERT Met172 mice yields mice 
heterozygous for either SERT Ile172 or SERT Met172 (SERTI172/Met172) with both Slc6a4 alleles 
sharing the E39R152 haplotype. These heterozygous mice were the parental animals for the 
homozygous SERT Ile172 (wildtype; WT) and SERT Met172 mice used in our studies. Initial 
characterizations of SERT levels, activity, and monoamine homeostasis were performed upon 
homozygous mice generated from heterozygous breedings. Because SERT levels, 5-HT clearance, 
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raphe 5-HT neuron firing rates, growth rates, and basal TST and FST behaviors were found to be 
equivalent in heterozygous bred SERT Ile172 and Met172 animals on both the 129S6/S4 
(Thompson et al, 2011) and C57BL/6J backgrounds (these studies), we performed chronic drug 
treatment studies using WT and SERT Met172 mice generated from homozygous breedings. All 
animal studies were performed in accordance with protocols approved by the Vanderbilt 
University Animal Care and Use Committee. 
 
Drugs 
All general biochemical reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise noted, and were of the highest grade available. Fluoxetine HCl, citalopram HBr, 
and paroxetine HCl were acquired from TCI Chemicals (Portland, OR, USA). For ex vivo analyses, 
all drugs were prepared as 10mM stock solutions in 100% DMSO. Final DMSO concentrations 
for SSRI studies were under 1%. All control conditions contained the highest level of DMSO that 
would be presented by the most concentrated SSRI solution. Prior to i.p. injections and subsequent 
acute behavioral studies, drugs were prepared fresh in 0.9% sterile saline and filtered for sterility 
(Nalgene syringe filter, 0.2 µm, 195-2520, ThermoFisher Scientific; Waltham, MA, USA).  
 
SERT Western Blotting Analysis 
 
Method 
Following sacrifice by rapid decapitation, brain tissue from 8 week old male mice from 
midbrain, hippocampus, and frontal cortex (without olfactory bulb) was dissected and subjected 
to western blotting analysis for SERT protein. Samples were resolved on 10% gels by SDS-PAGE, 
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gels were transferred overnight to PVDF membrane (Immobilon, IPVH00010, Millipore) and then 
SERT was probed using guinea pig anti-SERT primary antibody (Frontier, 5HTT-GP-Af1400, 
1:1000; Japan; 24 hrs at 4°C) and rabbit anti-guinea pig (1:10000; A-5545, Sigma; 1 hr at room 
temperature) as secondary antibody. Bands were detected by enhanced chemiluminescence 
(Clarity™ ECL substrate, Bio-Rad, Hercules, CA, USA). Membranes were stripped and loading 
was normalized after probing for mouse anti-β-actin (Sigma-Aldrich, A5441, 1:10,000; 1 hr at 
room temperature) and goat anti-mouse secondary antibody (1:10000; 115-035-062, Jackson 
ImmunoResearch, West Grove, PA, USA; 1 hr at room temperature). Blots were imaged and band 
density was quantified using ImageJ (http://imagej.nih.gov/ij/). For accurate comparisons, WT and 
SERT Met172 samples were intercalated, and only samples from one brain region were contained 
on each blot. Values at each brain region were compared using Students t test, with alpha 
stringency set at P = 0.05. 
 
Results 
We sought to confirm that the SERT Met172 mutation did not alter SERT protein 
expression when expressed on a C57BL/6J background. Indeed, quantitative western blot analysis 
of SERT protein expression revealed no differences in frontal cortex, hippocampal, or midbrain 
SERT protein levels between WT and SERT Met172 mice (Figure 7).  These data indicate a lack 
of consequential effects of the SERT Met172 mutant on basal SERT expression, aligning with 
prior studies (Henry et al, 2006; Thompson et al, 2011). Additionally, this confirms that there are 
no consequences from the act of backcrossing the SERT Met172 locus onto the C57Bl/6 genetic 
background with respect to the ability to express the SERT protein.  
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Figure 7. SERT Protein Expression in SERT Met172. The SERT Met172 mutant imposes altered 
pharmacological sensitivity with normal SERT expression and function. SERT protein expression 
was measured via Western blotting (left), and normalized to β-actin levels (right). SERT 
expression did not differ between WT and Met172 mice (two-tailed Student t test, P >0.05; n=5 
per genotype and condition).  
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While we kept a close tab via PCR and strainotyping with respect to the coding sequence 
of SERT during the speed congenic approach to the backcrossing, there was still a possibility that 
regulatory elements and SERT gene promotor regions could be disrupted, for example, creating a 
situation where C57Bl/6 gene promotors would be less able to express SERT Met172 protein. 
These data indicate that our backcrossing efforts did not disrupt the ability of our hybrid mice to 
express either WT or SERT Met172. 
 
Brain Monoamine Steady State Composition 
 
Method 
Male mice (8 weeks old) were sacrificed by rapid decapitation and brain regions of frontal 
cortex, hippocampus, and midbrain were dissected on ice and then rapidly frozen in test tubes on 
ethanol/dry ice and stored at -80 °C until extraction for assessment of monoamine 
neurotransmitters and metabolites. Monoamine levels were determined by HPLC/EC methods as 
described previously (Thompson et al, 2011) in the Vanderbilt Brain Institute Neurochemistry 
Core. Briefly, tissue samples were subjected to organic extraction in order to solubilize whole 
tissue neurotransmitters and their metabolites. The aqueous fraction containing these monoamines 
are forced through a chromatographic column via high pressure injection. This column separates 
the various monoamines via size and polarity and exit the column at different times. At this point, 
sample fractions are exposed to an electrochemical detector, and given a certain voltage oxidizes 
the substances in the sample based upon their redox potential. Sample oxidation generates a small 
electrical current, that, when compared to known concentrations of monoamines, can allow back 
calculation to determine exact concentration of the monoamine in the sample. Metabolite levels 
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were normalized to tissue extract protein concentration (Pierce BCA, #23225; ThermoFisher 
Scientific). Values at each brain region were compared using Students t test, with Bonferroni 
repeated measure correction, with alpha stringency set at P = 0.05. 
 
Results 
After organic extraction of neurotranmitters and their metabolites and subsequent 
chromatographic separation and electrochemical detection, we could determine that monoamine 
neurotransmitter and metabolite levels did not differ between genotypes across all brain regions 
(Table 2). 
 
Saturation Uptake Kinetic Analysis of SERT 
 
Method 
Following sacrifice via rapid decapitation, the whole brains of 8-12 week old male mice 
were dissected on ice and used for synaptosomal preparations as described previously (Thompson 
et al, 2011). Briefly, midbrain sections were mechanically homogenized in 0.32M sucrose in 5mM 
HEPES buffer. This homogenate was subjected to a low gravity centrifugation (10 min, 4°C at 
1,000x g) in order to remove large cellular components (eg. mitochronria, nuclei, and large 
membranes) from the reconstituted nerve terminals, classified as ‘snaptosomes’. The supernatant 
after this first spin contains the synaptosomes. The synaptosomes are then pelleted via a high 
gravity centrifugation (15 min, 4°C at 10,000x g).  
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Table 2. Biogenic Amines in SERT Met172. Values presented as mean ± SEM (ng/mg protein). 
Tissue levels were determined by HPLC-EC analyses as noted in Methods. Tissue levels of 5-HT, 
5-HIAA, DA, DOPAC, and NE did not differ between WT and Met172 mice (n= 4 per condition, 
two-tailed Student’s t test). 
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The pellet was resuspended in KRH buffer containing glucose (for synaptosomal viability 
throughout the preparation and assay), pargyline (MAOI, prevents enzymatic metabolism of 5-
HT), and ascorbic acid (preservative, prevents spontaneous oxidation of 5-HT). Equal volumes of 
synaptosomes were then incubated at 37°C for 5 minutes with serial dilutions of 5-HT stock 
containing 10% [3H]5-HT (PerkinElmer, NET498001MC, Waltham, MA, USA). At each 
concentration of 5-HT, parallel samples were incubated in the presence of 1μM paroxetine (an 
SSRI), defining non-specific uptake (any residual radioactivity in these samples would be due to 
non-SERT uptake, passive diffusion, or indicate washing stringency), which was subtracted from 
total counts to yield specific uptake. 5-HT uptake into synaptosomes was terminated via addition 
of ice cold PBS buffer, and vacuum filtration through 0.3% polyethyleneimine treated glass fiber 
filters (GF/B, Whatman, Pittsburgh, PA, USA). Synaptosomes were assessed for protein 
concentration for normalization of 5-HT levels across experiments (Pierce BCA; ThermoFisher). 
Data were fit to rectangular hyperbolic Michaelis-Mentin Kinetic regression curve fits (Graphpad 
Prism 6.0). Kinetic parameters (Km and Vmax) were compared using Students t test, with alpha 
stringency set at P = 0.05. 
 
Results 
 Raw values of radioactive uptake were converted into moles, via corrections for 
scintillation counting efficiency (using known concentrations of radioactivity), non-specific 
uptake, and the total time allotted in the uptake experiment. These data were fit to the amount of 
5-HT added to the tubes, and fit to a Michaelis-Menten rectangular hyperbola to determine the 
kinetic parameters Km and Vmax (Graphpad Prism). We found no genotype effects on ex vivo 5-HT 
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transport kinetics in whole brain synaptosomes, neither in 5-HT Km or 5-HT transport Vmax (P 
>0.05) (Figure 8). 
 
Synaptosomal Competition Uptake Analysis 
 
Method 
Following sacrifice via rapid decapitation, the midbrains of 8-12 week old male mice were 
dissected on ice and used for synaptosomal preparations as described above, and previously 
(Thompson et al, 2011). For competition uptake assays, equal volumes of synaptosomes were 
incubated with 20 nM [3H]5-HT (PerkinElmer) and varying concentrations of inhibitors and 
incubated at 37°C for 10 minutes, followed by vacuum filtration and scintillation spectroscopy 
methodology as described above. Data were fit to single site competition regression curve fit 
(Graphpad Prism 6.0).  
 
Results 
After confirming normal SERT expression and activity, we sought to verify whether the 
C57BL/6J backcrossed SERT Met172 allele maintained its reduced sensitivity to specific SERT 
antagonists (Henry et al, 2006; Thompson et al, 2011). To accomplish this, we performed 
competitive [3H]5-HT uptake using midbrain derived synaptosomes of WT and SERT Met172 
mice (Figure 9). These studies revealed the expected reductions in potency for fluoxetine (~20 
fold) and citalopram (~500 fold) at SERT Met172.  
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Figure 8. Saturation Uptake Kinetics. The SERT Met172 mutant imposes altered pharmacological 
sensitivity with normal SERT expression and function. Saturation uptake kinetics in WT and 
SERT Met172 whole brain synaptosomes. WT and Met172 do not differ in 5-HT transport activity 
(WT: Km 73.04±15.66 nM; Vmax 1.18±0.07 pmol/min-mg protein; Met172: Km 102.0±24.61 nM; 
Vmax 1.22±0.09 pmol/min-mg protein: two-tailed unpaired Student t test, P > 0.05, n = 
6/condition).  
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Figure 9. Synaptosomal Competition of 5-HT Uptake. The SERT Met172 mutant imposes altered 
pharmacological sensitivity with normal SERT expression and function. Competition 5-HT uptake 
analysis. Fluoxetine (WT KI=8.54 ± 0.02 x 10
-8 M, SERT Met172 KI=9.03 ± 0.03 x 10
-7 M), 
citalopram (WT KI=2.07 ± 0.05 x 10
-8 M, SERT Met172 KI=7.91 ± 0.05 x 10
-6 M), and paroxetine 
(WT KI=2.00 ± 0.03 x 10
-9 M, SERT Met172 KI=1.80 ± 0.04 10
-9 M) were assessed for their ability 
to compete with [3H]5-HT uptake. (n = 4/condition). 
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In contrast, paroxetine was unaffected by the Met172 variant, as demonstrated by its 
equivalent potency of 5-HT uptake inhibition in WT, consistent with predictions from transfected 
cell studies (Henry et al, 2006) and prior synaptosomal studies (Thompson et al, 2011). These data 
indicate that the backcrossing onto the C57Bl/6 did not impact the pharmacological sensitivity of 
the SERT Met172 variant, and additionally that the magnitude of these disrupted sensitivities were 
preserved from in vitro studies as well as the previously assessed 129S6/S4 mouse line containing 
the SERT Met172 variant. These data indicate that our attempts to dose animals within this ‘dose 
window’, where a dose of SSRI could fully inhibit WT SERT yet render no functional antagonism 
on SERT Met172, will be fruitful after these backcrossing efforts. 
As an aside, many people have taken interest in the findings that the pharmacological 
inhibition of paroxetine at SERT is unaffected by the I172M substitution. Of those, most have 
some training in structural biology, and take these findings as evidence that paroxetine is an 
allosteric inhibitor of SERT via allosteric binding at the purported S2 SERT binding site (Plenge 
et al, 2012; Plenge and Mellerup, 1985). In our own studies and collaborative efforts, we have 
observed through computational SERT homology model docking studies that paroxetine does bind 
at the ‘orthosteric’ 5-HT binding site, where most other SERT blockers are computationally 
predicted to bind (Kaufmann et al, 2009). Moreover, these structures confirm that the stabilized 
SERT structure bound to paroxetine does not present Ile172 towards the binding pocket in a way 
that one would predict perturbed paroxetine binding in the presence of the substituted Met172. 
Based upon these data of the unaltered pharmacological sensitivity in synaptosomes, we can only 
say that high affinity binding of paroxetine to SERT does not require Ile172. Though our data does 
not rule out the possibility of S2 binding site activity of paroxetine, together with the homology 
model docking studies, I do not feel compelled to assert that paroxetine engages the S2 site to 
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achieve SERT antagonism. Such S2 activity would require perfect and indistinguishable 
competitive binding for 5-HT, all while remaining completely allosteric of the orthosteric S1 5-
HT binding site; I do not feel convinced of that possibility.  
 
Conclusions 
 
 The backcrossing the SERT Met172 mouse onto the C57Bl/6 was necessary for further 
experimentation regarding the acute and chronic SSRI sensitivity studies, though it was necessary 
to first ensure that the act of backcrossing did not unexpectedly augment any of our foundational 
assumptions regarding the impacted sensitivity of SERT Met172 to SSRI inhibition with 
maintained efficacy with respect to 5-HT transport capability. To test this, we chose to validate 
core facets of these assumptions, namely ensuring that the I172M substitution did not alter the 
expression of SERT protein, biogenic amine homeostasis, SERT specific 5-HT uptake kinetics, or 
the predicted altered pharmacology for SSRIs. I was able to validate that these foundational 
assumptions were not altered following the backcrossing onto the C57Bl/6 genetic background. 
While we expected these findings, it was necessary to confirm before moving forward onto more 
complicated queries pertaining to SSRI antidepressant efficacy and the role of SERT antagonism 
for their actions.  
 The importance of these findings is multifaceted. Firstly, should we see any differences in 
SSRI behavioral sensitivity in the SERT Met172 mice, such an observation could be confounded 
by changes in total SERT protein expression, leading to unbalanced dose administration, and/or 
altered 5-HT receptor expression or sensitivity. Any minute changes to SERT protein expression 
basally or over development could dramatically or subtly alter neurodevelopment, which we would 
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hope to see in gross morphology (data not shown) or monoamine homeostasis, which are unaltered. 
Such changes could impact basal behavioral effects or sensitivity to SSRIs. Of further importance, 
the premise of these studies is that we have only altered pharmacology of some SSRIs at SERT 
without impacting its basal function with respect to 5-HT uptake. Any aberrations in normative 
function in SERT would create an abnormal state basally, and any conclusions we would draw 
from SSRI behavioral sensitivity studies could not be attributed solely to deficient SERT binding 
since many other compensatory effects would also be present in such a mouse. Importantly, I saw 
no differences in SERT Met172 compared to WT SERT in the 5-HT uptake kinetics, which mirrors 
what I observed in the biogenic amine level analysis, which would have been altered were SERT 
kinetics maligned in any functional capacity. And lastly, I was able to show that the backcrossing 
did not impact the lowered affinities of fluoxetine and citalopram for SERT Met172. These 
findings indicate that the SERT Met172 mouse, on a biochemical scale, has been validated to a 
degree to which we can comfortably move forward towards the assessment of SERT specific 
effects of acute and chronic SSRI sensitivity in a confound-free manner.  
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CHAPTER III 
 
ACUTE BEHAVIORAL SENSITIVITY OF SERT MET172 TO SSRI 
 
Note: The work presented in this chapter was published as: Nackenoff AG, Moussa-Tooks AB, 
McMeekin AM, Veenstra-VanderWeele J, Blakely RD (2015). Essential Contributions of 
Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram 
in the SERT Met172 Mouse. Neuropsychopharmacology 
 
 
Introduction 
 
In the prior chapter, I described studies that show that SERT Met172 protein is expressed 
as efficiently as WT SERT, can function equivalently to WT SERT with respect to 5-HT uptake, 
and does not alter brain monoamine homeostasis. Thus, the C57Bl/6 SERT Met172 mouse is 
validated as a model to assess the functional consequences of the loss of SSRI antagonism of 
SERT—due to the perturbed affinity for most SSRIs for SERT Met172—in a confound free 
manner. Provided this shift in pharmacological sensitivity, I should be able to administer a dose of 
the SSRI that is able to functionally antagonize WT SERT but not SERT Met172 in vivo, assuming 
that the ‘dose window’—the gap between IC80’s of WT and SERT Met172—falls within range of 
behaviorally relevant doses of SSRIs. Based upon prior validation studies (Thompson et al, 2011), 
we know that a relatively high, behaviorally relevant dose of 20 mg/kg of both fluoxetine and 
citalopram are able to hit this ‘dose window’, where this dose is able to functionally antagonize 
WT SERT but not SERT Met172. This would provide the desired situation where the SSRIs 
fluoxetine and citalopram are present at normal levels in the brain in SERT Met172 mice, yet fail 
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to engage and functionally antagonize its SERT, leaving those compounds free to engage off-target 
proteins and receptors that may contribute to antidepressant actions, as some have suggested. In 
short, since the only differences in SSRI response between WT and SERT Met172 would solely 
be due to engagement at SERT, we can determine definitively whether SERT antagonism is 
required for the behavioral efficacy of SSRIs in the acute models of antidepressant efficacy tail 
suspension test (TST) and forced swim test (FST).  
We chose the TST and FST due to their wide adoption and extensive history in the field of 
antidepressant screening (Crowley et al, 2005; Lucki et al, 2001; Porsolt et al, 1977b; Steru et al, 
1985). Clinical antidepressants—including fluoxetine, citalopram, and paroxetine—are known to 
promote escape-like behavior in mice when presented with an inescapable stressor, such as 
suspension by the tail (TST) or placement in a cylinder of water (FST). These tests evolved from 
early depression models, notably the original canine learned-helplessness shuttlebox assay (Maier 
and Seligman, 1976; Overmier and Seligman, 1967). This model could reliably produce a 
depression-like state in animals that are presented a series of inescapable shocks, to a point where 
an opportunity to escape is presented, they engage in maladaptive behavior termed ‘learned 
helplessness’ whereby they fail to seek the escape from the now escapable shock grid. This assay 
was then adapted for small rodents and found to produce similar results (Seligman and Beagley, 
1975). Animals treated with antidepressants are more likely to engage in escape-like behavior than 
non-treated control animals, in part validating the utility of animal models for human psychotropic 
drug response (Leshner et al, 1979). The disadvantage of the learned helplessness shuttlebox assay 
is that it requires multiple days of training and repeated sessions to produce the learned 
helplessness phenotype. In an attempt to produce a quicker developing depression-like state and 
antidepressant sensitive model, the forced swim test (FST) was developed (Porsolt et al, 1977b). 
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This model involves placing a rodent in a cylindrical container filled partly with water, where the 
animal swims rapidly in escape-like exploratory behavior until it acquires a ‘learned helplessness’ 
phenotype and floats, usually over the course of a single 6-minute session. Originally this test was 
performed in rats, which require 2 total sessions on sequential days to observe an antidepressant 
induced increases in escape-like swimming behavior (Porsolt et al, 1977b). Mice only require one 
single 6-minute session to observe the antidepressant sensitive escape-like swimming behavior 
(Porsolt et al, 1977a). Animals treated with a single dose of antidepressant will engage in more 
escape-like swimming behavior, traditionally plotted as a reduction in immobility time due to the 
predominant immobility/floating behavior in this assay. Additionally, another rapid antidepressant 
sensitivity screen was developed inspired by Porsolt’s FST, denoted the tail suspension test (TST) 
(Steru et al, 1985), involving the suspension of a mouse by its tail, representing the inescapable 
stress, and monitoring the mobility and escape-like behavior like in the FST. This assay could not 
utilize rats as their increased body weight precludes the successful ability to suspend them by their 
tail for the time required in this assay. Antidepressants suppress the ‘learned helplessness’ 
phenotype of simply hanging and instead promote rapid movement of escape-like behavior. The 
antidepressant-like effect in these assays is usually described as ‘resiliency’ due to the promotion 
of increased escape-like behavior and suppression of the ‘learned helplessness’, as seen through 
the lens of the original shuttlebox assay. Though one could argue that this escape-like behavior in 
these assays is maladaptive as floating/hanging conserves energy, especially considering that the 
water, or suspension by the tail, while unpleasant and represents a potential predator stress 
environment, is not an equivalent stressor to the shock grid. It is this reason that the FST and TST 
loses some face and construct validity that the shuttle box assay possesses. But when these assays 
lose these types of validity, they importantly gain practical utility and retain the predictive validity 
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of antidepressant sensitivity. This predictive validity is most significant, in that drugs that are 
clinically effective antidepressants will reliably produce behavioral effects in the FST and TST, 
which is the major reason why they are still widely utilized in the field of antidepressant research 
as well as in pharmaceutical antidepressant drug development. 
Previous efforts in the lab sought to assess the functional requirement of SERT antagonism 
for the SSRI antidepressant effect in the TST and FST. Unfortunately, the 129S6/S4 genetic 
background of the SERT Met172 mice in those studies precluded their usefulness in these acute 
behavioral SSRI sensitivity assays, either due to poor effect size or directionality of the SSRI 
induced behavioral effect. In hopes of optimal interpretation of the SERT dependency of SSRI 
actions, we backcrossed this SERT Met172 mouse onto a more suitable background for behavioral 
assays. In this effort, we repeat those attempts to ascertain whether acute behavioral sensitivity to 
SSRIs require SERT antagonism, utilizing the predictively valid TST and FST behavioral assays.  
 
Animal Procedures 
 
All behavioral assays were performed upon behaviorally naïve 8-12 week old male mice 
in the Neurobehavioral Core lab at the Vanderbilt University Medical Center. Animals were held 
at 12 hour light:dark cycle (light cycle: 7:00 to 19:00 hours), and all experimentation occurred 
between 13:00 and 18:00 hours. Animals were transferred to housing within the facility and 
allowed to acclimate for at least 1 week prior to behavioral manipulations. For acute drug studies, 
animals were acclimated to handling the day prior to experimentation, at which point body weight 
was measured for drug dosing considerations. All drugs for acute drug studies were prepared fresh 
and administered in 0.9% sterile saline solution at 20 mg/kg (10 μL/g body weight). This dose was 
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utilized to match our prior studies where we demonstrated significant functional SERT occupancy 
in vivo in WT but not SERT Met172 mice (Thompson et al, 2011) as assessed by microdialysis 
studies, and representing a relatively high behaviorally relevant dose (Crowley et al, 2005), which 
would maximize the potential to detect off-target effects. All experiments and data analyses were 
scored manually utilizing instantaneous sampling and binning methods of scoring while performed 
blind to drug condition and genotype. 
 
Tail Suspension Test (TST) 
 
Method 
Mice were allowed to acclimate for 1 hour in the testing room at full white room 
illumination, away from the main colony. Mice were injected (i.p) with saline vehicle, fluoxetine, 
citalopram, or paroxetine 30 min before a 6 minute TST. The apparatus allows for multiple mice 
to be run at the same time, though mice are visually isolated from each other in 5 sided opaque 
plexiglass boxes, with the open side facing towards the room for video capture and handling 
purposes. Thirty minutes after injection, mice were then suspended by taping the tail to a vertical 
aluminum bar and activity was recorded by video. Immobility was manually quantified as the time 
when mice are motionless, excluding minute limb movements. Data was analyzed via two-way 
ANOVA and Bonferroni post-hoc tests (Graphpad Prism 6.0). 
 
Results 
Having validated the C57BL/6J SERT Met172 model as having normal SERT expression 
and function, yet disrupted ex vivo sensitivity to the SSRIs fluoxetine and citalopram, we moved 
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to assess the efficacy of these drugs in behavioral assays that are known to be sensitive to acute 
antidepressant administration (Porsolt et al, 1977b; Steru et al, 1985). WT and SERT Met172 mice 
display equivalently high rates of immobility in the TST. As expected, WT mice showed a robust 
decrease in immobility following acute fluoxetine and citalopram administration (Figure 10), 
with effect sizes that match those observed in the literature accounting for age, genetic background 
strain, and drugs utilized (Crowley et al, 2005). SERT Met172 mice, however, displayed no 
response to either drug (Figure 10). Importantly, paroxetine equivalently suppressed immobility 
in WT and SERT Met172 mice in the TST, consistent with the inability of the Met172 substitution 
to perturb paroxetine interactions. This important control also demonstrates a normal capacity of 
the SERT Met172 mice to translate SERT inhibition and elevations in extracellular 5-HT into 
enhanced mobility in both tests. 
 
Forced Swim Test (FST) 
 
Method 
Mice were allowed to acclimate for 1 hour in the testing room at full white room 
illumination, away from the main colony. Mice were injected (i.p) with saline vehicle, fluoxetine, 
citalopram, or paroxetine 30 min before a 6 minute FST. Mice were placed in the center of a 15 
cm diameter clear plexiglass cylinder filled with tap water (25-27 °C) to a depth of approximately 
15 cm for the 6 minute FST and activity was recorded by video.  
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Figure 10. Tail Suspension Test. Actions of fluoxetine and citalopram in the TST arise from SERT 
antagonism.  All tests were performed 30 min after i.p. injection of 20mg/kg drug. Time immobile 
in a 6-minute TST. Two way ANOVA revealed significant main effects of genotype (F(1,72) = 
17.11, P < 0.05), treatment (F(3,72) = 10.82, P < 0.05), and interaction effect (F(3,72) = 4.62, P < 
0.05).  WT mice display significant decreases in immobility time in response to all drug treatments. 
Met172 mice display significant decreases in immobility time only in response to paroxetine. * 
indicates significance (P<.05) compared to vehicle treatment via Bonferonni posttests (n = 10-12 
per genotype and condition). 
  
 68 
Multiple mice were assessed at the same time, though mice were kept visually unaware of 
the other mice via black plastic separators. Immobility was manually quantified as the time when 
mice floated or only made movements to maintain balance. Data was analyzed via two-way 
ANOVA and Bonferroni post-hoc tests (Graphpad Prism 6.0). 
 
Results 
 Given that the FST and TST report presumably identical effects of acute SSRI 
administration, we expected similar findings in the FST as we observed in the TST. In the FST, 
both WT and SERT Met172 mice display high rates of immobility, given that C57Bl/6 display the 
highest rates of immobility of the most commonly experimentally utilized mouse strains (Crowley 
et al, 2005; Lucki et al, 2001). We found that WT animals display reduced immobility time 
following administration of all fluoxetine, citalopram, and paroxetine. Like the results in the TST, 
SERT Met172 mice are behaviorally insensitive to fluoxetine and citalopram (Figure 11). 
Additionally, SERT Met172 mice are still responsive to paroxetine, due to the antidepressant’s 
pharmacological insensitivity to the I172M substitution; this responsiveness to paroxetine also 
shows that our SERT Met172 animals are behaviorally responsive to traditional monoaminergic 
antidepressants as well as showing that our behavioral paradigm was effective for the SERT 
Met172 mice. These results fully mirror what I observed in the TST, namely that SERT 
antagonism—which is functionally lost in fluoxetine and citalopram in the SERT Met172 model—
is required for the acute behavioral effects of SSRIs.  
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Figure 11. Forced Swim Test. Actions of fluoxetine and citalopram in the FST arise from SERT 
antagonism.  All tests were performed 30 min after i.p. injection of 20mg/kg drug. Time immobile 
in a 6-min FST. Two way ANOVA revealed significant effects of genotype (F(1,71) = 18.80, P < 
0.05), treatment (F(3,71) = 15.92, P < 0.05), and interaction effect (F(3,71) = 4.52, P< 0.05). WT 
mice display significant decreases in immobility time in response to all drug treatments. Met172 
mice display significant decreases in immobility time only in response to paroxetine. For A-B, * 
indicates significance (P<.05) compared to vehicle treatment via Bonferonni posttests (n = 10-12 
per genotype and condition). 
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The only differences that we observed between the TST and FST are that the FST has a 
larger effect size than the TST (Crowley et al, 2005; Lucki et al, 2001). When analyzing behavioral 
sensitivity to SSRIs in C57Bl/6 mice, it could be useful to utilize the FST in favor of the TST, due 
to the C57Bl/6 displaying among the highest rates of immobility in these assays as well as the 
smallest behavioral response to SSRIs (Crowley et al, 2005; Lucki et al, 2001). Due to the high 
rates of use of C57Bl/6 mouse lines because of their extensive utility in various mouse behavioral, 
genetic, and proteomic analyses, the field should be aware of potential false negative findings of 
antidepressant properties of drugs if only using the TST for procedural convenience. I have 
encountered many reports of negative results in the TST with known SSRIs (various personal 
communications), supporting a strain-dependent limitation of the TST. 
 
Conclusions 
 
 With the biochemical validation showing that the I172M substitution does not impact 
SERT expression or function, the first question we wanted to answer was whether the loss of SERT 
antagonism of SSRIs, brought about via SERT Met172, would ablate acute behavioral sensitivity 
in traditional preclinical tests of antidepressant sensitivity. In other words, we wished to ascertain 
whether SERT antagonism is required for SSRI-mediated antidepressant efficacy. In this aim, I 
utilized behavioral assays that are only sensitive to a single administration of SSRIs, namely the 
TST and FST, which are utilized by the pharmaceutical industry for antidepressant drug screening 
efforts.  
The reason behind this motivation is due to a multitude of reports exist describing the 
interactions of SSRIs with non-SERT targets at physiologically relevant concentrations. When 
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these targets are manipulated specifically, they have been found to recapitulate antidepressant-like 
effects in the TST and FST. Furthermore, certain gene knockout studies deleting these non-SERT 
receptors have provided evidence for a role in the antidepressant effect of SSRIs in TST and FST, 
suggesting SERT as unnecessary for the acute antidepressant-like effects of SSRIs. Although there 
have been studies that show that knocking out SERT ablates the behavioral sensitivity of SSRIs in 
the FST and TST (Holmes et al, 2002), the SERT knockout studies are plagued by compensatory 
alterations that produces a non-native environment in which these SSRIs are being evaluated. In 
short, there is no definitive reason to assume conclusively from the SERT knockout studies that 
SERT is a requisite component of SSRI antidepressant action. 
 Here, we utilize the SERT Met172 model, which is devoid of the confounds that are present 
in the SERT knockout model. We tested whether SERT is required for acute behavioral efficacy 
of two SSRIs, citalopram and fluoxetine. We administered these drugs to both WT and SERT 
Met172 mice using relatively high behaviorally relevant dose of the drugs, including paroxetine 
as a positive control. The dose we utilized (20 mg/kg i.p.) was chosen due to prior work that 
showed that this dose fell within the ‘dose window’ and attained separation between WT and SERT 
Met172 with respect to functional SERT antagonism, and due to our desire to maximize any 
potential for non-SERT interactions and contributions to behavioral endpoint analysis. In these 
efforts, I found that all three SSRIs are able to reduce immobility time in both the TST and FST, 
relative to saline treated control mice, as expected since this is a well characterized feature of 
antidepressants in these assays. SERT Met172 mice, however, failed to respond to both fluoxetine 
and citalopram, whereas paroxetine was able to significantly reduce immobility time. Paroxetine 
is capable of this feat in SERT Met172 mice because of its insensitivity to the I172M substitution, 
and also serves as a positive control acting as an active SSRI in these SERT Met172 mice, proving 
 72 
that these knock-in mice are still capable of a traditional serotonin mediated antidepressant-like 
effect. What these experiments show is that by only changing the pharmacological sensitivity of 
SERT, thus otherwise retaining a physiologically and neurologically normal mouse, these other 
non-SERT targets that are theoretically being engaged in both the WT and SERT Met172 mouse 
are insufficient alone to produce an antidepressant effect. Conversely, we can show definitively 
with the most specific assay to date that SERT is required for the acute behavioral sensitivity to 
the SSRIs fluoxetine and citalopram. 
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CHAPTER IV 
 
BEHAVIORAL AND BIOCHEMICAL SENSITIVITY OF SERT MET172 TO CHRONIC 
SSRI 
 
Note: The work presented in this chapter was published as: Nackenoff AG, Moussa-Tooks AB, 
McMeekin AM, Veenstra-VanderWeele J, Blakely RD (2015). Essential Contributions of 
Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram 
in the SERT Met172 Mouse. Neuropsychopharmacology 
 
Introduction 
 
 In our prior studies, we were able to demonstrate that the acute behavioral responses to 
SSRI antidepressants (fluoxetine and citalopram), require SERT antagonism. These findings are 
important in their own right, but are solely derived from acute single dose responses, meaning that 
the results we are observing are likely due to the supraphysiological increases in 5-HT signaling 
brought about via functional SERT antagonism by the SSRIs in the central nervous system (CNS). 
Whereas SSRIs are able to penetrate the CNS in both mice and human within 1 hour of peripheral 
drug administration, humans do not experience clinical remediation of depression symptoms after 
a single administration of SSRI. In fact, SSRI antidepressant pharmacotherapy requires, 
minimally, 4 weeks of chronic administration before any clinically measurable antidepressant 
effects are observable. 
 The temporal disconnect between human antidepressant clinical efficacy (4 weeks) and the 
behavioral sensitivity in the TST and FST assays is cause to evaluate whether they reflect 
manipulation of the same biological phenomena. This temporal incongruity suggests that human 
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clinical efficacy requires much more than just the increases in extracellular 5-HT brought about 
following a single acute SSRI administration. Although the TST and FST have predictive validity 
for clinical utility of antidepressant efficacy, these tests do not accurately reflect or produce the 
biological changes that are required for human clinical efficacy, and thus are not the most valid 
models for measuring clinically relevant aspects of antidepressant mechanisms. The TST and FST 
are utilized in the field of antidepressant pharmacology for their ease of use, require no training of 
the animals, and most importantly because they have predictive validity for agents that are 
clinically efficacious as antidepressants. Because the TST and FST do not require chronic SSRI 
administration, they cannot accurately produce or measure the necessary biological components 
or adaptations that are required for chronic antidepressant efficacy. It is for this reason that we 
sought tests that are sensitive only to chronic—but not acute—SSRI administration. What could 
be true for the requirements in acute SSRI sensitivity assays may not hold true for the molecular 
requirements for chronic SSRI sensitivity. Namely, while SSRIs require SERT antagonism for 
acute behavioral efficacy in the TST and FST, there is no guarantee that SERT antagonism is 
required for chronic behavioral sensitivity to SSRIs. 
 In this aim, we implemented the novelty induced hypophagia (NIH) assay, which is a subtle 
anxiogenic procedure in which animals reduce food consumption in a novel environment (Dulawa 
and Hen, 2005). These assays have been utilized for the screening of traditional anxiolytics, but 
have also been shown to be sensitive to chronic—but not acute—antidepressant administration. 
The premise of the assay is that the mouse is trained to consume a palatable substance in a stress-
free manner in its home cage under low light conditions, which are not stress inducing. On the test 
day, the mouse is transferred to a new cage that lacks bedding, and the cage is placed on a relatively 
reflective surface in a room with bright white lights, but in the presence of the same palatable 
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substance that they have been trained to consume. These sets of conditions produce an anxiety-
like state, and promotes anxious exploratory behavior. The major endpoint measure is the latency 
of the mouse between when it was placed in the novel anxious environment and when it first licks 
the palatable substance.  
The NIH test is a modification of the novelty suppressed feeding (NSF) task, and as such 
utilizes a liquid palatable substance where the NSF assay uses a small single food pellet (Dulawa 
and Hen, 2005). Because of this, one can also measure the total amount of palatable liquid 
consumed over the 30-minute test, which can also tap into the hedonic desire of the animal, a trait 
that is stimulated following successful antidepressant regimens in human patients. The other 
advantage of the NIH modification is it requires no food deprivation/restriction of the animal. This 
reduces the stress put on the animal, as well as providing a more natural environment for which to 
measure this potential hedonic drive. The NSF assay does not have this luxury since hunger, 
brought about by food restriction, is a strong motivating force, and thus can reduce the predictive 
value and effect size of the behavioral assay. Chronic antidepressants, in this assay, promote the 
reduction in latency to consume the palatable substance as well as increase the total amount 
consumed in the novel cage. These results indicate the anxiolytic component of the antidepressant 
effect that is often seen in addition to antidepressant effects in the clinic. 
Based upon the necessity for chronic SSRI administration for behavioral efficacy in the 
NIH test, this assay already shows some face and construct validity than that of either the TST or 
FST, and therefore much more suitable as a behavioral model of antidepressant efficacy. But it is 
also important to consider the other factors that are evident upon chronic SSRI administration, 
which could further illuminate whether the NIH assay is a suitable test to measure chronic 
antidepressant sensitivity. Following the discoveries of adult neurogenesis in rodents, it was 
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further discovered that adult neurogenesis can indeed happen in other mammals, including 
humans, in regions including the hippocampus (Eriksson et al, 1998; Malberg et al, 2000; van 
Praag et al, 2002). These findings led investigators to determine the neurological utility of adult 
neurogenesis, and why the brain would keep a stable pool of adult neural progenitor stem cells. 
Further efforts in the field of depression research found that depressed patients exhibit reduced 
hippocampal volume, and that antidepressant therapy can rescue this phenotype and recover these 
volume losses in successfully treated individuals. In animal studies, it was shown that chronic 
stress paradigms reduced basal rates of hippocampal neurogenesis, and that chronic antidepressant 
drug administration could recover rates of hippocampal neurogenesis to normal levels (Murray et 
al, 2008; Warner-Schmidt and Duman, 2006). In unstressed animals, chronic SSRI 
administration—but not acute—could stimulate rates of hippocampal neurogenesis, and on the 
same timescale of human clinical efficacy (Malberg et al, 2000).  
Though these findings are intriguing, it was unclear whether adult hippocampal 
neurogenesis was a coincidental result of chronic antidepressant pharmacotherapy or whether it 
indeed was a necessary intermediate mechanism of antidepressant efficacy. To test the requirement 
of hippocampal neurogenesis for the behavioral actions of SSRIs, the Hen group decided to block 
adult neurogenesis during chronic antidepressant pharmacotherapy in mice and then test whether 
mice were still behaviorally responsive to chronic SSRI (Santarelli et al, 2003). To accomplish 
this, they chose to focally X-ray irradiate a vertical column (masked by lead shield) of the mouse 
brain that covered the hippocampus. The X-irradiation induces double stranded DNA breaks, while 
the largely senescent CNS would be largely unaffected, much like cancer therapy only the highly 
proliferative cells would be disrupted to a significant degree. And because these neurogenic events 
require mitosis from the neural stem cell pool before maturation and functional integration into the 
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hippocampus, the X-irradiation is able to prevent successful mitotic events from occurring, and 
thus ablating hippocampal neurogenesis, while leaving the rest of the brain arguably intact. It was 
under these conditions that they ran the NSF assay to see whether the loss of hippocampal 
neurogenesis could disrupt behavioral sensitivity to chronic SSRI treatment. What they found is 
that the animals where hippocampal neurogenesis was prevented were insensitive to chronic SSRI 
treatment and displayed no antidepressant-like effects in the NSF assay, as opposed to untreated 
antidepressant administered mice. In sum, these seminal studies showed that adult hippocampal 
neurogenesis is required for the behavioral efficacy of chronic SSRI administration. 
The evidence of adult hippocampal neurogenesis occurring in human patients, the fact that 
the phenomena is stimulated following chronic SSRI administration, and that it is required for 
behavioral efficacy in the NSF/NIH test suggests increased face and construct validity of the NIH 
test for the evaluation of SSRI sensitivity over the acute TST and FST assays. Additionally, this 
provides a non-behavioral endpoint for analysis for SSRI action and the dependency of SERT for 
antidepressant actions of SSRIs. While the TST and FST are important quick measures of 
antidepressant efficacy, we now have at our disposal more construct valid endpoints for which to 
measure antidepressant efficacy that are more congruent with human clinical features.  
 
Materials 
 
Drugs 
For chronic administration studies, drugs were dissolved in tap water and filtered for 
sterility (Stericup-HV, 0.45 µm, PVDF; SCHVU05RE, Millipore, Billerica, MA, USA). Drinking 
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rates were monitored and found to be unaffected between genotypes or by drug treatments (data 
not shown). 
 
Novelty Induced Hypophagia (NIH) 
 
Method 
Animals were trained to consume a palatable substance (Vanilla Ensure®) in their home 
cage under low red light conditions (~50 lumens) in the testing room for a total of 3 days of 30 
min sessions. On the first day of testing, mice were moved to a novel cage with no bedding and 
high white light illumination (~1200 lumens), where the latency to first consume Vanilla Ensure®, 
as well as the amount consumed after 30 min (in grams), were measured. On the following day, 
latency and consumption values of Vanilla Ensure® were assessed in the home cage under low 
light. To avoid ordering effects, the two testing days were switched for half of the mice. We 
administered citalopram, fluoxetine, or paroxetine in the drinking water (160 mg/L) for 28 days 
prior to behavioral screening, which was designed to accomplish a ~20 mg/kg-day chronic dosing 
regimen (David et al, 2009; Santarelli et al, 2003; Warner-Schmidt et al, 2011). Drug dosage was 
chosen for continuity with the acute drug sensitivity studies described above, as well as producing 
drug serum concentrations that are on the high end of clinically relevant serum concentrations 
(Dulawa and Hen, 2005), maximizing the potential to detect off-target activity. Animals were 
singly housed during training and testing phases. Data was analyzed via two-way ANOVA and 
Bonferroni post-hoc tests (Graphpad Prism 6.0). 
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Results 
Although the FST and TST are tests with predictive validity for antidepressant efficacy, 
we sought to evaluate the SERT-dependency of SERT actions in the Met172 model using tests 
that more closely mirror the time course associated with SSRI clinical efficacy. Thus, we 
implemented the NIH test, a behavioral paradigm sensitive to chronic, but not acute, antidepressant 
administration (Dulawa and Hen, 2005). The NIH test involves monitoring the latency of animals 
to approach and consume a known palatable substance in a novel, stressful environment, where 
SSRIs reduce latency and enhance consumption after chronic but not acute administration (Dulawa 
and Hen, 2005). We administered citalopram, fluoxetine, or paroxetine in the drinking water 
(160mg/L) for 28 days prior to behavioral screening. Compared to home cage testing, vehicle 
treated mice display significant increases in the latency to initially consume the palatable 
substance, upon presentation. Following chronic SSRI administration, WT mice displayed a 
significantly reduced latency to consume Vanilla Ensure® in the novel cage compared to vehicle 
condition (Figure 12). SERT Met172 mice administered paroxetine displayed similar reductions 
in latency as WT animals, whereas those provided fluoxetine or citalopram showed no significant 
reductions relative to vehicle condition. Paralleling our findings with latency, WT mice also 
displayed increased novel cage consumption following all SSRI treatments whereas SERT Met172 
mice displayed increased consumption only with paroxetine administration (Figure 12).  
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Figure 12. Novelty Induced Hypophagia Test. SERT antagonism is required for the chronic effects 
of fluoxetine and citalopram in the NIH test. A: Latency to consume Ensure® in novel cage was 
recorded. Two way ANOVA revealed significant main effects of genotype (F(1,97) = 4.81, P < 
0.05) and treatment (F(3,97) = 5.97, P < 0.05), but not a interaction effect (F(3,97) = 1.92, P > 
0.05). WT mice display significant reductions in latency following chronic SSRI administration, 
whereas Met172 mice display significant reductions only following paroxetine administration. B: 
Consumption effects: mice were left in novel cage for a total of 30 minutes and allowed to freely 
consume vanilla Ensure®. Two way ANOVA revealed significant main effects of genotype 
(F(1,97) = 8.53, P < 0.05) and treatment (F(3,97) = 6.10, P < 0.05), but not an interaction effect 
(F(3,97) = 1.46, P > 0.05). WT mice significantly increase consumption following chronic SSRI 
administration. SERT Met172 mice only increase consumption following paroxetine 
administration. For A-B, * indicates significance (P <.05) compared to vehicle treatment 
Bonferroni post-hoc tests (n = 12-18 per genotype and condition) 
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Hippocampal Neurogenesis 
 
Method 
 Proliferation: Following chronic administration of SSRIs and behavioral screening in the 
NIH test, mice were assayed for levels of hippocampal stem cell proliferation. Mice were 
administered 5-bromo-2'-deoxyuridine (BrdU; 4 x 75mg/kg i.p., every 2hr; Sigma-Aldrich, St. 
Louis, MO, USA) to pulse label newly proliferating S-phase mitotic cells. 24 hours following the 
last injection of BrdU, mice were anesthetized via injection of 100 mg/kg i.p. pentobarbital and 
transcardially perfused with ice-cold PBS, followed by ice-cold 4% paraformaldehyde. Brains 
were sectioned (40 μm) via a freezing stage sliding microtome (Leica, SM2000R, Buffalo Grove, 
IL, USA). Every sixth section of the hippocampus (plates 41-61 (Paxinos and Franklin, 2004)) or 
the subventricular zone (SVZ; plates 27-40) were immunostained for BrdU incorporation (mouse 
anti-BrdU; 1:1000; BD#347580; BD Biosciences; Franklin Lakes, NJ, USA) and detected 
following secondary antibody incubation (biotinylated donkey anti-mouse; 1:500; PA1-28627; 
ThermoFisher), ABC amplification (VectaStain; Vector Labs; Burlingame, CA, USA), and 
diaminobenzidine (DAB) detection. Brightfield stitched images were captured (Zeiss Axio 
Imager.M2) and stored for analysis. BrdU+ cells in the subgranular zone (SGZ) of the 
hippocampus or SVZ were counted using the ITCN (Image-based Tool for Counting Nuclei) 
plugin for ImageJ (Byun et al, 2006) by an observer blinded to genotype and drug treatment. Total 
counts were extrapolated to whole region analyzed, accounting for the harmonic mean of sections 
per region and initial sampling limits.  
Survival: We injected a separate cohort with BrdU prior to administration of SSRIs. 
Proliferating cells at steady state were pulse labeled with BrdU (4 x 75mg/kg i.p., every 2hr), and 
 82 
then their drinking water was then supplanted with SSRI infused drinking water (at 160 mg/L). 
After 4 weeks of SSRI administration, mice were sacrificed and brain tissue collected and 
developed using the immunohistochemistry procedures described above. BrdU+ cell 
quantification for proliferation measures included the SGZ and the granule cell layer of the dentate. 
Cell counting was performed as described above. Data was analyzed via two-way ANOVA and 
Bonferroni post-hoc tests (Graphpad Prism 6.0). 
 
Results 
 Hippocampal neurogenesis is a non-behavioral measure of antidepressant efficacy that has 
been shown to be sensitive to chronic, but not acute, antidepressant administration, and irradiation 
studies demonstrate neurogenesis as essential for SSRI efficacy in the NIH test (Santarelli et al, 
2003). SSRIs promote both hippocampal stem cell proliferation rate and survival of newly 
generated hippocampal stem cells (Wang et al, 2008). Consistent with these studies, chronic 
administration of fluoxetine, citalopram, and paroxetine robustly stimulated versus vehicle treated 
mice (~2x increase over vehicle) the proliferation rate (Figure 13) of hippocampal stem cells in 
WT mice, assessed via BrdU+ immunohistochemistry. In contrast, only paroxetine was able to 
enhance hippocampal stem cell proliferation (Figure 13B) in SERT Met172 mice, with similar 
magnitude of stimulation as seen in WT mice. Importantly, we saw no effect of chronic SSRI 
administration upon the stimulation of stem cell proliferation in the SVZ across both genotypes 
(Figure 14), concurrent with other studies showing the exclusivity of SSRI stem cell effects to 
the SGZ (Malberg et al, 2000; Santarelli et al, 2003).  
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Figure 13. Hippocampal Neurogenesis. SERT antagonism is required for the stimulation of 
hippocampal stem cell proliferation and survival following chronic fluoxetine and citalopram. A. 
Example images of hippocampal stem cell proliferation studies. Scale bar represents 100 µm. 
Dotted line represents the border of the of the granular cell layer of the dentate gyrus for visual 
aid. B. Proliferation: Following administration of SSRIs, WT mice display significant increases in 
stem cell proliferation rate. Met172 mice display significant increases in proliferation only after 
paroxetine. Two way ANOVA revealed significant effects of genotype (F(1,19) = 4.60, P < 0.05), 
treatment (3,19) = 8.88, P < 0.05), and interaction effect (F(3,19) = 5.06, P < 0.05). C. Survival: 
Newly generated stem cells survive significantly more in SSRI treated mice than vehicle. SERT 
Met172 mice display increased survival rates only after paroxetine. Two way ANOVA revealed 
significant main effect of genotype (F(1,22) = 6.04, P < 0.05) and treatment (F(3,22) = 6.03, P < 
0.05), but not on interaction effect (F(3,22) = 2.47, P > 0.05. For A-C, * indicates significance 
compared to vehicle (P <.05) following Bonferroni post-hoc tests (n = 4-5 per genotype and 
condition). 
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Figure 14. Stem cell proliferation in SVZ. Following chronic SSRI administration, SVZ stem cell 
proliferation rate (rate analysis 24 hours following BrdU injection) is unchanged, irrespective of 
genotype. Results are normalized to WT vehicle treated condition. Two-way ANOVA found no 
significant effects of treatment (F(1,3) = 0.59, P > 0.05) or genotype (F(1,1) = 0.64, P >0.05) (n = 
4 per genotype and condition). 
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Most basally proliferated stem cells do not survive and functionally integrate into the 
dentate gyrus of the hippocampus (Eriksson et al, 1998; Malberg et al, 2000). As such, we 
observed a roughly 75% pruning of basally proliferated stem cells in vehicle treated mice in our 
paradigm. WT mice, when chronically administered fluoxetine, citalopram, and paroxetine 
following BrdU pulse labeling of hippocampal stem cells, display increased survival rates of 
basally proliferated stem cells (Figure 13C). Parallel to the proliferation experiments, SERT 
Met172 mice do not display increased survival of the basally proliferated hippocampal stem cell 
pool following administration of fluoxetine and citalopram (Figure 13C). SERT Met172 mice, 
however, do display increased survival of the stem cell pool following chronic administration of 
paroxetine (Figure 13C). 
 
Conclusions 
  
 In the previous chapter, I presented the findings concerning the SERT dependence of 
behavioral effects following acute administration of SSRIs. These analyses were performed as the 
majority of the assertions of non-SERT targets as responsible for antidepressant efficacy of SSRIs 
derive from utilizing acute antidepressant sensitive behavioral models. If these non-SERT binding 
events were important for the behavioral effects of SSRIs in the FST and TST, SSRIs should still 
be effective in the SERT Met172 mouse model following a single administration of SSRI. SERT 
Met172 mice, however, do not respond behaviorally to SSRI treatment in the FST and TST, 
indicating that SERT antagonism is required for the acute behavioral efficacy of SSRIs, and 
additionally that these non-SERT engagements of SSRIs—should they be occurring—are 
insufficient alone to produce an antidepressant effect in these acute behavioral models. These 
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models, as stated previously, are not truly representative and efficacious in testing the chronic 
nature of SSRI administration that is required for clinical antidepressant efficacy. When SSRIs 
must be administered at high levels for weeks, this suggests that the simple proposed 
pharmacological activity at SERT may not be a critical mechanism on a chronic administration 
timescale, and that other lower affinity targets engaged over the long term may be responsible for 
the antidepressant effects of SSRIs. This scenario is intriguing considering that SSRIs have been 
shown to modulate nerve branching and growth in a non-SERT manner (Bonnin et al, 2012), and 
that new nerve growth is important and required for chronic SSRI efficacy (Santarelli et al, 2003). 
Given the shortcomings of the TST and FST for testing these more complicated scenarios, we next 
moved to test the importance of SERT antagonism onto behavioral and biochemical models that 
are sensitive to chronic—but not acute—SSRI administration. 
 Here, I first test the ability of SSRIs to induce antidepressant-like effects in the NIH test, a 
model mixing aspects of anxiety and anhedonia, which is sensitive to chronic SSRIs (Dulawa and 
Hen, 2005; Santarelli et al, 2003). On its own, the delayed timescale to antidepressant efficacy is 
important for establishing some semblance that the NIH test is sensitive to similar biological 
processes as are occurring in clinical populations taking SSRIs. The NIH test is believed to 
measure certain core aspects of depression, namely anxiety and anhedonia, both of which are 
presented in patients afflicted with depression, and are remedied following successful 
antidepressant treatment. In fact, mice that have been chronically administered SSRIs display 
reduced anxiety and anhedonia (here hypophagia to a known palatable substance) in the NIH test 
compared to vehicle treated control mice (Dulawa and Hen, 2005; Santarelli et al, 2003), though 
it is unknown whether this effect of SSRIs requires SERT antagonism. Utilizing the SERT Met172 
mouse, we can assess this question due to its selective removal of the ability of SERT blockers to 
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bind and inhibit SERT, yet retaining all other non-SERT CNS targets for these SSRIs to engage 
and potentially create antidepressant effects. When I administer SERT Met172 mice SSRIs 
chronically, these mice do not display any anxiolytic or hedonic-like effects in the NIH. These 
SERT Met172 mice, in other words, are behaviorally insensitive to chronic SSRI in the NIH test, 
indicating that, like the acute tests, SERT antagonism is required for the chronic behavioral effects 
of SSRIs. 
 Next, we needed to investigate another important facet of chronic SSRI actions, namely 
their ability to stimulate hippocampal neurogenesis. Hippocampal neurogenesis is ongoing, but 
decreases with age (Kuhn et al, 1996). This process is supported by the proliferation of stem cells 
in the subgranular zone of the dentate gyrus of the hippocampus, and these cells differentiate into 
functional neurons and integrate into the dentate gyrus of the hippocampus (van Praag et al, 2002), 
though most do not survive this process (Eriksson et al, 1998). Chronic SSRI administration, 
however, robustly increases the rate of stem cell proliferation and additionally increases the rate 
of survival among basally proliferated stem cells (Wang et al, 2008). The timescale of this 
enhanced proliferation effect of SSRIs occurs along the timeframe like that required for clinical 
efficacy of SSRIs, as well as when behavioral effects are seen in the NIH test (Santarelli et al, 
2003). Additionally, when neurogenesis is prevented, mice are not behaviorally sensitive to SSRIs 
in the NIH test (Santarelli et al, 2003). We thus felt it was an important endpoint to measure in 
addition to behavioral sensitivity in the NIH test, as some studies have shown neurogenesis 
independent behaviors that are still sensitive to chronic SSRIs (David et al, 2009), as well as strain 
differences in the requirement of neurogenesis for NIH behavioral efficacy of SSRIs (Holick et al, 
2007). However, in these studies, we did observe congruent effects of behavioral efficacy and 
hippocampal neurogenesis in our mice. WT mice, when chronically administered SSRIs display 
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an increased proliferation rate of hippocampal stem cells. These effects were limited to the SGZ 
and did not extend to another important stem cell niche of the SVZ (Alvarez-Buylla and Garcı́a-
Verdugo, 2002). These findings corroborate earlier work stating the selectivity of SSRI-induced 
stem cell proliferation to the SGZ and not the SVZ (Malberg et al, 2000; Santarelli et al, 2003), 
further highlighting the importance of the SGZ in the antidepressant response. Basally proliferated 
stem cells in WT mice are also sensitive to administration of SSRIs, displaying increased survival 
rates. When I chronically administered fluoxetine or citalopram to SERT Met172 mice, which are 
behaviorally insensitive in NIH test, these mice display no increase in the proliferation rate or 
survival of proliferated cells compared to vehicle treated control mice, though SERT Met172 mice 
are still responsive to paroxetine in both measures.  
 Taken together, these data from the behavioral NIH test and the effects upon hippocampal 
neurogenesis indicate that SERT antagonism is required for the chronic behavioral and 
biochemical effects of SSRIs. While the full pathway and effects brought about by chronic 
antidepressant administration have not been entirely defined or evaluated, these endpoints have 
been well characterized by the field to be critical for chronic SSRI efficacy. While these results 
may not be the most surprising to some, given the well characterized serotonin hypothesis of 
depression and SSRI antidepressant efficacy, there have been many characterizations of non-SERT 
SSRI engagements that may be contributing towards antidepressant efficacy, and no other models 
or assays have been able to dispel these notions or indicate without doubt or caveat that SERT is 
required for the acute and chronic behavioral and biochemical effects of SSRIs. Our tests, utilizing 
the SERT Met172 mice, clearly show that SERT is required for the antidepressant effects of SSRIs. 
These findings represent the most specific analyses to date supporting a role for SERT in both 
acute and chronic SSRI behavioral and biochemical actions in vivo.  
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CHAPTER V 
 
ANTIDEPRESSANT SENSITIVITY TO THE NOVEL ANTIDEPRESSANT 
VORTIOXETINE IN SERT MET172 
 
Note: This work was accomplished with the assistance of members of the Blakely laboratory and 
Lundbeck Research USA, under the direction of Dr. Randy Blakely and Dr. Connie Sanchez, 
respectively. Chronoamperometry experiments were performed by Dr. Nicole Baganz and 
microdialysis experiments were performed by Dr. Linda Simmler, within the Blakely laboratory. 
Slice competition binding experiments were performed by Dr. Alan Pehrson of Lundbeck 
Research USA. 
 
Introduction 
 
Depression is one of the most common psychological disorders, with incidence rates 
approaching 7% (Kessler et al, 2005), lifetime incidence 17% (Kessler, 2005), and among the 
leading contributors to global disease burden (Ferrari et al, 2013). The most common 
pharmaceutical treatment options rely upon serotonin selective reuptake inhibitors (SSRI), which 
act to prevent the serotonin transporter (SERT) from removing serotonin (5-HT) from the synaptic 
space, thereby prolonging 5-HT signal duration. Despite this, SSRIs have limited utility due to 
high rates of pharmacological insensitivity (Warden et al, 2007) and delayed clinical efficacy. To 
improve efficacy, a number of drugs have been developed that offer additional target engagements, 
including other transporters and receptors, though always retaining actions at SERT. This shift 
represents a desire to develop newer pharmacological treatments based upon updated scientific 
understanding of the complexities of depression and limitations of existing treatments. One of 
these drugs is vortioxetine, the most recently approved FDA-approved antidepressant that targets 
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SERT as well as 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3 and 5-HT7 receptors (Mørk et al, 2012). The 
introduction of these new mechanisms raises the question as to whether the 5-HT receptor actions 
alone—without SERT inhibition—could be efficacious as an antidepressant. There is precedence 
for this expectation, given that many 5-HTR directed ligands possess antidepressant-like effects in 
preclinical animal behavioral studies (Artigas, 2013; Carr and Lucki, 2010). Of note, 
antidepressant-like effects can be produced by activation of 5-HT1A (Singh and Lucki, 1993), 5-
HT1B (Tatarczyńska et al, 2005), 5-HT2C (Cryan and Lucki, 2000), and 5-HT4 (Lucas et al, 2010) 
receptors. Additionally, antidepressant-like effects can be generated via antagonism of 5-HT2A 
(Patel et al, 2004), 5-HT3 (Ramamoorthy et al, 2008), and 5-HT7 (Wesołowska et al, 2006) 
receptors. Although these 5-HT receptor directed ligands have been shown to be efficacious in 
preclinical animal studies, none have been proven clinically superior to SSRI antidepressants, 
either due to poor metabolic profile, limited efficacy, or side effect profile. The study of 
vortioxetine provides a unique opportunity to question whether it is possible to recapitulate an 
antidepressant effect without SERT inhibition in a clinically relevant molecule. 
 In order to selectively remove the SERT component of vortioxetine action, one could use 
the SERT knockout mouse. This approach would be counterproductive considering the SERT 
knockout mouse displays reductions in CNS tissue 5-HT levels (Bengel et al, 1998), 5-HT neurons 
(Lira et al, 2003), and altered dorsal raphe firing rates (Lira et al, 2003). Particularly concerning 
are the observed changes in 5-HT receptor expression in SERT knockout mice (Cour et al, 2001; 
Fabre et al, 2000; Li et al, 2000; Rioux et al, 1999). Were we to utilize the SERT knockout mouse, 
our findings of potential SERT-independent efficacy would be confounded, for example, by the 
alterations in 5-HT1A expression—one of the major non-SERT targets of vortioxetine—and would 
be clinically non-generalizable. 
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 Our approach to ameliorate this problem is to utilize the SERT Met172 model, a novel 
transgenic mouse model that disrupts high-affinity binding of SERT antagonists without affecting 
5-HT transport capability at SERT, preserving monoamine homeostasis (Nackenoff et al, 2015; 
Thompson et al, 2011). Through this approach, we will be able to remove the actions of 
vortioxetine at SERT but preserve its effects at other 5-HT receptors in a system devoid of 
developmental alterations (Figure 15). Should vortioxetine remain behaviorally efficacious in 
SERT Met172 mice, this would indicate that SERT may not be a critical target for future 
development of 5-HT directed antidepressants, and that these future efforts would have more 
freedom pursuing specific 5-HT receptors to recapitulate the traditional antidepressant response, 
potentially presenting lesser side-effect profile and quicker clinical efficacy.   
 
Animals 
 
SERT Met172 knock-in mice were created as described previously (Thompson et al, 2011). 
These animals were then backcrossed onto a C57BL/6 genetic background for future utility in 
behavioral assays and described previously (Nackenoff et al, 2015). Due to functional coding 
differences between 129S6 and C57BL/6 mice in the 5-HTT gene (Carneiro et al, 2009), the ‘WT’ 
animals here are the result of parallel backcrossing of 129S6 mice onto the C57BL/6 genetic 
background, preserving the 129S6 5-HTT polymorphisms (Nackenoff et al, 2015). Animals used 
in all experiments were male mice aged 8-12 weeks (at time of beginning of experimental 
manipulation) generated from homozygous WT and knock-in (SERT Met172) breeders. All 
animal studies were performed in accordance with protocols approved by the Vanderbilt 
University animal care and use committee. 
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Figure 15. Research Strategy for Vortioxetine in SERT Met172. Cartoon diagram of combined 
effects of vortioxetine in WT and SERT Met172. Vortioxetine is sensitive to the SERT Met172 
substitution. Here, we propose the potential maintained efficacy of vortioxetine in the SERT 
Met172 model due to its maintained actions directly at 5-HT receptors 
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Drugs  
 
Vortioxetine HBr was provided by Lundbeck Research USA (Paramus, NJ, USA), and 
Paroxetine HCl was procured from TCI Chemicals (Portland, OR, USA). For in vitro and ex vivo 
studies, vortioxetine was prepared at 10mM stock solutions in 100% DMSO. Final DMSO 
concentrations for these studies were under 1%. All control conditions contained the highest level 
of DMSO that would be presented by the most concentrated vortioxetine solution. For acute animal 
studies, vortioxetine was prepared fresh at 5 and 10mg/kg (free base) and paroxetine at 20 mg/kg, 
dissolved in 10% β-cyclodextrin/0.9% sterile saline solution (vehicle), sterile filtered (0.2 µm 
syringe filter, 195-2520, ThermoScientific, Waltham, MA, USA), and administered intraperitoneal 
(i.p.) at 10uL/g animal weight.  
 
In Vitro Analysis of Vortioxetine Competition of 5-HT Uptake 
 
Method 
 HEK-293T cells were cultured at 37ºC in modified DMEM cell media containing 10% 
dialyzed fetal bovine serum (to eliminate 5-HT in growth media) and antibiotics. Cells were 
transfected with 5µg of plasmid DNA from either WT hSERT or SERT Met172 containing 
pcDNA3 plasmids (Invitrogen). Plasmid DNA was preincubated and loaded into artificial 
membrane using TransIT (3µL per µg DNA; Mirus, Madison, WI, USA) for 15 minutes. A cellular 
suspension containing 5 x 106 cells in cell growth media was then added to this transfection mixture 
and incubated for 30 minutes, allowing the artificial membranes to fuse and deliver plasmid DNA 
into the cells. Afterwards, the cell and transfection suspension was loaded onto poly-D-lysine 
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coated (to aid adherence) 12 well plates. A separate equal aliquot was plated in a separate plate for 
protein determination at the time of uptake, affording normalization by cellular protein levels. The 
cells were allowed to plate, grow, and express SERT from the plasmid DNA for 48 hours. At the 
time of the radiouptake assay, cell media was replaced with Krebs-Ringer HEPES buffer (KRH) 
assay buffer containing pargyline (MAOI, prevents enzymatic metabolism of 5-HT), and ascorbic 
acid (preservative; prevents spontaneous oxidation of 5-HT). Cells were then preincubated with 
various concentrations of vortioxetine for 10 minutes at 37ºC. Cells were then incubated with 20 
nM [3H]5-HT (PerkinElmer, NET498001MC, Waltham, MA, USA) and allowed to accumulate 5-
HT for 10 minutes at 37ºC. Assay buffer was then aspirated off and cells were washed three times 
in assay buffer. Cells were then solubilized in scintillation fluid (Microscint 20, 6013621, 
PerkinElmer) overnight, before scintillation spectroscopy (Topcount, PerkinElmer). Uptake 
counts were normalized to protein concentration (Pierce BCA; ThermoFisher), averaged across 
experiments, and limited to maximum (uninhibited 5-HT uptake condition) and minimum via full 
block (1 µM paroxetine; defines non-specific uptake) conditions. Competition curve was fit to a 
single site inhibition model (Graphpad Prism 6.0). 
 
Results 
 The SERT I172M substitution disrupts affinity for many SERT directed ligands without 
affecting 5-HT affinity or uptake via SERT (Henry et al, 2006; Thompson et al, 2011). We were 
able to determine that vortioxetine is indeed sensitive to the SERT I172M substitution (Figure 
16), and that the shift in inhibition efficacy (~20 fold) is on par with that of fluoxetine, which we 
have demonstrated that can achieve functional SERT inhibition at a single dose in WT but not in 
SERT Met172 mice (Nackenoff et al, 2015; Thompson et al, 2011).   
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Figure 16. In Vitro Vortioxetine Competition 5-HT Uptake. Competition 5-HT uptake analysis in 
HEK-293T cells transfected with pcDNA3 plasmids containing WT SERT or SERT Met172. 
Vortioxetine (WT: KI 21.9nM +/- 1.1; Met172 KI 425nM +/- 1.07) was assessed for their ability 
to compete with [3H]5-HT uptake. (n = 4/condition). Vortioxetine is less able to inhibit 5-HT 
uptake in cells tranfected with SERT Met172, as opposed to WT SERT. This affinity reduction for 
SERT Met172 is on the order of ~20 fold decreased potency. 
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These data suggest that we should be able to achieve similar success with vortioxetine, and 
that the ‘dose window’ we see here is not too small in our pursuit to remove the SERT component 
from the actions of vortioxetine. Though, this system is slightly artificial given the in vitro nature 
as well as the transfection conditions, so it would be more suitable to test this pharmacological 
sensitivity profile of vortioxetine in more suitable native-like system (ie. Ex vivo synaptosomal 5-
HT competition uptake) before any actual attempts towards analyzing the requirement of SERT 
for the actions of vortioxetine.  
 
Ex vivo Synaptosomal Competition 5-HT Uptake 
 
Method 
Following sacrifice via rapid decapitation, the whole brains of 8-12 week old male mice 
were dissected on ice and used for synaptosomal preparations as described previously (Thompson 
et al, 2011). Briefly, midbrain sections were mechanically homogenized in 0.32M sucrose in 5mM 
HEPES buffer. This homogenate was subjected to a low gravity centrifugation (10 min, 4°C at 
1,000x g) in order to remove large cellular components (eg. mitochondria, nuclei, and large 
membranes) from the reconstituted nerve terminals, classified as ‘synaptosomes’. The supernatant 
after this first spin contains the synaptosomes. The synaptosomes are then pelleted via a high 
gravity centrifugation (15 min, 4°C at 10,000x g). The pellet was resuspended in KRH buffer 
containing glucose (for synaptosomal viability throughout the preparation and assay), pargyline 
(MAOI, prevents enzymatic metabolism of 5-HT), and ascorbic acid (preservative, prevents 
spontaneous oxidation of 5-HT. Equal volumes of synaptosomes were incubated with 20 nM 
[3H]5-HT (PerkinElmer) and varying concentrations of vortioxetine and incubated at 37 °C for 10 
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minutes. Uptake was terminated via vacuum filtration through GF/B filter (Whatman, Pittsburgh, 
PA, USA) and three washes with ice cold 1x PBS buffer. Specific uptake was defined by 
subtracting uptake obtained in the presence of 1μM paroxetine. Competition curve was fit to a 
single site inhibition model (Graphpad Prism 6.0) 
 
Results 
 In order to assess whether the antidepressant actions of vortioxetine require SERT 
antagonism, we first needed to verify that vortioxetine is sensitive to the I172M substitution. 
Utilizing [3H]5-HT uptake into midbrain derived synaptosomes, and competition with 
vortioxetine, we demonstrate that vortioxetine is 20 fold less potent at SERT Met172 compared to 
WT SERT (Figure 17). These data corroborate what was found utilizing in vitro cellular 
transfection and competition uptake assays. This shift is roughly equivalent to the shift in potency 
of fluoxetine in the same paradigm, which we have shown can still render separations in functional 
SERT antagonism between these two SERT variants, it should therefore be possible to attain 
functional SERT antagonism with a single in vivo dose of vortioxetine in WT SERT mice that 
renders inconsequential antagonism in SERT Met172 mice. These studies alone cannot confirm 
this possibility, so further steps must be taken to ensure a separation in SERT binding as well as 
antagonism, both in reconstituted and functional determinations of these effects. 
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Figure 17. Ex Vivo Vortioxetine 5-HT Uptake Competition. The SERT Met172 mutant imposes 
altered pharmacological sensitivity with normal SERT expression and function. Competition 5-
HT uptake analysis in midbrain derived synaptosomes. Vortioxetine (WT: KI 17.1nM +/- 2.0; 
Met172: KI 262nM +/- 2.0) was assessed for their ability to compete with [
3H]5-HT uptake. (n = 
4/condition). Like the in vitro studies, vortioxetine displays reduced potency for SERT Met172 vs 
WT SERT (~20-fold reduction). 
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Ex Vivo SERT Occupancy 
 
Method 
 We administered vortioxetine at 5 and 10 mg/kg i.p. to WT and SERT Met172 mice 1 hour 
prior to sacrifice. Following decapitation, brains were removed and frozen on dry ice and stored 
at -20°C until further use. Frontal cortex was coronally sliced at 20 µm thickness approximately 
0.9-0.7mm anterior from Bregma (Paxinos and Franklin, 2004) via cryostat, and mounted onto 
slides. Slides were stored in slide boxes with desiccator pellets at -20oC until use. Slide boxes were 
allowed to defrost following 30 minutes of constant high flow air stream prior to opening. Slides 
were incubated in assay buffer (50 mM Tris HCl, 120 mM NaCl, and 5 mM KCl (pH=7.4)) 
containing 1nM [3H]paroxetine for 2h at room temperature. Non-specific binding was determined 
via incubation in excess (1 µM) non-radiolabeled paroxetine in assay buffer. Slides were then 
washed twice in assay buffer for 30 minutes, each at room temperature. Slides were allowed to air 
dry following washes for 30 minutes before transferal to a vacuum desiccator for at least 1 hour.  
Autoradiographic analysis was then performed upon the slides using a Beta Imager 
(Biospace Lab, Paris, France). Bound radioactivity was measured by the Beta Imager for 24 hours, 
and quantified using the β-Vision software (Biospace lab, Paris, France). Surface radioactivity 
(measured as counts per min per millimeter squared, or cpm/mm2) was measured from a region of 
interest defined a priori based on the results of receptor mapping experiments using 
[3H]paroxetine, and included the lateral and medial septum, the nucleus accumbens, and the 
olfactory tubercle.  
Total binding for a given mouse brain was determined by taking the average cpm/mm2 
from each of four replicate slices. Nonspecific binding was determined by averaging cpm/mm2 
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from the four brain slices in the nonspecific binding condition. Specific binding was determined 
for each mouse brain by subtracting the average nonspecific binding from total binding. Specific 
binding levels for each brain were then normalized to the average specific binding from the vehicle 
treated animals and expressed as a percent of average vehicle specific binding.  
Fractional receptor occupancies were determined by subtracting these normalized values 
from 100.  Fractional SERT occupancies observed in wild type or I172M mice were compared 
using a two way between subjects analysis of variance (ANOVA), with the factors being defined 
by genotype and dose. Where appropriate, post hoc analysis was conducted using Fisher’s 
protected t. Alpha value stringency was set at P = 0.05. 
  
Results 
 We aimed to validate that behaviorally relevant concentrations of vortioxetine would not 
fully saturate SERT Met172, which could limit the selectivity of our approach to selectively 
remove the SERT component of vortioxetine via the SERT Met172 model. The first way we chose 
to validate this idea was through brain slice competition binding. It was necessary to utilize 
radiolabeled and non-radiolabeled paroxetine as the competitive ligand due to its insensitivity to 
the I172M substitution. Pre-administration of the behaviorally relevant doses of 5 and 10 mg/kg 
vortioxetine (Guilloux et al, 2013) were able to produce robust SERT occupancy in WT animals, 
nearing and exceeding the requisite SERT occupancy for acute antidepressant efficacy of 
traditional pure SSRIs (Meyer et al, 2004). At both doses, SERT Met172 mice displayed 
significant reductions in vortioxetine SERT occupancy compared to WT mice (Figure 18).  
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Figure 18. Ex Vivo Vortioxetine SERT Occupancy. Vortioxetine occupancy at SERT following 
peripheral administration of behaviorally relevant doses of vortioxetine. Coronal brain sections 
were harvested from mice that were administered 5 or 10 mg/kg vortioxetine (i.p.), which were 
sacrificed 1 hour following drug administration (the time by which behavioral analyses would 
occur in other studies).  
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However, the SERT Met172 mice did display appreciable levels of SERT occupancy, 
which could be problematic for our future studies. It should be noted, however, that both in in vitro 
and behavioral studies, classical SSRI occupancy at SERT must reach >80% occupancy to attain 
functional antagonism of SERT to yield inhibition of 5-HT uptake or antidepressant-like effects in 
the TST and FST (Meyer et al, 2004). So, it may not be problematic for our future experiments, 
as this lower level of vortioxetine occupation at SERT in the SERT Met172 animals may be 
inconsequential with respect to functional SERT antagonism. Though we cannot be sure of this 
given solely this assay, we must consider assays that are sensitive to functional SERT antagonism 
in a complete animal in vivo system. 
 
In Vivo Chronoamperometry 
 
Method 
 In vivo chronoamperometry with carbon fiber electrodes (30 μm diameter) was carried out 
according to the methods described previously (Thompson et al, 2011). The electrode–
micropipette recording assembly was lowered into the CA3 region of the dorsal hippocampus 
[anteroposterior (AP), −1.94 from bregma; mediolateral (ML), +2.0 from midline; dorsoventral 
(DV) −2.0 from dura] of anesthetized mice. To assess 5-HT clearance kinetics, 5-HT was pressure 
ejected in increasing volumes to attain signal amplitudes matching in vitro calibration standards 
of approximately 0.5 to 10 μM. To examine the effect of vortioxetine on 5-HT clearance, 
exogenous 5-HT was intrahippocampally applied by pressure-ejection before and after peripheral 
(i.p.) injection of 10 mg/kg vortioxetine, and T80 values collected at 10 minute intervals.  
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Results 
 In order to assess whether the levels of SERT occupancy produce functional SERT 
antagonism in vivo in SERT Met172 mice, we first utilized in vivo chronoamperometry, which can 
measure real-time 5-HT clearance kinetics following exogenous administration of 5-HT (Daws et 
al, 1998; Schenk et al, 1983). This technique is sensitive to pre-administration of SSRIs, indicated 
by the delay in amount of time required to clear 80% of peak 5-HT signal (T80), which is indicative 
of functional SERT antagonism (Baganz et al, 2008), and has been previously been validated to 
be sensitive to our SERT Met172 model (Thompson et al, 2011). Following peripheral 
administration of vortioxetine and measuring clearance kinetics every 10 minutes, we found 
significant elevations in T80 in WT mice across all time points compared to pre-drug baseline 
(Figure 19). SERT Met172, however, display no such increase in T80 following administration of 
vortioxetine, indicating that the levels of SERT occupancy that are produced in SERT Met172 
animals are not functionally relevant and are unable to produce functional SERT-mediated 5-HT 
clearance in the hippocampus. 
 
In Vivo Microdialysis 
 
Method 
For in vivo microdialysis, a guide cannula was implanted above the lateral hippocampus 
(stereotactic coordinates for the tip of the guide cannula were -3.18 A/P, 2.8 M/L, and -1 D/V, 
relative to bregma).  
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Figure 19. In Vivo Chronoamperometry of Vortioxetine-Inhibited 5-HT Clearance. Vortioxetine 
induced delayed clearance of 5-HT in dorsal hippocampus, detected via in vivo 
chronoamperometry. Extrasynaptic 5-HT content was measured from the CA3 region of the 
hippocampus in real time, via in vivo electrochemical detection. Vortioxetine (10 mg/kg, i.p) is 
able to delay 5-HT clearance in WT SERT but not SERT Met172, indicating functional SERT 
antagonism in WT but not SERT Met172 mice (P < 0.05, two way RMANOVA) 
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After recovery from surgery, the guide cannula was replaced with a microdialysis probe (3 
mm active site, 20’000 Da cut-off, from Synaptech, MI) and perfused with aCSF (149 mM NaCl, 
2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, pH 7.2) at a flow-rate of 1 µL/min. aCSF samples 
were collected in 20 min intervals before and after 10 mg/kg vortioxetine (i.p.). 5-HT levels were 
quantified with HPLC/EC in the Vanderbilt Brain Institute Neurochemistry Core. Data were 
expressed as the level of 5-HT relative to pre-injection baseline. Probe location was verified post-
mortem via coronal brain slice procedures (40 µm). Data were analyzed via two-way RMANOVA, 
alpha stringency set to P = 0.05. 
 
Results 
 Because in vivo chronoamperometry requires exogenous application of 5-HT, we felt it 
necessary to ensure that a behaviorally relevant dose of vortioxetine is incapable of producing 
functional SERT antagonism of endogenous 5-HT clearance in SERT Met172 mice. We thusly 
chose to explore this effect utilizing in vivo microdialysis. In this setup, behaviorally relevant doses 
of SSRIs administered are peripherally, leading to functional antagonism of SERT, elevating 
extracellular 5-HT in the extra-synaptic space, where it can be sampled with a microdialysis probe. 
Using this approach, we showed that SSRIs are unable to functionally antagonize SERT Met172, 
and sustain normal levels of 5-HT (Thompson et al, 2011). As shown here, vortioxetine can 
produce elevated levels of extracellular 5-HT in WT mice, indicative of functional SERT 
antagonism (Figure 20). Vortioxetine fails to stimulate extracellular levels of 5-HT in SERT 
Met172 mice (Figure 20), indicating that the highest concentration of vortioxetine we utilize in 
the behavioral studies is unable to functionally antagonize the 5-HT clearance by SERT Met172. 
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Figure 20. In Vivo Microdialysis of Vortioxetine-Induced Elevations in Extrasynaptic 5-HT. 
Vortioxetine induced increases in extrasynaptic 5-HT in dorsal hippocampus, detected via in vivo 
microdialysis. Dialysate was sampled from the CA3 region of the hippocampus every 20 minutes, 
and assessed for 5-HT content, via electrochemical detection. Vortioxetine (10 mg/kg, i.p) is able 
to elevate extrasynaptic 5-HT levels in WT SERT but not SERT Met172, indicating functional 
SERT antagonism in WT but not SERT Met172 mice (P < 0.05, two way RMANOVA) 
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Acute Behavioral Paradigm Animal Procedure 
 
All behavioral assays were performed upon behaviorally naïve 8-12 week old male mice 
in the Neurobehavioral Core lab of the Vanderbilt University Medical Center. Animals were 
housed with a 12:12 hour light:dark cycle (light cycle: 7:00 to 19:00 hours), and all 
experimentation occurred between 13:00 and 18:00 hours. Animals were transferred to housing 
within the facility and allowed to acclimate for at least 1 week prior to behavioral manipulations. 
For acute drug studies, animals were acclimated to handling the day prior to experimentation, at 
which point body weight was measured to establish appropriate drug dose. All drugs were prepared 
fresh and dissolved in 10% β-cyclodextrin/0.9% sterile saline solution and injected intraperitoneal 
at 10 μL/g body weight with either vehicle solution or 5 or 10 mg/kg vortioxetine. These doses 
were utilized to match prior studies by other research groups investigating the effects of 
vortioxetine in WT animals (Guilloux et al, 2013; Mørk et al, 2012). These prior studies, using 
WT C57Bl/6 mice, indicate high SERT occupancy was achieved at these doses as well as 
significant behavioral sensitivity. Our choice of these doses that reflects our desire to eliminate 
SERT occupancy in SERT Met172 mice to determine whether these doses maintain behavioral 
efficacy of vortioxetine without SERT antagonism. All experiments and data analyses were scored 
manually utilizing instantaneous sampling and binning methods of scoring while performed blind 
to drug condition and genotype. 
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Tail Suspension Test (TST) 
 
Method 
Mice were injected (i.p) with 10% β-cyclodextrin vehicle or vortioxetine (5 or 10 mg/kg) 
60 minutes before a 6 minute TST. Mice were then suspended by taping the tail to a vertical 
aluminum bar and activity recorded by video. The apparatus allows for multiple mice to be tested 
at the same time. Mice are visually isolated from each other in 5 sided opaque plexiglass boxes, 
with the open side facing towards the room for video capture and handling purposes. Sixty minutes 
after injection, mice were then suspended by taping the tail to a vertical aluminum bar and activity 
was recorded by video. Immobility was defined when mice are motionless, excluding minute limb 
movements. Time immobile was manually assessed by an observer blinded to genotype and drug 
treatment. Data were analyzed following planned Student t comparisons, alpha stringency of P = 
0.05. 
 
Results 
 Following the indications reported above that we can selectively remove the SERT 
antagonism from the pharmacological actions of vortioxetine, but maintain its actions at 5-HT 
receptors, we aimed to probe whether vortioxetine was still behaviorally efficacious in the TST in 
SERT Met172 mice. As expected, WT animals in the TST display significantly increased time 
mobile relative to vehicle condition in response to both doses of acute vortioxetine and the SSRI 
paroxetine (Figure 21). SERT Met172 mice also display significant increase in mobility in 
response to the active SSRI paroxetine, which is insensitive to the Met172 substitution. 
Interestingly, the SERT Met172 mice displayed significant increases in mobility following both 
doses of vortioxetine (Figure 21).  
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Figure 21. Tail Suspension Test with Vortioxetine. Actions of vortioxetine in the TST arise 
independently of SERT antagonism.  All tests were performed 30 min after i.p. injection of 
20mg/kg drug. Time mobile in a 6-minute TST. Two-way ANOVA revealed significant main 
effects of genotype.  WT and Met172 mice display significant increases in mobility time in 
response to both doses of vortioxetine. Replotted are data from other experiments indicating the 
loss of efficacy of pure SSRIs citalopram and fluoxetine, yet maintained efficacy of paroxetine in 
Met172 mice. * indicates significance (P<.05) compared to vehicle treatment via planned students 
T test posttests (n = 10-12 per genotype and condition). 
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Forced Swim Test (FST) 
 
Method 
Mice were injected (i.p) with 10% β-cyclodextrin vehicle or vortioxetine 60 minutes before 
a 6-minute FST. Mice were placed in the center of a 15 cm diameter clear plexiglass cylinder filled 
with tap water (25-27 °C) to a depth of approximately 15 cm for the 6 minute FST and activity 
was recorded by video. Multiple mice were assessed at the same time, though, as with the TST, 
mice were kept visually unaware of the other mice via black plastic separators. Immobility was 
defined when mice only make movements to maintain balance. Time immobile was manually 
tabulated by an observer blinded to genotype and drug treatment. Data were analyzed following 
planned Student t comparisons, alpha stringency of P = 0.05. 
 
Result 
 Given that we can remove the SERT antagonism from the pharmacological actions of 
vortioxetine, but maintain its actions at 5-HT receptors, we aimed to probe whether vortioxetine 
was still behaviorally efficacious in the FST in SERT Met172 mice. As expected, WT animals in 
the FST display significantly increased time mobile relative to vehicle condition in response to 
both doses of acute vortioxetine and the SSRI paroxetine (Figure 22). Paralleling the maintained 
efficacy of vortioxetine in the TST, SERT Met172 mice show significant increases in mobility 
following treatment with both doses of vortioxetine and paroxetine (Figure 22). Vortioxetine has 
been shown to induce climbing behavior in WT mice (Guilloux et al, 2013), which is thought to 
be due to its ability to enhance norepinephrine release in the prefrontal cortex (Mørk et al, 2012) 
via 5-HT3 mediated silencing of forebrain cortical GABAergic neurons (Puig et al, 2004).  
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Figure 22. Forced Swim Test with Vortioxetine. Actions of vortioxetine in the FST arise 
independently of SERT antagonism.  All tests were performed 30 min after i.p. injection of 
20mg/kg drug. Time mobile and climbing in a 6-minute FST. Two-way ANOVA revealed 
significant main effects of genotype.  WT and Met172 mice display significant increases in 
mobility time in response to both doses of vortioxetine. Replotted are data from other experiments 
indicating the loss of efficacy of pure SSRIs citalopram and fluoxetine, yet maintained efficacy of 
paroxetine in Met172 mice. Also shown is the SERT independent dose dependent increase in 
vortioxetine induced climbing behavior in both WT and SERT Met172 mice. * indicates 
significance (P<.05) compared to vehicle treatment via planned student’s T test posttests (n = 10-
12 per genotype and condition). 
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We observed this climbing-enhancing effect in our WT mice, in that vortioxetine could 
dose dependently increase climbing behavior in the FST (Figure 22), a trait that SSRIs like 
paroxetine do not possess (Detke et al, 1995). SERT Met172 mice also display increased climbing 
behavior following acute vortioxetine administration, but not after paroxetine (Figure 22). 
Together, these findings indicate that despite the loss of SERT antagonism, vortioxetine is still 
able to produce mobility enhancing effects in the TST and FST.  
 
Novelty Induced Hypophagia (NIH)  
 
Method 
Animals were trained to consume a palatable substance (Vanilla Ensure®) in their home 
cage under low red light conditions (~50 lumens) in the testing room for a total of 3 days of 30 
min sessions. On the first day of testing, mice were moved to a novel cage with no bedding and 
high white light illumination (~1200 lumens), where the latency to first consume Vanilla Ensure®, 
as well as the amount consumed after 30 min (in grams), were measured. On the following day, 
latency and consumption values of Vanilla Ensure® were assessed in the home cage under low 
light. To avoid ordering effects, the two testing days were switched for half of the mice. We 
administered vortioxetine in specially formulated rodent chow (to accomplish a ~10 mg/kg-day 
dosing regimen) for 28 days prior to behavioral screening, (David et al, 2009; Santarelli et al, 
2003; Warner-Schmidt et al, 2011). Drug dosage was chosen for continuity with the acute drug 
sensitivity studies described earlier, as well as to produce serum concentrations of drug that are on 
the high end of clinically relevant serum concentrations in humans for traditional SSRIs (Dulawa 
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and Hen, 2005). Animals were singly housed during training and testing phases. Data were 
analyzed using two-way ANOVA and Bonferroni post hoc tests (Graphpad Prism 6.0). 
 
Results 
As noted above, the FST and TST are tests with predictive validity for antidepressant 
efficacy. Here we sought to evaluate the SERT-dependency of vortioxetine actions in the SERT 
Met172 model using an assay that possess more construct validity, and is thus more likely to 
measure the neurobiological processes that are required for human clinical efficacy. Thus, we 
implemented the NIH test, a behavioral paradigm sensitive to chronic, but not acute, antidepressant 
administration (Dulawa and Hen, 2005). The NIH test involves monitoring the latency of animals 
to approach and consume a known palatable substance in a novel, stressful environment, where 
SSRIs reduce latency and enhance consumption after chronic but not acute administration (Dulawa 
and Hen, 2005). We administered vortioxetine in specially formulated chow for 28 days prior to 
behavioral screening. Following vortioxetine administration, WT mice displayed a reduced latency 
to consume Vanilla Ensure® in the novel cage compared to vehicle condition (Figure 23). SERT 
Met172 mice, also display reduced latency to consume the Vanilla Ensure® in the novel cage. 
These findings suggest that despite ablating the functional effects of vortioxetine at SERT via the 
SERT Met172 substitution, the actions of vortioxetine at serotonin receptors are sufficient to 
produce antidepressant-like activity in the NIH assay. In other words, the chronic antidepressant 
behavioral activity of vortioxetine in the NIH test does not require SERT antagonism. 
We had suspected the potential possibility of SERT-independent antidepressant effects of 
vortioxetine prior to our initial efforts, due to the direct actions of vortioxetine upon the 5-HT1A 
receptor (Mørk et al, 2012).   
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Figure 23. Novelty Induced Hypophagia with Vortioxetine. SERT antagonism is not required for 
the chronic effects of vortioxetine in the NIH test. Latency to consume Ensure® in novel cage was 
recorded. Two-way ANOVA revealed significant main effects of genotype. WT and Met172 mice 
display significant reductions in latency following chronic SSRI administration. * indicates 
significance (P <.05) compared to vehicle treatment following Two Way ANOVA and Bonferroni 
post-hoc tests (n = 20-25 per genotype and condition).  Two Way ANOVA revealed significant 
main effect of drug (F(1,78) = 13.26, P < 0.05), but not of genotype (F(1,78) = 0.10, P > 0.05) or 
interaction (F(1,78) = 0.06, P > 0.05. 
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5-HT1A activation has also been shown to stimulate hippocampal stem cell proliferation, 
as opposed to survival (Benninghoff et al, 2012; Klempin et al, 2010). 5-HT1A receptors has been 
shown to be implicated in chronic behavioral and biochemical changes observed with SSRIs in the 
NIH assay, as well as hippocampal stem cell proliferation (Santarelli et al, 2003), a process that is 
required for chronic behavioral efficacy of SSRIs in the NIH test. Based upon these prior 
observations, we hypothesized that vortioxetine would show SERT-independent behavioral effects 
in the NIH by showing reduced latency to consume Vanilla Ensure® in the novel cage. These 
predictions were realized, provided the preserved efficacy of vortioxetine in the SERT Met172 
mice. It would be interesting to compare the effect size of latency suppression between WT and 
SERT Met172 mice, as to ascertain whether SERT antagonism provides greater behavioral 
efficacy, though the assay was not powered to test this question. In our experiments, we could 
detect no differences in the magnitude of the effect sizes between the two groups, suggesting that 
SERT antagonism is rather inconsequential with respect to the actions of vortioxetine. Though one 
must also consider the limits in detection, and possible maximum effect that may be limiting this 
line of questioning. The NIH test provides sufficient dynamic range to detect antidepressant 
sensitive effects (Dulawa and Hen, 2005; Santarelli et al, 2003), though the magnitude is largely 
dictated by the strength of the anxiogenic paradigm and not perfectly suited for the separation of 
antidepressant strength (Dulawa and Hen, 2005). We cannot be sure which receptor, or set of 
receptors, is required for the activity of vortioxetine in this assay, though, reasonably, we can state 
that chronic vortioxetine does not require SERT antagonism for efficacy in the NIH test, and that, 
likely, its residual actions on 5-HT receptors are sufficient to produce the behavioral efficacy of 
vortioxetine in the NIH test. 
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Hippocampal Neurogenesis 
 
Method 
Proliferation: Following chronic administration of SSRIs and behavioral screening in the 
NIH test, mice were assayed for levels of hippocampal stem cell proliferation. Mice were 
administered 5-bromo-2'-deoxyuridine (BrdU; 150mg/kg i.p.; Sigma-Aldrich, St. Louis, MO, 
USA) to pulse label newly proliferating S-phase mitotic cells. 24hr following the last injection of 
BrdU, mice were anesthetized via injection of 100 mg/kg i.p. pentobarbital and transcardially 
perfused with ice-cold PBS, followed by ice-cold 4% paraformaldehyde. Brains were sectioned 
(40 μm) via freezing stage sliding microtome (Leica, SM2000R, Buffalo Grove, IL, USA). Every 
sixth section of the hippocampus (plates 41-61 (Paxinos and Franklin, 2004)) was immunostained 
for BrdU incorporation (mouse anti-BrdU; 1:1000; BD#347580; BD Biosciences; Franklin Lakes, 
NJ, USA) and detected following secondary antibody incubation (biotinylated donkey anti-mouse; 
1:500; PA1-28627; ThermoFisher), ABC amplification (VectaStain; Vector Labs; Burlingame, 
CA, USA), and diaminobenzidine (DAB) detection. Brightfield stitched images were captured 
(Zeiss Axio Imager.M2) and stored for analysis. BrdU+ cells in the subgranular zone (SGZ) of the 
hippocampus were counted using the ITCN (Image-based Tool for Counting Nuclei) plugin for 
ImageJ (Byun et al, 2006) by an observer blinded to genotype and drug treatment. Total counts 
were extrapolated to whole hippocampus, accounting for the harmonic mean of hippocampal 
sections per mouse and initial sampling limits.  
Survival: We injected a separate cohort with BrdU prior to administration of SSRIs. 
Proliferating cells at steady state were pulse labeled with BrdU (150mg/kg i.p.), and then their 
drinking water was then supplanted with SSRI infused drinking water (at 160 mg/L). After 4 weeks 
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of SSRI administration, mice were sacrificed and brain tissue collected and developed using the 
immunohistochemistry procedures described above. BrdU+ cell quantification for proliferation 
measures included the SGZ and the granule cell layer of the dentate. Cell counting was performed 
as described above. Data were analyzed using two-way ANOVA and Bonferroni post hoc tests 
(Graphpad Prism 6.0). 
 
Result 
 Proliferation:  Hippocampal neurogenesis is known to be stimulated after chronic, but not 
acute, antidepressant administration, which occurs along similar timescales of chronic SSRI 
behavioral sensitivity. Through the use of irradiation ablation studies, hippocampal neurogenesis 
has been shown to be required for the behavioral efficacy of chronic SSRI administration in the 
NIH test (Santarelli et al, 2003). SSRIs promote both hippocampal stem cell proliferation rate and 
survival of newly generated hippocampal stem cells (Wang et al, 2008), of which vortioxetine is 
no different (Guilloux et al, 2013). Consistent with these studies, chronic administration of 
vortioxetine stimulated the proliferation rate (Figure 24) of hippocampal stem cells in WT mice, 
assessed via BrdU+ immunohistochemistry. Vortioxetine was also able to stimulate the 
proliferation rate of these hippocampal stem cells in SERT Met172 mice (Figure 24), which 
agrees with prior studies that hippocampal stem cell proliferation stimulation tracks with 
behavioral efficacy in the NIH test.  
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Figure 24. Hippocampal Neurogenesis: Proliferation Stimulation by Vortioxetine. SERT 
antagonism is not required for the stimulation of hippocampal stem cell proliferation and survival 
following chronic vortioxetine administration. Proliferation: Following administration of SSRIs, 
WT and Met172 mice display significant increases in stem cell proliferation rate. * indicates 
significance compared to vehicle (P <.05) following Two Way ANOVA Bonferroni post-hoc tests 
(n = 4 per genotype and condition). Two way ANOVA revealed insignificant effects of genotype 
(F(1,10) = 3.20, P > 0.05), significant effects of drug (F(1,10) = 78.29, P < 0.05), and insignificant 
interaction (F(1,10) = 0.50, P < 0.05). 
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These data corroborate our findings that vortioxetine can sufficiently stimulate hippocampal stem 
cell proliferation due to the SERT-independent actions of vortioxetine, potentially via 5-HT1A 
receptor activation, given that 5-HT1A receptor activation leads to the proliferation of these stem 
cells (Benninghoff et al, 2012; Klempin et al, 2010) and is required for both proliferation and 
efficacy of chronic SSRI behavioral efficacy in the NIH test (Santarelli et al, 2003). These data 
also indicate that SERT antagonism is not required for the proliferative component of hippocampal 
neurogenesis induced by chronic vortioxetine. Our findings support the potential for directly 
engaging specific 5-HT receptors as opposed to simply invoking SERT antagonism for the 
development of future antidepressant drugs. 
 Survival:  After the neural progenitor cells proliferate and divide in the subgranular zone, 
they can differentiate into neurons and their functional integration and dendritic arborization into 
the hippocampus (van Praag et al, 2002). Most of these proliferated cells, however, do not survive, 
and the pruning of proliferated cells is thought to be under the control of 5-HT receptors (Klempin 
et al, 2010). The major effect of chronic SSRIs for behavioral efficacy in the NIH test is their 
stimulatory effect upon the stem cell proliferation, though they can also promote the survival of 
basally proliferated stem cells (Klempin et al, 2010). The function of the hippocampal 
neurogenesis, both proliferation and the survival/integration processes, is not fully understood, but 
has been implicated to maintain hippocampus-dependent behavioral plasticities (Benninghoff et 
al, 2012). In this aim, we tested to see the contribution of vortioxetine towards promoting the 
survival of basally proliferated hippocampal stem cells, and whether this process required SERT 
antagonism. Following a pulse label of basally proliferating hippocampal stem cells with BrdU, 
we administered vortioxetine to WT and SERT Met172 animals for 4 weeks. Following the 
immunohistochemistry for the BrdU label, we found that both WT and SERT Met172 mice display 
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increased rates of survival (Figure 25). These data indicate that stem cell survival component of 
vortioxetine, as well as stem cell proliferation, does not require SERT antagonism, and that its 
array of activity at other targets, specifically 5-HT receptors, is sufficient to stem cell proliferation 
and survival.  
  
Conclusions 
  
 The rationale for the use and development of vortioxetine in the clinic stems from the broad 
and engagement of multiple 5-HT receptors following SSRI administration. With SSRI 
administration and subsequent SERT blockade, all 5-HT receptors are stimulated and activated 
due to this generic enhancement of serotonergic signaling, some of which might be deleterious to 
the desired antidepressant profile (Ramamoorthy et al, 2008; Wesołowska et al, 2006). It could 
thus be beneficial to develop pharmacological agents that can selectively target specific 5-HT 
receptors, limiting actions at receptors that diminish efficacy or those that produce unacceptable 
side effects, all while possibly eliminating traditional engagement at SERT. Vortioxetine aims to 
accomplish this aim of specific 5-HT receptor engagement through its actions as an agonist at 5-
HT1A and as a partial agonist at 5-HT1B. Vortioxetine is also an antagonist at 5-HT3 and 5-HT7 
receptors, and retains significant activity as a SERT antagonist (Mørk et al, 2012), though whether 
its activity at SERT is relevant for clinical efficacy has not been tested.  
 Due to preclinical studies indicating potential antidepressant utility of compounds that 
target 5-HT receptors that vortioxetine targets individually, our lab sought to query whether these 
SERT-independent 5-HT receptor actions of vortioxetine could be sufficient to produce 
antidepressant effects.   
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Figure 25. Hippocampal Neurogenesis: Survival Preservation with Vortioxetine. SERT 
antagonism is not required for the survival of basally proliferated hippocampal stem cells 
following chronic vortioxetine administration. Survival: Following administration of BrdU, 
vortioxetine was administered to WT and SERT Met172 mice. WT and Met172 mice display 
significant increases in survival of stem cells. * indicates significance compared to vehicle (P <.05) 
following Two Way ANOVA and Bonferroni post-hoc tests (n = 4 per genotype and condition). 
Two Way ANOVA revealed insignificant main effect of genotype (F(1,9) = 0.37, P > 0.05), 
significant effect of drug (F(1,9) = 25.08, P < 0.05), and insignificant interaction (F(1,9) = 0.56, P 
> 0.05) 
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In order to accomplish this task, we utilized the SERT Met172 mouse model, to selectively 
reduce the ability of vortioxetine to bind and inhibit SERT, all while preserving SERT expression 
and function and thus free from the compensatory alterations that plague the SERT knockout 
model (Bengel et al, 1998; Cour et al, 2001; Fabre et al, 2000; Li et al, 2000; Lira et al, 2003; 
Rioux et al, 1999). Utilizing the SERT Met172 model, vortioxetine actions at these 5-HT receptors 
are preserved while limiting SERT antagonism. In this aim, I tested whether vortioxetine retained 
antidepressant properties in acute and chronic models of antidepressant efficacy. In the acute tests 
for antidepressant sensitivity, vortioxetine is able to reduce immobility time equivalently in both 
WT and SERT Met172 mice in both the TST and FST, indicative of an antidepressant-like effect. 
Interestingly, vortioxetine is able to produce a climbing effect in the FST in both WT and SERT 
Met172 mice, an effect that is not produced by SSRIs and other SERT blockers and that is usually 
seen in norepinephrine enhancing antidepressants, such as NET blockers, though vortioxetine has 
no significant activity at norepinephrine receptors or NET (Mørk et al, 2012). This effect is thought 
to be due to the antagonist effect of vortioxetine at 5-HT3 receptors (Puig et al, 2004). The relevant 
antagonism of 5-HT3 receptors, which are thought reside on GABAergic interneurons in the PFC, 
would effectively reduce the GABAergic inhibition of norepinephrine release in the PFC, thereby 
driving this climbing effect in the FST (Puig et al, 2004). This interesting effect further exemplifies 
the SERT independence of vortioxetine in acute antidepressant-sensitive assays. Together, our 
findings reveal that vortioxetine does not require SERT for its antidepressant activity in assays that 
are sensitive to acute antidepressant administration. 
 As has been noted previously, these acute measures of antidepressant efficacy are not 
ostensibly measuring the same biological processes that arise during the timecourse of clinical 
antidepressant efficacy, which requires weeks of chronic administration. Moreover, many 
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preclinical compounds that have shown antidepressant-like efficacy in the TST and FST, have 
failed in clinical trials or failed to surpass antidepressant efficacy of SSRIs. Therefore, there is no 
guarantee that the SERT independence of vortioxetine in the ability to produce antidepressant-like 
effects in the TST and FST would translate to chronic antidepressant sensitive models. 
Alternatively, the actions of vortioxetine at 5-HT receptors could merely act in an accessory 
manner, dependent upon that overall enhancement of serotonergic tone brought about by SERT 
inhibition. However, 5-HT1A stimulation has been shown to drive hippocampal stem cell 
proliferation (Klempin et al, 2010), and the presence of the receptor is required for the stimulatory 
effects on hippocampal stem cell proliferation and chronic antidepressant sensitivity (Santarelli et 
al, 2003). Given the stimulatory actions of vortioxetine at 5-HT1A receptors, vortioxetine may 
drive hippocampal stem cell proliferation and chronic antidepressant sensitivity, via a 5-HT 
receptor linked pathway as opposed to SERT antagonism.  
 I next tested the ability of vortioxetine to induce antidepressant-like effects in assays that 
are sensitive to chronic—but not acute—antidepressant administration. After administering 
vortioxetine chronically to WT and SERT Met172 mice, I then found that both WT and SERT 
Met172 mice were behaviorally responsive to the drug, with respect the anxiolytic properties of 
consumption latency values. These data indicate that SERT is not required for the chronic 
behavioral actions of vortioxetine, and that the combined 5-HT receptor activity of vortioxetine is 
sufficient to produce an antidepressant effect. Next, I tested the ability of vortioxetine to stimulate 
hippocampal stem cell proliferation, and whether this process required its ability to inhibit SERT. 
Using the same models as previously, both WT and SERT Met172 mice displayed significant 
increases in hippocampal stem cells following chronic vortioxetine administration, indicating 
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again that vortioxetine does not require activity at SERT for this effect and that the 5-HT receptor 
activity profile of vortioxetine outside of SERT binding is sufficient to produce this effect. 
 My findings show that vortioxetine does not require activity at SERT to produce 
antidepressant effects in models that are sensitive to either acute or chronic antidepressant 
administration. Although these data are limited in scope to the SERT-independent efficacy of 
vortioxetine, they demonstrate the principle that future iterations of serotonergic antidepressant 
drugs may not require SERT antagonism. The field of antidepressant pharmacology has largely 
stagnated surrounding the dogma that engagement at SERT is required for clinical efficacy. 
Elevations in 5-HT brought about by SERT antagonism produces global enhancement 5-HT 
receptor activation, which may be deleterious towards antidepressant profile, as well as enhancing 
side effect profile. Next generation serotonergic antidepressants would be wise to engage those 5-
HT receptors that are beneficial to producing antidepressant effects while avoiding those that 
negate those effects. Vortioxetine is able to accomplish this aim, albeit with major activity at 
SERT. It is able to do so with a single chemical compound, which is remarkable and surprising in 
its own right, though I do not expect future drug development efforts to achieve this feat, nor 
should it absolutely be necessary to do so. These studies do provide justification for future 
development of multitargeted drugs at a preclinical level, and could usher in a new wave of 
serotonergic based antidepressants that lack appreciable activity at SERT, and representing a 
logical next step in the development of serotonergic antidepressants lacking SERT antagonism.   
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE EXPERIMENTATION 
 
 The purpose of these studies was multifaceted, all designed to assess the requirement of 
SSRIs to antagonize the serotonin transporter for its antidepressant effects. The complicated and 
delayed nature by which antidepressants exert their effects in the clinical population has generated 
some doubt to the serotonin hypothesis of depression, and there have been various examples that 
have directly questioned whether the antidepressant effects of SSRIs are enacted through SERT 
antagonism. Up until this point, there have been no definitive tests or models that have been able 
to address these concerns without significant caveats. The SERT knockout mouse, while intriguing 
to test the nature by which SERT is required for the antidepressant effects of SSRIs, exhibits major 
compensatory alterations that perturb normal neurodevelopment and serotonergic homeostasis, 
rendering an abnormal environment within which the SSRIs act. Though the studies using the 
SERT knockout model suggest that SSRIs do require SERT antagonism (Holmes et al, 2002), the 
confounds that plague the model have done little to dispel the multiple lines of research suggesting 
the role of non-SERT SSRI targets involved in the antidepressant effects of SSRI 
pharmacotherapy.  
 The SERT Met172 mouse model was developed in part to test this question of SERT 
dependence of SSRI antidepressant activity (Thompson et al, 2011). This effort was led by Dr. 
Randy Blakely, who sought to create a model that did not have the problems the SERT knockout 
model possesses, in part to test the SERT dependence of SSRI actions. The aim of this endeavor 
was to create a model that lacks pharmacological inhibition of SSRIs at SERT, but lacks the 
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compensatory alterations seen in the SERT knockout model. This effort led the group to pursue 
the observed differences in pharmacological sensitivity of different serotonin transporters across 
phylogeny to SSRIs (specifically human and mouse SERT compared to Drosophila SERT), and 
ascertain which amino acid residues were integral to that shift in pharmacological sensitivity. The 
result of much mutagenesis work was that Ile172 was highly responsible for high affinity SSRI 
binding at human and mouse SERT, whereas the corollary amino acid in Drosophila (methionine), 
when substituted into human or mouse SERT, could recapitulate the reductions in SSRI sensitivity 
seen in Drosophila SERT (Henry et al, 2006). DNA encoding this substitution (Ile172Met; I172M) 
was then achieved in mice via embryonic knock-in homologous recombination techniques. The 
substitution did not impact SERT protein expression, SERT surface expression, CNS biogenic 
amine levels, or SERT protein function (Thompson et al, 2011). Importantly, behaviorally relevant 
doses of SSRIs could not functionally antagonize SERT Met172 in in vivo paradigms (Thompson 
et al, 2011). The genetic background of the mouse in which the embryonic knock-in was created, 
however, was not conducive to further behavioral experimentation, including achieving the 
answers pertaining to whether SERT interactions are required for SSRI antidepressant activity. 
The importance of these efforts, as well as for the plans for this mouse moving forward, dictated 
that the SERT Met172 mouse be backcrossed onto a suitable genetic background. Here, we show 
the results of the studies on the SERT Met172 mouse following the backcrossing onto the C57Bl/6 
background. I first ensured that the act of backcrossing did not perturb the observation that SERT 
Met172 is benign with respect to SERT protein expression, CNS biogenic amine levels, and SERT 
protein function, and induced these parameters equivalently to WT littermates (Nackenoff et al, 
2015). Additionally, the expected loss of potency for SERT antagonists, fluoxetine and citalopram, 
were preserved in the C57Bl/6 SERT Met172 model, with maintained sensitivity for paroxetine, 
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which serves as an important positive control for our experiments (Nackenoff et al, 2015). Because 
of the utility of the C57Bl/6 mouse model for behavioral testing, we next moved to behavioral 
assays that are sensitive to acute administration of SSRIs. Should SSRIs retain behavioral activity 
in SERT Met172 mice, this would indicate that SSRIs do not require SERT antagonism, since 
behaviorally relevant doses of SSRIs do not functionally antagonize SERT Met172 and thus 
maintained CNS interactions with other non-SERT targets would be producing the antidepressant-
like effects in these acute SSRI sensitive tests. When I tested these mice in the TST and FST, I 
found that SERT Met172 mice fail to respond to fluoxetine and citalopram, paralleling their 
inability to antagonize SERT Met172 in vivo. Thus, acute antidepressant effects of the SSRIs 
fluoxetine and citalopram in the preclinical forced swim and tail suspension tests require SERT 
antagonism.  
 Since acute preclinical tests of antidepressant sensitivity do not accurately reflect the 
complex nature of clinical response to antidepressants, we next wanted to move to assays that are 
sensitive to chronic—but not acute—SSRI administration. These tests would best to parallel the 
chronic nature of SSRI antidepressant administration that is required for clinical efficacy. In this 
aim, I tested the ability of chronic SSRI administration to induce antidepressant-like effects in the 
NIH test. SERT Met172 mice fail to respond behaviorally to chronic SSRI in this test (Nackenoff 
et al, 2015). Additionally, I also investigated the degree to which SSRIs can enhance hippocampal 
stem cell proliferation in the SERT Met172 mice, an effect that occurs with chronic SSRI 
administration, and is required for chronic SSRI behavioral sensitivity (Santarelli et al, 2003). Like 
the lack of sensitivity in the NIH test, following chronic administration of SSRI SERT Met172 
mice fail to display enhanced hippocampal stem cell proliferation, nor do they display any 
increased rates of survival of basally proliferated stem cells (Nackenoff et al, 2015), both of which 
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are produced by chronic SSRI administration in WT mice. These data indicate that both acute and 
chronic antidepressant effects induced by SSRIs require SERT antagonism. These results are 
important in their own right, due the fact that they represent the most specific set of assays to date 
that could definitively state that SERT antagonism is required for the antidepressant efficacy of 
SSRIs. 
 The SERT Met172 mouse model was not created solely for this purpose, however. A 
significant advantage over the SERT knockout model is that while both models remove the 
pharmacological target of SSRIs [at behaviorally and clinically relevant doses], the SERT Met172 
model is devoid of the compensatory alterations produced by the SERT knockout model. This is 
important when considering the future potential of the SERT Met172 model that cannot be 
achieved by the SERT knockout. Because of the multifaceted and temporally complex nature of 
the antidepressant effect seen clinically, much work has been done to isolate the key facets of the 
antidepressant response, which are obviously more complicated that simply SERT antagonism. 
Were we able to identify the necessary downstream biological alterations and responses to chronic 
SSRI administration that bring about clinical antidepressant efficacy, we could potentially directly 
aim to produce those necessary changes through new drug treatment strategies in order to produce 
new faster treatments for depression. Isolating these necessary changes, however, is difficult due 
to the nature by which SSRIs also engage other non-SERT targets. Any attempts to identify the 
genetic consequences of chronic SSRI administration in mice would generate datasets that would 
contain both SERT-specific changes in addition to those alterations brought about by engagement 
of SERT-independent targets. The SERT knockout model can be utilized, but as noted before, the 
compensatory alterations found in that model render an abnormal environment in which these 
SSRIs can act. And unlike behavior, biochemical alterations that arise with chronic administration 
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may be more sensitive to compensatory alterations, and any such findings would severely cloud 
the accuracy of perceived SERT-specific effects of SSRIs. The SERT Met172 mouse model 
represents the best control condition for the elucidation of SERT specific effects of chronic SSRI 
administration. When compared against WT mice, since SERT Met172 mice only remove the 
ability of SSRIs to bind and antagonize SERT, any molecular or cellular changes seen in SERT 
Met172 can only be due to non-SERT interactions of SSRIs and can be easily removed from WT 
datasets. Efforts to conduct those studies are currently underway, and soon we can start 
deconstructing the serotonin path towards antidepressant efficacy. Identifying the key essential 
elements on the serotonin dependent pathway of antidepressant efficacy can illuminate essential 
components in the antidepressant response, as well as identify potentially better targets of future 
antidepressants. Through prior studies, we know that SSRIs impact the expression of kinases 
(Rausch et al, 2002), BDNF and other neurotrophic elements (Alme et al, 2007; Castrén and 
Rantamäki, 2010), NMDA receptor subunit expression (Boyer et al, 1998), PKA pathway sensitive 
transcription factor CREB expression (Nibuya et al, 1996), as well as 5-HT receptor expression 
and sensitivity (Hensler, 2002), among many others. Whether these effects result from SERT 
antagonism is unknown. Our attention will focus on neurotrophic factors in the hippocampus, as 
neurogenesis seems to be a critical element in the antidepressant effect invoked by chronic SSRI 
administration, and may represent a future direct target for antidepressants, skipping SERT 
antagonism entirely (Malberg and Schechter, 2005). Though only through comparisons to the 
SERT Met172 model can we determine which of these are dependent upon enhancement in 
serotonergic tone and SERT antagonism. 
 These attempts represent a desire to further isolate the key facets of antidepressant actions 
and develop more efficient techniques by which we can induce antidepressant effects. In very early 
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antidepressant therapies, albeit serendipitous, monoamine oxidase was targeted. These drugs 
produced enhancements in serotonergic signal transmission via the inhibition of the metabolism 
by monoamine oxidase. This approach, though clinically effective, is not the most efficient or 
specific means to enhance serotonergic neurotransmission. It was the only antidepressant 
pharmacotherapy at the time, and with improvements in antidepressant pharmacology, MAOIs are 
rarely utilized today. Following in the footsteps of MAOIs, tricyclic antidepressants were 
introduced, again serendipitously. These TCAs also enhanced serotonergic neurotransmission via 
the inhibition of the serotonergic synaptic clearance, allowing for an increase in 5-HT signal 
duration. Though these TCAs are arguably as efficient as current SSRI pharmacotherapies at 
inhibiting SERT and prolonging 5-HT signal duration, TCAs were largely abandoned clinically 
due to their cardiotoxic side effects and drug-drug interactions limited therapeutic utility. SSRIs 
represent the current standard of care for antidepressant pharmacotherapy, though they are not 
necessarily the most efficient and technologically advanced considering what we know about the 
role of different serotonin receptors that contribute to, or retract from, the antidepressant effect. In 
fact, though engagement of certain serotonin receptors is beneficial to the antidepressant effect, 
activating others can potentially be deleterious to the desired antidepressant effect (Nakagawa et 
al, 1998; Singh and Lucki, 1993; Wesołowska et al, 2006). This oppositional and competing nature 
of serotonin receptor activation events may contribute to the delayed clinical efficacy of SSRI 
antidepressants. At the least, it represents a technological barrier that could easily be traversed 
were we to create antidepressants that engage desired 5-HT receptor activity and removes the 
deleterious effects at others. 
 The novel antidepressant vortioxetine aims to accomplish this technological achievement 
(Guilloux et al, 2013; Mørk et al, 2012). Vortioxetine, while engaging and antagonizing SERT, 
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binds and activates 5-HT1A and 5-HT1B while antagonizing 5-HT3 and 5-HT7 receptors (Mørk 
et al, 2012). The strategy for this compound aims to possess faster therapeutic efficacy and/or 
reduced side effect profile, as 5-HT3 activation induces nausea and there already exists a clinical 
compound that antagonizes the 5-HT3 receptor for the reduction in nausea (Glare et al, 2011). 
Vortioxetine, while invoking traditional antidepressant actions at SERT, may not require its 
activity at SERT given that the antidepressant effect can be recapitulated by directly targeting one 
or more of the receptor targets invoked by vortioxetine outside of SERT antagonism 
(Ramamoorthy et al, 2008; Robinson et al, 1990; Singh and Lucki, 1993; Tatarczyńska et al, 2005; 
Wesołowska et al, 2006). We wanted to query whether the antidepressant effect invoked by 
vortioxetine required SERT antagonism, as SERT-independent antidepressant effects would 
represent a technological advancement beyond pure SERT engaging antidepressants. In my 
studies, I tested the ability of vortioxetine to induce antidepressant-like effects in the SERT Met172 
mouse model, using assays that are sensitive to acute and chronic SSRI administration. Firstly, I 
found that vortioxetine remains capable in inducing antidepressant-like effects in SERT Met172 
mice in the TST and FST, tests that are sensitive to acute single dose administration of vortioxetine, 
indicating that vortioxetine does not require SERT antagonism for its ability to induce 
antidepressant-like effects. Additionally, vortioxetine is still capable of inducing climbing effects 
in the FST in SERT Met172 mice, an effect brought about not by SERT antagonism, illustrating 
further that vortioxetine acts in a SERT-independent manner, within certain endpoints. I then 
moved to analyze whether chronic antidepressant actions of vortioxetine required SERT 
antagonism. As acute antidepressant sensitive measures are not representative of clinically relevant 
biological mechanisms required for antidepressant efficacy, we needed to move to assays that are 
only sensitive to chronic—but not acute—antidepressant administration. For this, we chose the 
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NIH test and subsequently assessed hippocampal neurogenesis, a process that is required for SSRI 
efficacy in the NIH test (Santarelli et al, 2003). Chronic administration of vortioxetine can induce 
behavioral sensitivity in the NIH test as well as stimulate the production of hippocampal stem cells 
(Guilloux et al, 2013). Our aim was to investigate whether the removal of SERT from the 
pharmacological profile of vortioxetine, through the use of SERT Met172, would render it 
incapable of producing antidepressant-like effects in chronic measures of SSRI efficacy. I found 
that following chronic administration of vortioxetine, SERT Met172 mice were still behaviorally 
responsive to vortioxetine in the NIH test. Additionally, I found that the major neurogenic 
endpoints in the stimulation of hippocampal stem cell proliferation, as well as survival, were 
preserved in SERT Met172 mice. These data provide strong preclinical evidence that SERT is not 
required for the chronic behavioral efficacy of vortioxetine, suggesting that the residual activity of 
vortioxetine at serotonin receptors is sufficient to produce an antidepressant effect, both acutely 
and chronically. 
 These data indicate the potential of future serotonin directed antidepressants that 
completely lack activity at SERT. As much as the technological advancement occurred from 
MAOIs to the SERT blockers that enhance of serotonin neurotransmission, so could this next leap 
beyond purely antagonizing SERT to achieve serotonergic signal enhancement by engaging 
serotonin receptors—or other targets—directly to produce the desired quality of antidepressant 
pharmacotherapy. Though vortioxetine achieves this with a single molecule, it is not reasonable 
or necessary to do so moving forward. I perceive that future therapies in this serotonergic 
framework could involve a mixture of serotonin receptor specific ligands, invoking different 
serotonin receptors as agonists, partial agonists, or full antagonists. This receptor specificity, 
however, will most likely invoke allosteric mechanisms as serotonin receptors, by definition, share 
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high functional homology at their orthosteric binding sites, which all must bind serotonin. This 
approach would most likely be applied initially in the creation of serotonin receptor subtype 
specific allosteric modulators (both negative and positive) which could be iteratively tested 
alongside SSRI administration in order to achieve a higher fidelity characterization of which 5-HT 
receptors are necessary for the antidepressant effect of SSRIs. Once the necessary 5-HT receptors 
have been identified for the efficacy of SSRIs, those compounds could easily be translated to 
systems amenable for human preclinical trials, either singularly or combinatorial in order to 
produce newer more efficient serotonergic antidepressant pharmacotherapies.  
This novel approach of direct selective actions at serotonin receptors would also be 
beneficial considering the absolute nature of SSRI pharmacotherapy, which requires nearly full 
saturation antagonism of the CNS systemic serotonin transporter in order to visualize any 
antidepressant efficacy. Depression symptom amelioration requires high SERT occupancy of 
SSRIs in order to achieve antidepressant effects, which produces high rates of incidence of 
unacceptable side effects in chronically treated individuals with depression. For the reason of side 
effects alone, this receptor specific approach would be very beneficial. On the other hand, with the 
nature of high dose necessity of SSRIs, one cannot finely control efficacy at certain 5-HT 
receptors, which are largely fully engaged following chronic SSRI administration, potentially 
leading to receptor desensitization, oversaturation, and addiction-like withdrawal sensations 
following pharmacotherapy cessation. It could be highly beneficial to introduce therapies that, 
instead of applying sledgehammer equivalent, all-or-nothing pharmacotherapies, would finely 
tune activity at certain serotonin receptors for subtler and better tolerated antidepressant regimens. 
As the field of neuroscience has accepted the CNS as more of a pathways of intercalating signaling 
networks, the field of pharmacology must also act accordingly and approach the depressed brain 
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as needing signaling recalibration instead of a whole organ that needs abrasive reshaping. It will 
first be necessary to achieve some receptor subtype specificity, but eventually the field of 
pharmacology will move to regionally-specific pharmacotherapies, though some approaches have 
been moderately successful in this regard, though with limited capability (Bortolozzi et al, 2012; 
Lladó-Pelfort et al, 2010). This regional specificity will be required as identical serotonin receptors 
act differently in different parts of the brain. Regional specificity will likely require elements that 
are not capable of single agent chemical structural elements. I anticipate that receptor specificity 
will be achieved with allosteric pharmacology, though region-specific delivery could likely be 
achieved via nanoparticle encapsulation. Nanoparticles have been studied for many years, mostly 
to deliver non-traditional agents past extensive first-pass metabolic mechanisms, as well as 
opportunities for long term delivery and extended release functionality. Recently, nanoparticles 
have been functionalized, allowing the penetration of a pharmaceutical compound (eg. a 
chemotherapeutic) and to deliver this agent preferentially to a desired site of action (eg. a tumor 
mass). In this example, the chemotherapeutic would normally act generally, but nanoparticle 
encapsulation and preferential delivery confers some regional specificity that would otherwise not 
be possible. This type of approach would be entirely possible given some moderate advancements 
in the field of nanoparticle encapsulation. In addition to the technologically capable process of 
developing 5-HT selective allosteric modulators, it is within grasp to create regionally specific 
delivery of 5-HT receptor subtype specific allosteric modulators to create a technologically 
superior serotonin directed pharmacological treatment compared to currently available SSRI 
pharmacotherapies. 
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APPENDICES  
 
In addition to the experimental efforts and results presented in chapters II-V, I have also 
pursued other efforts relating to aspects of delineating serotonin specificity of certain drugs using 
the SERT Met172 mouse model. These efforts included proposed collaborations that were not 
ultimately pursued, or preliminary work that developed into projects for other members of the lab. 
 
 
APPENDIX A. Sensitivity of the Mixed Action SNRI Antidepressant/Pain Medicines Milnacipran 
and Duloxetine to the SERT Met172 Substitution 
 
APPENDIX B. Characterization of the Disrupted Pharmacological Inhibition of Cocaine upon Ex 
Vivo Derived Synaptosomes from C57Bl/6 Backcrossed SERT Met172 Mice 
 
APPENDIX C. Adaptation of Novel Fluorescence-Based SERT Uptake Assay for Ninety-Six Well 
Transfected Cell Format 
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APPENDIX A. SENSITIVITY OF THE MIXED ACTION SNRI ANTIDEPRESSANT/PAIN 
MEDICINES MILNACIPRAN AND DULOXETINE TO THE SERT MET172 
SUBSTITUTION 
 
I have described in depth in chapter II the impact of the SERT Met172 substitution upon 
the ability for SSRIs to inhibit SERT mediated 5-HT uptake. These analyses were performed with 
the intention of analyzing the 5-HT dependent and independent actions of SSRIs. The SERT 
Met172 model is also useful for the evaluation of multitargeted drugs that include targets at SERT, 
like vortioxetine in chapter V. Here, I describe the sensitivities to the multitargeted drugs, 
milnacipran and duloxetine, upon the SERT Met172 substitution. These drugs are newly 
developed mixed SERT and NET inhibitor (SNRI) that are indicated as an antidepressant as well 
as for fibromyalgia-type pain (Arnold et al, 2004; Clauw et al, 2008; Gendreau et al, 2005; 
Nakagawa et al, 2008). SNRIs are partially effective treatments for pain, due to the downwardly 
projecting 5-HT and NE neuronal pathways synapsing upon endogenous opioid releasing neurons, 
which can regulate pain signal synergy in the dorsal horn of the spinal cord (Bardin, 2011; 
Mochizucki, 2004; Ossipov et al, 2010). Here, I determine the magnitude of the degree of the 
disrupted affinity of milnacipran and duloxetine for SERT Met172. This aim was meant to 
determine whether we could disrupt the actions of these drugs at SERT, leaving the drug with only 
major activity at NET, in order to determine the importance of SERT actions of the drug for its 
efficacy in models of chronic pain. 
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Experimental Procedure 
 
Expanding upon the initial characterization by Julie Field in WT hSERT and SERT Met172 
transfected cells, I determined whether this disrupted affinity for milnacipran and duloxetine is 
maintained in a more native preparation, utilizing SERT Met172 derived synaptosomes. Following 
sacrifice via rapid decapitation, the whole brains of 8-12 week old male WT and SERT Met172 
C57Bl/6 mice were dissected on ice and used for synaptosomal preparations as described 
previously (Thompson et al, 2011). Briefly, midbrain sections were mechanically homogenized in 
0.32M sucrose in 5mM HEPES buffer. This homogenate was subjected to a low gravity 
centrifugation (10 min, 4°C at 1,000x g) in order to remove large cellular components (eg. 
mitochondria, nuclei, and large membranes) from the reconstituted nerve terminals, classified as 
‘synaptosomes’. The supernatant after this first spin contains the synaptosomes. The synaptosomes 
are then pelleted via a high gravity centrifugation (15 min, 4°C at 10,000x g). The pellet was 
resuspended in KRH buffer containing glucose (for synaptosomal viability throughout the 
preparation and assay), pargyline (MAOI, prevents enzymatic metabolism of 5-HT), and ascorbic 
acid (preservative, prevents spontaneous oxidation of 5-HT). Equal volumes of synaptosomes were 
then incubated with varying concentrations of milnacipran and duloxetine at 37°C for 10 minutes. 
I then added 20 nM [3H]5-HT (PerkinElmer, NET498001MC, Waltham, MA, USA) to 
synaptosomes and allowed 5-HT accumulation for 10 min at 37°C. 5-HT uptake into synaptosomes 
was terminated via addition of ice cold PBS buffer, and vacuum filtration through 0.3% 
polyethyleneimine treated glass fiber filters (GF/B, Whatman, Pittsburgh, PA, USA). Competition 
uptake inhibition curves were fit to single site competition regression curve fit (Graphpad Prism 
6.0) 
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Results 
 
 As predicted by the in vitro characterization performed by Julie Field, both milnacipran 
and duloxetine are significantly sensitive to the SERT Met172 substitution when assessed in 
synaptosomal preparations. Milnacipran displays a ~17-fold reduction in inhibition potency at 
SERT Met172 compared to WT SERT (Appendix Figure 1). Duloxetine displays a ~170-fold 
reduction in inhibition potency at SERT Met172 compared to WT SERT (Appendix Figure 2). 
Based upon these rightward shifts in inhibition efficacy for SERT Met172, and that we have 
demonstrated that these shifts are permissible for strategies that produce functional SERT 
antagonism in WT but not SERT Met172 in vivo (Nackenoff et al, 2015; Thompson et al, 2011), 
we could utilize the SERT Met172 model to remove the actions of milnacipran and duloxetine at 
SERT to determine the importance of their actions at SERT for their efficacy as antidepressants or 
as analgesics. 
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Appendix Figure 1. Milnacipran Sensitivity to SERT Met172 Synaptosomes. The SERT Met172 
mutant imposes altered pharmacological sensitivity with normal SERT expression and function. 
Competition 5-HT uptake analysis in midbrain derived synaptosomes. Milnacipran (WT: KI 
526nM +/- 1.1; Met172: KI 8.90uM +/- 1.1) was assessed for their ability to compete with [
3H]5-
HT uptake. (n = 4/condition). Like the in vitro studies, milnacipran displays reduced potency for 
SERT Met172 vs WT SERT (~17-fold reduction).  
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Appendix Figure 2. Duloxetine Sensitivity to SERT Met172 Synaptosomes. The SERT Met172 
mutant imposes altered pharmacological sensitivity with normal SERT expression and function. 
Competition 5-HT uptake analysis in midbrain derived synaptosomes. Duloxetine (WT: KI 
17.1nM +/- 2.0; Met172: KI 262nM +/- 2.0) was assessed for their ability to compete with [
3H]5-
HT uptake. (n = 4/condition). Like the in vitro studies, duloxetine displays reduced potency for 
SERT Met172 vs WT SERT (~170 fold reduction). 
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APPENDIX B. CHARACTERIZATION OF THE DISRUPTED PHARMACOLOGICAL 
INHIBITION OF COCAINE UPON EX VIVO DERIVED SYNAPTOSOMES FROM C57BL/6 
BACKCROSSED SERT MET172 MICE 
 
 I have described earlier, in chapter II, the impact of the SERT Met172 substitution upon 
the ability for SSRIs to inhibit SERT mediated 5-HT uptake. These analyses were performed with 
the intention of analyzing the 5-HT dependent and independent actions of SSRIs. The SERT 
Met172 model is also useful for the determination of the importance of SERT antagonism for 
multitargeted drugs, that include SERT among their targets. Cocaine produces strong 
neuropsychotropic effects via its actions at DAT, SERT, and NET, where it functions as a reuptake 
blocker at all three of those proteins upon their respective neurotransmitter (Uhl et al, 2002). We 
have shown in lab previously that cocaine is sensitive to the SERT Met172 substitution (Henry et 
al, 2006; Thompson et al, 2011). Here, I expand upon those efforts and test whether this disrupted 
affinity of cocaine at SERT Met172 is maintained a more relevant reconstituted system for further 
assessment of in vivo SERT-dependent actions of cocaine. 
 
Experimental Procedure 
 
Expanding upon the initial characterization by Keith Henry, Brent Thompson, and Julie 
Field in WT hSERT and SERT Met172 transfected cells and synaptosomes of 129S6/S4 SERT 
Met172 mice, I determined whether this disrupted affinity for cocaine is maintained in a more 
native preparation, utilizing SERT Met172 derived synaptosomes. Following sacrifice via rapid 
decapitation, the whole brains of 8-12 week old male WT and SERT Met172 C57Bl/6 mice were 
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dissected on ice and used for synaptosomal preparations as described previously (Thompson et al, 
2011). Briefly, midbrain sections were mechanically homogenized in 0.32M sucrose in 5mM 
HEPES buffer. This homogenate was subjected to a low gravity centrifugation (10 min, 4°C at 
1,000x g) in order to remove large cellular components (eg. mitochondria, nuclei, and large 
membranes) from the reconstituted nerve terminals, classified as ‘synaptosomes’. The supernatant 
after this first spin contains the synaptosomes. The synaptosomes are then pelleted via a high 
gravity centrifugation (15 min, 4°C at 10,000x g). The pellet was resuspended in KRH buffer 
containing glucose (for synaptosomal viability throughout the preparation and assay), pargyline 
(MAOI, prevents enzymatic metabolism of 5-HT), and ascorbic acid (preservative, prevents 
spontaneous oxidation of 5-HT). Equal volumes of synaptosomes were then incubated with 
varying concentrations of cocaine at 37°C for 10 minutes. I then added 20 nM [3H]5-HT 
(PerkinElmer, NET498001MC, Waltham, MA, USA) to synaptosomes and allowed 5-HT 
accumulation for 10 min at 37°C. 5-HT uptake into synaptosomes was terminated via addition of 
ice cold PBS buffer, and vacuum filtration through 0.3% polyethyleneimine treated glass fiber 
filters (GF/B, Whatman, Pittsburgh, PA, USA). Competition uptake inhibition curves were fit to 
single site competition regression curve fit (Graphpad Prism 6.0) 
 
Results 
 
 As predicted based upon earlier characterizations, cocaine displays disrupted ability to 
inhibit SERT mediated 5-HT uptake in SERT Met172 derived synaptosomes, rendering a ~25-fold 
rightward shift in inhibition potency (Appendix Figure 3).  
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Appendix Figure 3. Cocaine Sensitivity to SERT Met172 Synaptosomes. The SERT Met172 
mutant imposes altered pharmacological sensitivity with normal SERT expression and function. 
Competition 5-HT uptake analysis in midbrain derived synaptosomes. Cocaine (WT: KI 1.12uM 
+/- 1.1; Met172: KI 27.1uM +/- 1.1) was assessed for their ability to compete with [
3H]5-HT 
uptake. (n = 4/condition). Like the in vitro studies, cocaine displays reduced potency for SERT 
Met172 vs WT SERT (~25-fold reduction). 
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Based upon previous efforts to select doses of SSRI that provide functional antagonism in 
SERT but not SERT Met172 in vivo (Nackenoff et al, 2015; Thompson et al, 2011), it should be 
possible to achieve a similar result with cocaine in the SERT Met172 model. This would allow the 
selective removal of SERT antagonism from the pharmacological properties of cocaine, and any 
residual effects of cocaine would not be dependent upon its actions at SERT, and conversely any 
effects lost would be due to the actions of cocaine at SERT. 
I oversaw the efforts of initial characterizations of SERT dependent behavioral effects of 
cocaine in the SERT Met172 model, an undergraduate honors project of Peter Chisnell upon the 
129S6/S4 genetic background SERT Met172 mice. Dr. Linda Simmler inherited this project in our 
lab following the backcrossing of the SERT Met172 mice onto the C57Bl/6 background. My 
findings also initiated collaborations that investigated the dependency of cocaine actions at SERT 
to trigger cocaine induced alterations in circadian rhythm. These efforts found that the well-
described actions of cocaine to alter circadian rhythm is in fact due to its actions at SERT, as 
cocaine-induced alterations in circadian rhythm are lost in SERT Met172 mice (Prosser et al, 
2014).  
Our main focus in the lab, however, has been to investigate the role of serotonin to 
modulate or support cocaine addiction related behaviors. In order to specifically analyze the 
specific roles of serotonin in cocaine action, we will need to pursue more complicated contingent 
measures of cocaine addiction. We have traditionally utilized locomotor chambers to analyze 
cocaine induced increases in locomotion, which is thought to measure raw cocaine sensitivity, but 
because cocaine is administered non-contingently, cannot measure desire to consume or pleasure 
derived from cocaine. Linda Simmler engaged in conditioned place preference (CPP) assays, 
which aim to measure how much the animal attains pleasure from consuming cocaine, though this 
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measure cannot measure drive to consume as cocaine is administered non-contingently. In order 
to assess the subtler modifications to addiction related behaviors, in which serotonin could be 
modulating, we need to investigate whether removal of SERT antagonism from cocaine action 
modulates contingent drug seeking behavior. To accomplish this, we need to initiate cocaine self-
administration paradigms. Optimally, this would entail cranial intraventricular injected cocaine 
upon an operant trained behavior (eg. nose poke), though this would require complicated 
individual surgeries upon all mice utilized for the study. Alternatively, one could administer 
cocaine through small operant behavior-mediated deliveries of cocaine infused water, though the 
route of administration is not as prompt as intracranial delivery, this would alleviate the burden of 
large number of stereotaxic surgeries required for intracranial cocaine delivery. Regardless of the 
method, the self-administration paradigm allows for the investigation into how desirable animals 
view cocaine, because the animal is able to determine the speed and total amount of cocaine 
deliveries over a session. Once basic parameters are established, one could modulate the operant 
paradigm to test the limits of drug seeking behavior, the strongest measure of which would be to 
deliver cocaine upon a progressive ratio, which increases the requirements placed upon the animal 
to access the next delivery of cocaine (eg. progressively increasing the number of nose pokes 
required for next subsequent delivery of cocaine). This tests the ‘break point’, which is a measure 
into the maximal amount of effort that an animal will expend in order to acquire the next delivery 
of cocaine.  
Another important measure would be to investigate alterations in withdrawal/extinction 
following self-administration. Additionally, we should also assess the role of serotonin on cocaine 
action for stress or cue induced reinstatement of drug seeking behavior. Should the actions of 
cocaine on serotonin modify the drug seeking behavior, SERT Met172 mice would display 
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alterations in their ‘break point’ and/or reinstatement behavior compared to WT mice, which 
would illustrate how serotonin modulates cocaine actions, and potentially illuminating new 
serotonergic mechanisms to target for future pharmacotherapies alleviating cocaine addiction. 
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APPENDIX C. ADAPTATION OF NOVEL FLUORESCENCE-BASED SERT UPTAKE 
ASSAY FOR NINETY-SIX WELL TRANSFECTED CELL FORMAT 
 
 All previously described SERT specific uptake assays in the preceding document utilize 
radiolabeled [3H]5-HT. The use of radiolabeling presents numerous problems. Firstly, 
radiolabeling is a safety hazard, necessitating proper personal protection, storage, and disposal to 
ensure minimal human and environmental contact to sources of ionizing and non-ionizing 
radiation. Additionally, while the use of radiolabeling provides a source of direct measurement of 
uptake, it can only do so as an endpoint analysis, where potentially critical information of the 
nature of uptake is lost and unable to be captured. In order to address these highlighted concerns, 
a fluorescent substrate was developed for the monoamine systems DAT, NET, and SERT (Blakely 
et al, 2011). This compound, IDT307, (Appendix Figure 4), is a functional derivative of MPP+ 
(an active metabolite of the infamous MPTP) which itself is a fluorescent substrate of DAT and 
NET, though IDT307 possesses much increased substrate capacity for SERT, allowing it to serve 
as a general fluorescent substrate for all three transporter systems (Blakely et al, 2011). 
Importantly, this fluorescence only occurs when the compound is internalized, allowing for high 
signal to noise and real time administration of uptake. Here, I describe my efforts to adapt and 
create efficient cell transfection for use in 96-well format for higher throughput analyses of 
modulations of SERT uptake. 
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Appendix Figure 4. Structure of IDT307. Comparison of the structure of IDT307 to MPTP and 
its metabolite MPP+ 
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Experimental Procedure 
 
 In order to prepare the cells for efficient transfection, I first setup the transfection in tube 
format, add suspended cells, and then plate this cell and transfection mix to 96-well plates for 
further experimentation. I explain this now in detail. 
 In 14 mL polystyrene tubes (Falcon), I add 2.5 mL of OptiMEM, and then add TransIT 
(Mirus) (at a ratio of 3uL TransIT per 1ug DNA transfected). I then swirl to mix, and let incubate 
at room temperature for 10 minutes, after which I add the appropriate amount of DNA and mix 
gently, followed by a 15-minute incubation. Here, I perform 5ug transfections of hSERT 
containing pcDNA3 plasmids (Invitrogen) (assuming a full 96 well plate transfection). I then take 
cultured cells and suspend them following a trypsin digest and resuspension in cell media. HEK-
293T cells were cultured at 37ºC in modified DMEM cell media containing 10% dialyzed fetal 
bovine serum (to eliminate 5-HT in growth media) and antibiotics. Once cells are suspended in 
new culture media, I count the cell concentration on a hemocytometer. From this, I calculate the 
volume needed for 5 x 106 cells and add this to the OptiMEM transfection reagent tube and wait 
20 minutes. After this, I adjust the volume of the reaction tube to 10 mL, adding fresh cell media. 
This cell transfection suspension is then dispensed at 100 uL per well to poly-D-lysine coated (to 
aid adherence) 96 well black sided clear-bottomed plates, and cells allowed to grow at 37ºC for at 
least 24 hours (best results are found with 36 hours). 
 On test day, cell media was aspirated off of the cells and replaced with Krebs-Ringer 
HEPES buffer (KRH) assay buffer containing pargyline (MAOI, prevents enzymatic metabolism 
of 5-HT), and ascorbic acid (preservative; prevents spontaneous oxidation of 5-HT). Cells were 
then preincubated with drugs for 10 minutes at 37ºC. Cells were then incubated with 1 uM (final) 
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IDT307 and allowed to accumulate at 37ºC. Immediately following administration of IDT307 to 
the wells, the plate is placed into the fluorescence measurement chamber (Flexstation) and 
assessed for uptake into cells. Excitation laser was set at 440nm and emission detection was set at 
520nm. 
 
Result 
 
 The purpose of this effort was to establish an easier and more reliable protocol for 96-well 
fluorescent IDT307 uptake assays in transiently transfected cells. These efforts mainly focused 
upon the transfection procedure. Traditional means of transfecting cells in 12 or 24 well format 
are easily suited for individual transfection of each well of cells (previously grown in a monolayer), 
though the 96 well format presents a problem for reliably doing so. Small variations in transfection 
reagent adherence to pipet tips of small volume administrations present potential large variability 
in transfection efficiency, causing inter-well variability independent of any treatment modulation. 
By transfecting and plating cells at the same time, this reduces the variability induced by individual 
well transfection procedures.  
 Here, I demonstrate the efficacy of the procedure. As shown, clear SERT-specific IDT307 
accumulation is seen in cells when compared against empty vector transfections and citalopram 
(SSRI) inhibited uptake (Appendix Figure 5). This assay can be used for situations that require 
higher throughput of transfection of multiple SERT variants or drug screening procedures which 
would not be best suited utilizing inefficient smaller plate formats. Though, an important caveat 
should be illuminated to any findings generated using IDT307 as opposed to 5-HT uptake studies.  
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Appendix Figure 5. Example trace of SERT-specific IDT307 accumulation. Fluorescence 
accumulation was conducted in the presence of 1uM IDT307 in HEK-293T cells transfected with 
either empty vector (pcDNA3) or hSERT, either uninhibited or in the presence of the SSRI 
citalopram (1uM). 
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As IDT307 and 5-HT are structurally dissimilar, there may be substrate-specific mechanisms that 
support/disrupt the actions of one substrate that may not be consequential for the other. Therefore, 
it may be useful to utilize IDT307 uptake assays when the situation dictates the screening of a 
large number of modulations, though important findings with IDT307 should ultimately be 
confirmed upon traditional substrate systems with smaller [3H]5-HT based uptake assays. 
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